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Abstract: The pathophysiology of chronic subdural haematoma and the role of the 
dexamethasone 
 
Chronic subdural haematoma (CSDH) is an encapsulated collection of blood and fluid 
overlying the surface of the brain, which is often treated with surgical drainage to prevent 
cerebral compression. Despite treatment it can recur, requiring further surgery and causing 
significant morbidity.  
 
Historically CSDH formation was considered to occur due to the aging and expansion of 
acute bleeding following head trauma. However, within this thesis the natural progression of 
CSDH was assessed with serial imaging following trauma and highlighted the novel process 
of CSDH formation from a normal CT. This was hypothesised to occur through injury 
initiating inflammation within the subdural space which drives formation of a hypervascular 
membrane responsible for fluid and blood accumulation over time. This theory was 
investigated by examining 68 CSDH samples for the presence of selected inflammatory 
markers and haemoglobin concentration. All pro-inflammatory markers were significantly 
elevated in CSDH fluid compared to venous blood, particularly vascular endothelial growth 
factor (VEGF). Haemoglobin degradation products were quantified with UV-Vis 
spectroscopy and more recent haemorrhage indicated an increased CSDH recurrence risk.  
 
This work was performed alongside the Dex-CSDH trial, a randomised, placebo-controlled 
trial of the potent anti-inflammatory dexamethasone. Blinded interim results of the trial are 
discussed, but the main focus are the scientific, mechanistic sub-studies. A method for 
detecting dexamethasone in CSDH and blood was developed using high performance liquid 
chromatography (HPLC), and suggested there is no accumulation of the drug within the 
CSDH space. However, many of the inflammatory markers were reduced post-operatively 
following dexamethasone treatment. Volumetric and density analysis of pre-operative and 
post-operative imaging was also performed and may aid prediction of which patients are 
more likely to have a poor outcome or recurrence. This could help identify patients in the 
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Chapter 1:  Introduction 
 
 
1.1 Background of Chronic Subdural Haematoma  
A Chronic Subdural Haematoma (CSDH) is an encapsulated collection of fluid and blood 
overlying the brain surface. Despite a large body of research on this condition since the early 
19th century, the process of how it is initiated and develops is still relatively unknown. A 
range of theories have been developed over the years but still doctors and scientists have 
varying views on the underlying pathophysiological processes that occur. It is well 
recognised to affect predominately the elderly population and probably have a delayed 
association with head trauma. Whilst there are reports of small CSDHs resolving, it is well 
established that they generally continue to enlarge over time. Once growing, the CSDH will 
expand until either treated or patient death from raised intracranial pressure. Thus, it is a 
source of significant morbidity and mortality in the elderly and through better understanding 
of the pathophysiological process, prompt diagnosis and appropriate treatment algorithms can 
be adopted. Currently, surgical drainage of CSDH forms the mainstay of treatment, but there 
is growing interest in pharmacological therapies, such as dexamethasone, which can be used 
in combination with surgery or as stand-alone treatment to encourage reabsorption and 
resolution of a CSDH. 
 
CSDH is considered a common entity in neurosurgical practice, and has an incidence of 
around 7.32-8.2 per 100,000 per annum in the peak demographic of over 65-year-olds 
(Asghar, 2002; Foelholm & Waltimo, 1975). The reported mean patient age in the literature 
is in the range of 68-77 years old and there is a clear predilection for men, with a ratio of 
around 1.7-2.9:1 of men to women (Baechli, Nordmann, Bucher, & Gratzl, 2004; Brennan et 
al., 2017; Gelabert-Gonzalez, Iglesias-Pais, Garcia-Allut, & Martinez-Rumbo, 2005; Goto et 
al., 2015; Santarius & Hutchinson, 2009; M. Wada et al., 2014). The reason for the gender 
bias is unclear, but as life expectancy has continued to rise, so does the number and age of 
patients under-going neurosurgical treatment for conditions such as this (Whitehouse, 
Jeyaretna, Wright, & Whitfield, 2016). The most common presenting symptoms include 
cognitive impairment, gait disturbance, limb weakness and headaches (Brennan et al., 2017; 
Santarius & Hutchinson, 2009). Such symptoms can lead to the suspicion of stroke, although 
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the onset is usually more insidious, and computed tomography (CT) imaging of the head is 











Figure 1.1; anatomical location of CSDH: (A) CT image of CSDH showing area of low density (dark 
grey) on the right side of the image, (B) corresponding graphic highlighting layers overlying the brain 
involved in CSDH. 
 
The earliest report of CSDH was an autopsy finding by Johannes Wepfer in 1657, and was 
followed by several other reports which developed into an understanding that CSDH 
involved a blood clot beneath the dura, surrounded by membranes (D'Errico & German, 
1930). It was Virchow, in 1857, who described the pathophysiology of CSDH as 
“pachymeningitis haemorrhagica interna”, or chronic inflammation of the dura, leading to 
fibrin exudation and growth of new capillaries (D'Errico & German, 1930). This was 
counteracted by the theory that traumatic head injury caused bleeding from bridging veins 
overlying the brain which resulted in CSDH (Markwalder, 1981; Putnam & Cushing, 1925; 
Trotter, 1914; Yamashima & Friede, 1984). More recently, there is growing evidence to 
suggest that both inflammation and trauma may be important in CSDH pathophysiology, but 
the mechanisms occurring are still obscure. Indeed, each CSDH may form through different 
processes rather than there being one homogenous disease entity. The aim of this thesis is to 
interrogate the possible processes in CSDH formation and ascertain the main underlying 
drivers. The overarching hypothesis is that inflammation is crucial to the development of 
CSDH and that dexamethasone, an anti-inflammatory drug, is a treatment option which could 
lead to less requirement for surgical intervention. A greater understanding of the 
inflammatory processes occurring in CSDH could be applied clinically to help predict the 




surgical management where appropriate. The clinical data presented herein was obtained 
from patients recruited to a UK multi-centre randomised control trial of dexamethasone in the 
treatment of CSDH patients, namely the Dex-CSDH trial, which is detailed later.  
 
1.1.1 The subdural space  
In order to investigate the pathophysiology of a CSDH an understanding of the anatomy of 
the meninges is required.  The brain is covered by three layers of cerebral meninges: the pia 
mater (which closely invests the brain cortex), the arachnoid mater (which contains 
cerebrospinal fluid (CSF) bathing the brain) and finally dura mater (the tough outer shell of 
fibrous tissue separating the brain from the skull). In the normal physiological state the dura 
and arachnoid mater are closely adherent, however their morphology is such that they are 
prone to separation in pathological circumstances (Moskala et al., 2007). A CSDH allows a 
space to develop between these layers, the so-called “subdural space” and new membranes 
form within this space, encapsulating blood and fluid (Figure 1.1B).  
 
In 1946 Inglis performed a histological analysis of the lining of the subdural space and 
identified a layer of specialised, modified connective tissue cells (Inglis, 1946). These cells 
had two essential roles; they could phagocytose, and they could develop into fibro-cellular 
connective tissue. This latter role explains the source of the fibrous membrane which forms 
around the CSDH. A further histological study has named these “dural border cells” and 
confirmed their ability to form CSDH membranes (Figure 1.2) (Haines, 1991). 
 
 
Figure 1.2; representation of dural border cell layer involved in CSDH formation (reproduced from 
(Kolias, Chari, Santarius, & Hutchinson, 2014). 
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Although there is the potential to create a subdural space in any brain, the risk is greatest in 
the elderly, thus explaining the demographic affected by CSDH. This can be explained by 
cerebral atrophy (shrinkage), which is ubiquitous in the aging population (Fox & Schott, 
2004; Giorgio et al., 2010). As the brain atrophies it will sag inwards, applying a gravitational 
force on the dural border cells. This is likely to mean that minimal further force, such as 
trivial trauma or head movement, could lead to separation of these cells and that this physical 
disruption acts as a stimulus for creating subdural membranes. A recent review on the 
causation of CSDH suggested that it would not be possible for a CSDH to occur unless there 
is a pre-existing capacious subdural space (as seen with cerebral atrophy) (K. Lee, 2016). 
Hence, the authors suggested rebranding CSDH as a “degenerative” disease, rather than a 
traumatic one.  
 
Several studies have assessed the degree of brain atrophy on baseline trauma scans prior to 
the development of a CSDH. One showed that the brain atrophy index (CSF volume as a 
percentage of total intracranial volume) was significantly higher in the baseline scans 
compared to age-matched controls (Jeong et al., 2016). Two further studies have identified 
significantly greater subdural depths (measured from cortex to skull) in baseline scans 
compared to other head injury controls (Han et al., 2014; Ju et al., 2015). However, there is 
some conflicting data with one study identifying no significant relationship between 
measures of cerebral atrophy and CSDH formation (J. J. Lee, Won, Y., Yang, T., Kim, S., 
Choi, C. S., Yang, J., 2015).  
 
Cerebral atrophy and the potential subdural space do appear to be contributive factors in the 
developing a CSDH, but cannot be the entire story. If that were the case then many more 
elderly patients would develop a CSDH, and, as cerebral atrophy is constant and progressive, 
one would expect all CSDHs to be recurrent and persistent. Whereas in reality, the majority 
of CSDHs resolve following adequate treatment and late recurrence is rare. Overall, it is 
difficult to quantify the degree to which cerebral atrophy contributes to CSDH 
pathophysiology, but this will be explored further in chapter two. 
 
1.1.2 The role of trauma: transformation from ASDH and SDG 
As previously mentioned, many authors support the theory that the pathogenesis of a CSDH 
is solely secondary to trauma, with tearing of cerebral bridging veins, which are encompassed 
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within the dura mater as they traverse from the brain surface to the dural-venous sinuses 
(Markwalder, 1981; Ommaya & Yarnell, 1969). This is supported by evidence that these 
veins are particularly vulnerable as they enter the subdural space, where the vessel wall is 
thinner and less well supported (Yamashima & Friede, 1984). However, this theory is 
questionable, as even a slow venous haemorrhage would accumulate sufficiently quickly for 
a patient to become clinically symptomatic within hours to days at most; rather than four to 
seven weeks, which is the mean time from trauma to onset of CSDH symptoms (Gelabert-
Gonzalez et al., 2005; Stroobandt, Fransen, Thauvoy, & Menard, 1995). Further to this, only 
approximately 60% of CSDH patients report any recent trauma and it has been argued that 
the pattern of blood spanning the cerebral convexities is inconsistent with a source of 
bleeding entirely from bridging veins, which neighbour the medial venous sinuses 
(D'Abbondanza & Loch Macdonald, 2014; Gelabert-Gonzalez et al., 2005; Nakaguchi, 
Tanishima, & Yoshimasu, 2001; Santarius & Hutchinson, 2009). Finally, although a CSDH 
can contain areas of acute haemorrhage, many are almost entirely “old” haematoma, seen as 
homogenous hypodensity on CT (Figure 1.1A). This is not in-keeping with the idea of 
continuous acute venous haemorrhage as a source of CSDH expansion over time, which 
would be exemplified by a significant layer of hyperdensity within all CSDHs.  
 
This is not to say that acute haemorrhage from bridging veins is not involved in at least some 
cases of CSDH. High acceleration injuries lead to sufficient strain on the bridging veins to 
cause rupture and rapid accumulation of blood leading to an acute subdural haematoma 
(ASDH) (Crooks, 1991). Although ASDH occurs in the same anatomical space as CSDH, it 
is a very different entity with more severe trauma resulting in the rapid accumulation of 
blood. This results in more severe levels of associated brain injury, high levels of coma and 
mortality (Bullock et al., 2006). The demographics of patients affected are also markedly 
different, with only 4% of ASDHs aged over 60, compared with 88% of CSDHs (Asan, 
2018). Despite the different patient populations affected there is clearly some cross over 
between these conditions, with a proportion of ASDH later becoming CSDH. This occurs in 
patients who have conservative (non-operative) management of an ASDH, either because the 
collection is small enough or the patient considered too unfit for surgery. Elderly patients, in 
particularly, can also tolerate relatively large ASDHs, with limited neurological impact, and 
therefore surgery will likely be avoided if the patient is clinically alert and stable. This relates 
back to the high proportion of cerebral atrophy in the elderly, allowing more space in the 
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intracranial compartment to compensate for even relatively large haematomas. Following 
conservative management, an ASDH can form a CSDH over weeks to months, whilst others 
spontaneously resolve (Laviv, 2014; K. B. Lee, WK; Doh, JW; Bae, HG; Yun, IG, 1998). 
 
The literature on the rate of transformation from ASDH to CSDH is extremely varied and is 
likely to depend largely on the inclusion criteria involved in the study. Lee et al. reported on 
177 conservatively managed ASDHs with a mean age of 60.84, showing only 16 (9%) 
developed a CSDH within 3 months (J. J. Lee, Won, Y., Yang, T., Kim, S., Choi, C. S., 
Yang, J., 2015). Laviv et al. looked only at low velocity ASDHs in patients with a mean age 
of 77.5, with 43/95 (45%) developing subsequent CSDH at mean of 23.3 days (Laviv, 2014). 
Further studies have described 18-21% of ASDHs transforming into CSDHs (Izumihara, 
Yamashita, & Murakami, 2013; Lucke-Wold, Turner, Josiah, Knotts, & Bhatia, 2016). 
Follow-up imaging may also be helpful, as around 25% of ASDHs showed expansion at one 
month and 73% of these formed a subsequent CSDH (Lucke-Wold et al., 2016). Age and 
gender do not appear to influence likelihood of CSDH formation after ASDH, but increased 
size and associated midline shift of ASDH do (Laviv, 2014; J. J. Lee, Won, Y., Yang, T., 
Kim, S., Choi, C. S., Yang, J., 2015; Mathew, Oluoch-Olunya, Condon, & Bullock, 1993). 
This may be because larger ASDHs take longer to resolve and therefore are more likely to 
develop neomembranes and transform into chronic collections. Inglis reported that 
haemorrhage in the subdural space could initiate proliferation of the dural border cells, hence 
why an ASDH can stimulate growth into a CSDH (Inglis, 1946). However, many animal 
studies have shown that the presence of blood alone, in the subdural space, is not sufficient to 
initiate progression to a CSDH, so there must be other factors at play (D'Abbondanza & Loch 
Macdonald, 2014; D'Errico & German, 1930; Goodell & Mealey, 1963).  
 
It is important to understand that whilst only a limited proportion of ASDHs become CSDHs, 
reciprocally only a small number of CSDHs were ever ASDHs. This is a relatively new 
concept to some, who believe that all CSDHs were ASDHs to start with. However, chapter 
two reviews a series of CSDH patients who were scanned at the time of recent trauma, 
showing that only a proportion had evidence of ASDH. Such data can only now be collected 
due to the increase in easy-access CT scanning in all emergency departments, and the low 




For patients who do not have an ASDH, an alternative route to formation of a CSDH by 
subdural hygroma (SDG) has been suggested (K. Lee, 1998, 2004; K. Lee, Bae, Park, & Yun, 
1994; K. B. Lee, WK; Doh, JW; Bae, HG; Yun, IG, 1998; Liu, Bakker, & Groen, 2014; 
Murata, 1993; Ohno et al., 1987; S. H. Park et al., 2008). SDG, also called subdural effusion, 
is an accumulation of modified CSF in the subdural space, which also requires separation of 
the dura-arachnoid interface (at the dural border cell layer) (K. Lee, 1998; K. B. Lee, WK; 
Doh, JW; Bae, HG; Yun, IG, 1998; Liu et al., 2014). Many consider brain atrophy and SDG 
synonymous, however although the former can cause the latter, SDG is a defined 
pathological condition which can cause cerebral compression requiring operative 
management (K. Lee, 1998; K. Lee et al., 1994; Liu et al., 2014). The morphology of the 
skull and as such the varying dependent role of gravity has also been suggested to influence 
SDG development (K. Lee, 2004). 
 
SDGs have been shown to form following traumatic head injury and it is conceivable that 
trauma cleaves open the dural border cells without causing haemorrhage but allowing 
accumulation of CSF in the subdural space. This could then activate the cascade of events 
(see later discussion on inflammation) leading to subsequent formation of a CSDH. Ohno et 
al. reviewed 715 head injuries over five years and showed that 6% of patients developed a 
SDG within one week of trauma, although this increased to 30% in those aged over 65 (Ohno 
et al., 1987). Another study found that only 1.5% of patients admitted with a head injury 
developed a SDG that was not there on admission (Ahn et al., 2016). Between 12-47% of 
SDGs have been reported to expand rather than resolve, and as such develop into a CSDH 
(Ahn et al., 2016; K. Lee, 2004; Liu et al., 2014; Murata, 1993; Ohno et al., 1987; S. H. Park 
et al., 2008). Conversely, when looking at the number of patients with CSDHs, 15% (24 out 
of 160) have been found to have a preceding diagnosis of a SDG (S. H. Park et al., 2008). 
The mean time interval from traumatic SDG to CSDH diagnosis is around seven to eight 
weeks and risk factors include male gender and bilateral SDGs (Ahn et al., 2016; S. H. Park 
et al., 2008). In the case where MRI is performed, diffuse pachymeningeal enhancement on 
MRI is more common in patients whose SDGs become CSDHs, and therefore may be a 
prognostic indicator (Ahn et al., 2016).   
 
There is some biochemical data to support the theory of CSDHs developing from SDGs. 
Kristopf. et al showed beta-trace protein (bTP), a marker for CSF, was present in 94% of 
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CSDHs, whilst Park found it in 100% of 31 CSDHs (Kristof, Grimm, & Stoffel-Wagner, 
2008; K. S. Park, Park, Hwang, Kim, & Hwang, 2015). However, this was contradicted by 
Jafari et al, who measured an alternative marker of CSF (beta-2-transferrin) and found this 
was only present in 24% of patients (Jafari, Gesner, Koziol, Rotoli, & Hubschmann, 2017). 
This difference may be explained by an exogenous source of bTP, as it is also present in 
plasma and is increased in pathologies such as renal failure. 
 
A recent paper identified the presence of increased “CSF spaces” ipsilateral to subsequent 
CSDH locations on the original trauma scans, but only when the scans were reviewed 
retrospectively (Olivero, Wang, Farahvar, Kim, & Wang, 2017). Therefore, this may 
represent a source of missed opportunity in identifying patients at risk for developing a 
CSDH after head injury. As with an ASDH, the lack of prior imaging in all CSDH patients 
makes it is impossible to define exactly how many CSDHs originate as SDGs and to what 
extent this crosses over with cerebral atrophy. During chapter two and seven imaging 
correlations for SDG and cerebral atrophy in relation to CSDH pathology are explored.  
 
1.1.3 CSDH membranes; angiogenesis and fibrinolysis. 
A summary of factors discussed thus far, which contribute to CSDH formation including age 
(predisposing to cerebral atrophy) and trauma (leading to ASDHs and SDGs) are shown in 
Figure 1.3. Pharmacological anti-aggregation (AA) and anti-coagulation (AC) therapies are 
also potential risk factors for increasing bleeding risk, although some AAs such as aspirin 
have anti-inflammatory properties which may also be relevant (see section 1.4.3). The final 
common stem of the pathway is inflammation, which is discussed in section 1.2, but a crucial 
source of inflammation, and bleeding, are the CSDH membranes, discussed here.  
 
Figure 1.3; processes involved in CSDH pathophysiology. 
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As previously discussed, the CSDH membranes form between the normally closely opposed 
dura mater and arachnoid mater (Figure 1.1 & 1.2). Proliferation of dural border cells form 
two new membranes enclosing the subdural cavity, which fills with fluid and haematoma. 
High concentrations of type-1 (PICP) and type-3 (PIIINP) procollagen are present in this 
fluid and suggest a fibro-proliferative process occurs, similar to that seen in wound healing 
(Heula, Sajanti, & Majamaa, 2009; Sajanti & Majamaa, 2003). This process is likely to occur 
as part of an attempt to repair the separated and damaged dural border cells. However, the 
collagen synthesis outweighs its breakdown, leading to the continuous formation of a 
collagen matrix and hence formation of the new CSDH membranes, or neomembranes (Heula 
et al., 2009). Internal and external membranes are formed, which relate to the layers 
contiguous with the arachnoid and dura mater respectively. 
 
The internal membrane is reported as containing collagen and fibroblasts only, and is 
therefore relatively non-functional with respect to driving CSDH growth (Sato & Suzuki, 
1975). One histological study using a scanning electron microscope (SEM) identified 
occasional blood vessels in the internal membrane, but even these seem to disappear with 
maturation of the CSDH (Moskala et al., 2007).  The external membrane, however, is 
considered more crucial in driving CSDH growth. It contains layers of fibroblasts and 
collagen fibers with the addition of inflammatory cells such as neutrophils, lymphocytes and 
macrophages (Hara, Tamaki, Aoyagi, & Ohno, 2009; Moskala et al., 2007; Nanko et al., 
2009; Shono et al., 2001). Importantly there are numerous highly permeable capillaries with 
thin walls containing thin or absent basement membrane and lacking smooth muscle cells and 
pericytes (Moskala et al., 2007; Yamashima, Yamamoto, & Friede, 1983). Gap junctions are 
also abundant within the capillary walls, allowing continued migration of erythrocytes, 
leucocytes and plasma from these vessels into the CSDH cavity (Sato & Suzuki, 1975; 
Yamashima et al., 1983).  
 
Development of new vessels (angiogenesis) within the CSDH membranes, is mediated by 
several markers. This includes angiopoietins (Ang); a group of growth factors involved in 
regulating angiogenesis and vascular permeability. They have been reported to play an 
important role in permeability of normal brain membranes, the so-called blood-brain-barrier 
(BBB), and therefore it is unsurprising that they may also be implicated in CSDH membrane 
permeability (Helmy, De Simoni, Guilfoyle, Carpenter, & Hutchinson, 2011). The two 
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ligands, Ang-1 and Ang-2, have the same tyrosine kinase receptor (Tie-2) but opposing 
effects on angiogenesis (Jones, Iljin, Dumont, & Alitalo, 2001). Higher levels of Ang-1 are 
present in mature vascular beds with stable microvascular networks and low permeability, as 
seen in normal brain tissue (Hohenstein, Erber, Schilling, & Weigel, 2005). In contrast, the 
CSDH outer membrane has been shown to over-express Ang-2 mRNA, which is likely to 
represent on-going angiogenesis with destabilization of blood vessel structure (Hohenstein et 
al., 2005). Vascular endothelial growth factor (VEGF) is another important angiogenic 
growth factor (discussed in more detail in section 1.2), which can modulate Ang-2, with both 
elevated at the time of neovascularization following ischaemia (Zhang et al., 2002). Hence, 
Ang-2 and VEGF over-expression may be the driving force for the new, fragile vessel 
formation in the CSDH membrane. This network of fragile vessels is the primary source of 
haemorrhage and serum protein exudation contributing to progressive CSDH growth 
(Fujisawa, Nomura, Tsuchida, & Ito, 1998; Tokmak, Iplikcioglu, Bek, Gokduman, & Erdal, 
2007).  
 
Haemorrhage is an essential part of CSDH formation and involves two key biomolecular 
processes; coagulation and fibrinolysis. Activation of the coagulation cascade involves 
converting prothrombin to thrombin, the latter of which can then cleave fibrinogen into 
fibrin, allowing clot formation (Figure 1.4) (Chapin & Hajjar, 2015). Fibrinolysis is the 
converse process, whereby fibrin is broken down into fibrin degradation products (FDPs) and 
clot breakdown facilitated. Plasmin is required to activate fibrinolysis; it is formed from 
plasminogen by tissue plasminogen activator (tPA) (Chapin & Hajjar, 2015).  
 
A study utilising Cr-labelled erythrocytes showed that CSDHs contain, on average, 6.7% 
acute haemorrhage, and that all CSDHs contain at least some active haemorrhage, which is 
highest in patients presenting with worse neurological deficits and higher density on CT (Ito, 
Yamamoto, Saito, Ikeda, & Hisada, 1987). High levels of FDPs in CSDH fluid are thought to 
represent excessive fibrinolysis, promoting continued haemorrhage (Heula, Ohlmeier, 
Sajanti, & Majamaa, 2013; Ito, Yamamoto, Komai, & Mizukoshi, 1976; Nomura, Kashiwagi, 
Fujisawa, Ito, & Nakamura, 1994b; Shim, Park, Hyun, Park, & Yoon, 2007). The levels of 
fibrin and FDPs are also higher in certain CSDH subtypes; mixed density and layered 
(Nomura, Kashiwagi, Fujisawa, Ito, & Nakamura, 1994a). This may signify different 
bleeding frequencies in CSDHs over time, causing haematoma growth to vary and different 
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patterns of blood to appear on imaging. These patterns and their possible relevance to CSDH 
pathology and prognosis are discussed in the imaging chapter, chapter seven. 
 
Higher levels of plasminogen at initial operation have been identified in patients 
subsequently experiencing a CSDH recurrence (Weir & Gordon, 1983). This suggests that 
markers of hyper-fibrinolysis may be able to predict those at highest risk of recurrence and 
therefore help guide treatment and/or follow-up. Similar findings have shown that higher 
levels of tPA at initial surgery indicate a higher risk of recurrence (Katano, Kamiya, Mase, 
Tanikawa, & Yamada, 2006). The tPA has been shown to be produced by blood vessel walls 
in the CSDH external membrane, and soluble tPA can diffuse directly into the CSDH cavity 
(Ito, Komai, & Yamamoto, 1978). Thrombomodulin also enhances fibrinolysis, and has been 
found in high levels in CSDH fluid, again with a suggested source from the vessel 
endothelium within the membranes, and a possible link to increased recurrence rates in 
certain CSDH sub-types on imaging (Kitazono et al., 2012; Murakami et al., 2002).  
 
Paradoxically, the hyperfibrinolytic mechanism causing CSDH growth has also been 
exploited as a treatment during CSDH surgical evacuation, with tPA infusion into the 
subdural space used to aid haemtoma liquefaction and washout (Neils et al., 2012). This led 
to substantially increased post-operative drainage volumes and significantly lower recurrence 
rates, but was only performed on 15 patients so is not well validated. The success of this 
treatment is likely to hinge on the very short half-life of most tPA drugs. Thus, short-term 
fibrinolysis whilst the CSDH is under-going drained may be helpful whilst more chronic 
hyperfibrinolysis only contributes to CSDH growth. 
 
The external membrane shows evolutionary changes over time with inflammation causing 
progression to a more mature, so-called “scar” membrane (Gandhoke, Kaif, Choi, 
Williamson, & Nakaji, 2013; Moskala et al., 2007). This type of membrane is associated with 
higher haemtoma thickness and attenuation on CT and suggests that CSDH growth and 
haemorrhage increases as the membranes mature and organise (Gandhoke et al., 2013). Asan 
et al. showed that CSDHs containing acute or subacute components expand the most 
frequently and rapidly, thus exemplifying this late stage of escalating haemorrhage and 
growth (Asan, 2018). Protein exudation is also at its highest rate in patients with worse 
neurology and mixed density CSDH, and therefore likely occurs in tandem with the 
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progressive haemorrhage (Tokmak et al., 2007). Analysis of CSDH contents, including ratio 
of acute haemorrhage and correlations with findings on imaging will be explored in chapters 






















1.2 Inflammatory markers of interest in CSDH 
This thesis aims to investigate the hypothesis that the linchpin of CSDH formation is 
inflammation. A range of inflammatory mediators that may potentiate this are shown in Table 
1.1, and are the topic of interest in this thesis. CSDH expansion has been postulated to occur 
due to the continued cycle created by chronic inflammation which creates a hypoxic 
environment, stimulating further mediator production (Tsutsumi et al., 2017).  
 
Table 1.1; key inflammatory mediators that may play a role in CSDH inflammation 
Inflammatory 
mediators 
Finding in CSDH References 
Vascular Endothelial 
Growth Factor (VEGF)  
 
Pro-angiogenic factor. Very high 
levels in CSDH fluid and mRNA in 
membranes and neutrophils. 
(Hara et al., 2009; Hohenstein et 
al., 2005; Hong et al., 2009; Hua 
et al., 2016; Kalamatianos et al., 
2013; Nanko et al., 2009; Shono 





Present in outer membrane and 
CSDH fluid. Contributes to poor 
capillary integrity. 
(Hua et al., 2016; Jung et al., 
2006; Nakagawa, Kodera, & 
Kubota, 2000) 
Interleukin-1 a and b Pro-inflammatory markers important 
in acute TBI with very limited 
investigation in CSDH to date. 
(Hutchinson et al., 2007; Pripp & 
Stanisic, 2014) 
Interleukin-6 and 8 Pro-inflammatory markers elevated 
in CSDH fluid, particularly in 
recurrent CSDH. 
(Frati et al., 2004; Hong et al., 
2009; Kitazono et al., 2012; 
Pripp & Stanisic, 2014) 
Interleukin-10 Anti-inflammatory marker elevated 
in CSDH, higher levels may help 
prevent recurrence.  
(Pripp & Stanisic, 2014; Stanisic, 
Aasen, et al., 2012; T. Wada et 
al., 2006) 
TNF-a Reduced levels in CSDH. (Stanisic, Aasen, et al., 2012) 
Chemokines; 
MCP-1 and IP-10 
Raised in CSDH fluid, likely to 
contribute to pro-inflammatory. 
(Stanisic, Lyngstadaas, et al., 
2012) 






1.2.1 Vascular endothelial growth factor (VEGF)  
VEGF is a family of seven growth factors which are the most important pro-angiogenic 
factors, and are involved in potentiating microvascular permeability (Hoeben et al., 2004). 
All members of the VEGF family share a common domain and share two tyrosine kinase 
receptors (VEGF-R), but for the purpose of this study it is considered as one factor (Hoeben 
et al., 2004). There is a wealth of evidence that VEGF and VEGF-R are found in significantly 
higher concentrations in CSDH fluid compared with peripheral blood and CSF (Hara et al., 
2009; Hohenstein et al., 2005; Hua et al., 2016; Kalamatianos et al., 2013; Nanko et al., 2009; 
Shono et al., 2001; Weigel et al., 2001). The difference in CSDH levels of VEGF can be 
more than 28 times that found in serum, with example serum levels of 355 pg/mL compared 
to 10,277 pg/mL in the CSDH fluid (Shono et al., 2001). This difference is higher than that 
seen with any of the subsequent inflammatory markers discussed. 
 
The source of this VEGF is debated but studies have shown it may be produced by 
neutrophils from within the CSDH fluid, infiltrating macrophages or the vascular endothelial 
cells within the CSDH membrane (Hohenstein et al., 2005; Nanko et al., 2009; Shono et al., 
2001). Either way, an excess of VEGF is capable of inducing angiogenesis and excessive 
vascular permeability which may contribute to the on-going rebleeding implicated in CSDH 
growth (Shono et al., 2001). This is supported to some degree by correlations between VEGF 
concentrations and CSDH imaging-subtypes which are thought to reflect increased re-
bleeding (Hua et al., 2016; Nanko et al., 2009). Further to this, higher levels of VEGF 
expression in the external membrane has been associated with a higher probability of CSDH 
recurrence (Hong et al., 2009). The external membrane has also provided information on the 
potential downstream signaling pathways involved, with Ras-Raf-MEK-ERK molecules 
identified as important in the pathway of VEGF-induced angiogenesis and disruption of 
endothelial gap junctions (Osuka et al., 2012). 
 
Other factors directly related to VEGF are also likely to be important, such as prostaglandin 
E (PGE2), which is synthesised from arachidonic acid by cyclooxygenase (COX)-2 and 
regulates VEGF expression (Hoeben et al., 2004). High PGE2 levels have been found in 
CSDH fluid, and correlated to the time interval from trauma, suggesting it might be a useful 
marker for monitoring escalating inflammation in CSDH (Hara et al., 2009). Hypoxia-
inducible factor-1a (HIF-1a) is a transcription factor integral to the body’s response to 
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hypoxia, which also regulates VEGF and VEGF-R gene expression (Hoeben et al., 2004). 
Positive staining for this factor has been found in CSDH membranes and correlates with 
VEGF concentration, so may also be a potential target for assessing the inflammatory 
response (Nanko et al., 2009).  
 
Although VEGF has a pro-angiogenic and potentially pro-inflammatory role it also has a 
contrasting role in promoting wound repair and neuroprotection, with a role in neurogenesis 
and recovery from traumatic brain injury (TBI) (Helmy et al., 2011; Hoeben et al., 2004; 
Thau-Zuchman, Shohami, Alexandrovich, & Leker, 2010). This exemplifies the paradoxical 
roles some mediators have in both potentially harmful inflammation and beneficial repair 
mechanisms, making them a challenging therapeutic target.   
 
1.2.2 Matrix metalloproteinases (MMPs) 
MMPs are a family of proteolytic enzymes responsible for digesting the extracellular matrix 
and are released by endothelial cells during the early stages of vessel growth (Burbridge et 
al., 2002). They play a critical role in angiogenesis, and their inhibition leads to suppressed 
angiogenic response with fewer and shortened blood vessels (Burbridge et al., 2002). 
Increased MMP expression is seen in almost all human diseases involving inflammation, and 
contributes to the inflammatory processes by modulating other mediators (e.g. cytokines and 
chemokines) (Manicone & McGuire, 2008). MMP-proteolysis of endothelial cell junctional 
proteins also alters barrier permeability, aiding infiltration of inflammatory cells into 
otherwise privileged compartments such as across the blood-brain-barrier (BBB) (Manicone 
& McGuire, 2008). High MMP-9 and MMP-2 expression have been identified in 
haemorrhagic brain tumours with associated basement membrane disruption (Jung et al., 
2006). It was suggested that these MMPs, alongside VEGF, were responsible for the 
instability of newly formed blood vessels in the tumour, leading to a higher risk of 
haemorrhage. High levels of MMP-9 have also been identified in the peripheral blood, CSF 
and in peri-contusional brain fluid in acute TBI patients, and may be contributing to BBB 
breakdown and hence brain oedema (Gong et al., 2012; Grossetete, Phelps, Arko, Yonas, & 
Rosenberg, 2009; Guilfoyle et al., 2015) 
 
Two studies examining MMPs in CSDH membranes and fluid have highlighted MMP-1, -2 
and -9 as being present and likely factors contributing to the formation of fragile, leaky 
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capillaries causing haemorrhage into CSDHs (Hua et al., 2016; Nakagawa et al., 2000). The 
levels of MMP-2 and -9 also correlated with VEGF concentration, suggesting a combined 
angiogenic process (Hua et al., 2016).  
 
1.2.3   Cytokines  
Cytokines are a crucial part of the body’s immune response. They are small, inducible 
proteins that are released by all cell types involved in the inflammatory response. Different 
families of cytokines are described, based on their structure and receptor-type, with 
chemokines being a sub-family specifically involved in leukocyte recruitment. It is difficult 
to know the relevance of each individual cytokine as it is well recognised that they work in 
cascades, influence one another, can compete for receptors and act antagonistically or 
synergistically. A gross analysis of pro- and anti-inflammatory cytokines in CSDH, shows 
they are both raised in CSDH fluid compared with serum, but that the balance is significantly 
more pro- than anti-inflammatory (Pripp & Stanisic, 2014; Stanisic, Aasen, et al., 2012). It is 
important to consider the balance of both pro- and anti-inflammatory molecules, and how this 
changes over time. Not all inflammatory markers are detrimental all of the time and certain 
markers which are perceived to be harmful may be required in reparative processes at later 
time points. However, there is evidence that elevated levels of many cytokines (such as IL-1, 
IL-6, IL-8 and TNF-a) have been associated with worse outcomes following TBI, therefore 
they may also be valuable in predicting outcome in CSDH (Rodney, Osier, & Gill, 2018).  
 
Interleukin 1 (IL-1)  
IL-1 was the first cytokine to be discovered, and although 11 different molecules compose 
the family (IL-1a, IL1-b, IL-18, IL-33, IL-36a, IL-36b, IL-36g, IL-1Ra, IL-36Ra, IL-38, IL-
37), often only IL-1a and -1b are considered when referring to IL-1 (Garlanda, Dinarello, & 
Mantovani, 2013). These two ligands have very similar biological properties which are 
considered pro-inflammatory and they act on the same receptor, IL-1R1.  
 
IL-1a mediates the early phase of inflammation and it is present as a precursor in astrocytes, 
which is released when cell death via necrosis occurs (Garlanda et al., 2013). It is then 
immediately active and behaves as an “alarmin” for the inflammatory cascade of cytokines 
and chemokines to begin. IL-1b is also a precursor but requires cleavage with caspase-1 to 
release the activated form into the extra-cellular space (Garlanda et al., 2013). It is produced 
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by haematopoetic cells such as blood monocytes, macrophages, dendritic cells and brain 
microglia. Both play a role in the adaptive immune response by enhancing the function of B 
and T cell subsets and activate neutrophils, monocytes and macrophages as part of the innate 
immune response (Sims & Smith, 2010). The IL-1R1 receptor can be blocked by binding of 
IL-1ra which inhibits the actions on IL-1 and therefore potentially has an anti-inflammatory 
effect (Hutchinson et al., 2007; Rothwell & Luheshi, 2000). IL-1 activity can also be reduced 
by binding it to an alternate receptor, IL-1RII, which is a decoy receptor with no onward 
signaling, and has been shown to be induced by dexamethasone, exerting an anti-
inflammatory effect (Colotta et al., 1993).  
 
When assessing the cerebral response to TBI, IL-1a and IL1-b and their receptor activation 
has been considered important. Mouse studies have demonstrated that inhibition of IL-1b can 
results in reduced microglial activation and infiltration with neutrophils and T cells, which 
may relate to reduction in hemispheric tissue loss and cognitive decline (Clausen et al., 
2009). This is supported by human TBI studies which have correlated high levels of IL-1ra 
with a more favourable neurological outcome than patients with low levels (Hutchinson et al., 
2007). IL-1ra/IL-1b ratio was also significantly higher in patients with a favourable outcome 
and it is suggested that this ratio may relate to the balance between the patients pro- and anti-
inflammatory state. Early clinical and pre-clinical studies have supported IL-1ra as a 
potentially protective treatment against brain injury from conditions such as stroke and 
subarachnoid haemorrhage, which drives continued interest in this molecule (Brough, 
Rothwell, & Allan, 2015). Despite this, there has been relatively little focus on IL-1 in 
CSDH. Only one study has measured IL-1b and perhaps surprisingly the levels were 
significantly lower in CSDH fluid when compared with serum (Pripp & Stanisic, 2014). This 
study also looked at IL-1ra, and found no significant difference in levels when comparing 
serum and CSDH fluid. No studies have reviewed IL-1a. If inflammation is considered more 
critical than trauma in the formation of a CSDH, then this may explain why the role of IL-1 is 
very different, this will be explored further in the neurochemistry work in this thesis. 
 
Interleukin 6 and 8 (IL-6 and IL-8) 
IL-6 and IL-8 are being discussed together because in many conditions their production is 




IL-6 is an important inflammatory cytokine secreted by a variety of cells including 
fibroblasts, monocytes and endothelial cells (Benveniste, 1998). It has a key role in the acute 
response to inflammation, promoting B and T cell differentiation, platelet production, acute 
phase protein induction and can enhance leukocyte recruitment by upregulating chemokines 
adhesion molecules (Benveniste, 1998; Kishimoto et al., 1992). It is released in response to 
soft tissue trauma and haemorrhage, and dysregulated IL-6 has been linked to autoimmune 
diseases and cancer (Ayala et al., 1991; Kishimoto et al., 1992). It is also recognised to have 
some neurotropic and neuroprotective effects, particularly within the field of TBI 
(Benveniste, 1998; Helmy et al., 2011).  
 
IL-8 is from a family of small, polypeptide cytokines that have pro-inflammatory and 
reparative properties (Oppenheim, Zachariae, Mukaida, & Matsushima, 1991). It is 
classically recognised as a neutrophil-chemoattractant, with IL-8 acting as a stimulus to draw 
neutrophils, and other inflammatory cells carrying the IL-8 receptor, to the site of IL-8 
release (Oppenheim et al., 1991). Conversely, it has also been shown to act in an anti-
inflammatory manner, limiting the extent of leucocyte adhesion to vessel walls at sites of 
inflammation (Gimbrone et al., 1989). It is certainly known to be able to modulate its own 
receptor expression, and this may be important in controlling response to inflammation. More 
latterly IL-8 has also been recognised to play a key role in angiogenesis, with production 
from endothelial cells, leucocytes and fibroblasts resulting in capillary tube formation, 
endothelial cell proliferation and MMP-2 release (Li et al., 2005).  
 
Both IL-6 and IL-8 have been identified as being significantly elevated in CSDH fluid (Frati 
et al., 2004; Hong et al., 2009; Kitazono et al., 2012; Stanisic, Aasen, et al., 2012). The JAK-
STAT transcription factors have been identified in external membranes as the potential 
down-stream signaling pathway regulated by the IL-6 (Osuka et al., 2016; Osuka et al., 
2013). Most significantly, high levels of both IL-6 and IL-8 have been correlated with 
increased risk of CSDH recurrence, and the related imaging features of recurrence (Frati et 
al., 2004; Hong et al., 2009). As discussed, whilst these cytokines can be considered pro-
inflammatory, they also have protective functions. Therefore, it is difficult to know whether 
high levels in patients with recurrence signifies that they are the driving force for CSDH 
expansion or whether they are indicative of the protective response occurring in reaction to 
an expanding CSDH.  A lower risk of recurrence has been correlated with increased levels of 
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anti-inflammatory cytokines (i.e. IL-10) (Pripp & Stanisic, 2014; Stanisic, Aasen, et al., 
2012). Therefore, the overall balance of cytokines may be useful in predicting the risk of 
recurrence. Cytokine patterns have also been correlated with the time interval since injury 
and it may be this, and hence the stage of the inflammatory cycle, that is actually important in 
predicting recurrence (Pripp & Stanisic, 2014; Stanisic, Aasen, et al., 2012). 
 
Interleukin 10 (IL-10) 
Considered an anti-inflammatory cytokine, IL-10 has a role in deactivating T cells, 
monocytes and macrophages and reducing subsequent pro-inflammatory cytokines 
production (e.g. IL-1) (Moore, O'Garra, de Waal Malefyt, Vieira, & Mosmann, 1993; 
Seymour & Henderson, 2001). In one study on CSDH patients, the majority were found to 
have low (<60 pg/ml) rather than high (>200 pg/ml) concentrations of IL-10 (T. Wada et al., 
2006). The lower concentrations were also associated with lower concentrations of IL-6 and -
8 suggesting there is a reciprocal response of anti-to pro-inflammatory cytokines in the 
body’s attempt to control inflammation. Some reports have suggested consistently raised 
levels of IL-10, as well as the anti-inflammatory cytokine IL-13, when comparing CSDH 
fluid with serum (Kitazono et al., 2012; Stanisic, Aasen, et al., 2012). As cytokines are 
known to vary in their temporal profile, the likelihood is that levels will vary between 
patients depending on the stage of inflammation at the time of sampling. Different inclusion 
criteria for studies and time patterns from trauma to surgery might be important. Observing 
the relative levels of cytokines at more than one time-point would be helpful in clarifying the 
patterns occurring. This thesis aims to obtain such data for the first time, with inflammatory 
marker analysis at multiple time points from operation up to three days post-operatively (see 
chapters five and six).   
 
Tumour Necrosis Factor (TNF-a) 
TNF-a is widely accepted as a pro-inflammatory cytokine which has two receptors, one of 
which is also linked to the activation of nuclear factor kappa B (NFkB), a family of 
transcription factor proteins involved in apoptosis (Casault et al., 2018) and other 
inflammatory processes. As well as relating to cellular apoptosis and necrosis, TNF-a has 
been identified to have a range of effects specifically related to TBI, including changes in 
endothelial permability, cerebral oedema and translocation of leucocytes (Casault et al., 
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2018). The resultant affect appears to be an increased mortality and poor outcome in TBI 
patients who have elevated levels of TNF-a (Casault et al., 2018).  
Only one study has assessed TNF-a in CSDH fluid and found reduced levels compared to 
serum, but very little is known about its interaction with other cytokines and how this relates 




Chemokines are small proteins, often released in response to cytokines, which are responsible 
for trafficking of cells such as monocytes, neutrophils and lymphocytes, to the site on 
inflammation (Deshmane, Kremlev, Amini, & Sawaya, 2009).  
 
Monocyte chemoattractant protein-1 (MCP-1), also called Chemokine ligand 2 (CCL2), as 
the name suggests is responsible for attracting monocytes and can be produced by cell types 
such as endothelial and fibroblasts but mostly by the monocytes themselves (Deshmane et al., 
2009). The activity of monocytes can be varied and includes macrophage-mediated 
angiogenesis, which may also be relevant to CSDH pathophysiology (Deshmane et al., 2009). 
Raised levels of MCP-1 have been identified in human CSF in the early stages following 
TBI, and mouse models suggest the associated macrophage accumulation with MCP-1 may 
contribute to secondary brain injury (Semple, Bye, Rancan, Ziebell, & Morganti-Kossmann, 
2010). Other mouse studies looking at different types of cortical brain injury have shown 
rapid accumulation of macrophages after injury with associated increased levels of MCP-1, 
Interferon gamma-induced protein-10 (IP-10) and macrophage inflammatory protein (MIP-1) 
mRNA expression (Hausmann et al., 1998). IP-10, also called chemokine ligand 10 
(CXCL10), can attract both monocytes and T lymphocytes, whilst MIP-1a and b, also known 
as chemokine ligand 3 (CCL3), attract different types of lymphocyte to the site of 
inflammation (Schall, 1993; Taub et al., 1993).  
 
Only one study has assessed MCP-1 and IP-10 in CSDH and found both to be in higher 
concentrations in CSDH compared to serum, but little is known about how they interact with 
other chemokines and cytokines (Stanisic, Lyngstadaas, et al., 2012). No previous studies 




1.3 Imaging and CSDH recurrence 
 
Application of CT in clinical CSDH diagnosis is ubiquitous, therefore whilst other imaging 
techniques such as magnetic resonance imaging (MRI) may provide more detailed 
information (Hosoda, Tamaki, Masumura, Matsumoto, & Maeda, 1987), CT has more 
clinical relevance. Overall, CT is a reliable tool for visualising a CSDH and provides 
information on the volume, density and impact (mass effect) of the CSDH on underlying 
brain (Figure 1.5). 
 
 
Figure 1.5; example CT of CSDH, areas of high density (white) and low density (black) and mass 
effect exerted on underlying brain causing compression of normal brain structures.  
 
On normal CT imaging the structures found within the intracranial cavity include grey 
matter, white matter and cerebrospinal fluid (CSF). Each of these have different densities on 
CT, as measured in Hounsfield units (HU) (Cala, Thickbroom, Black, Collins, & Mastaglia, 
1981). In general blood appears as “hyperdense”, or white, in relation to surrounding tissues, 
but the density gradually decreases as clotted blood ages, and can eventually overlap with 
that of grey matter, making distinguishable boundaries difficult (Table 1.2) (Ito et al., 1984; 
Nowinski et al., 2014). This commonly occurs in CSDH, where the haematoma can be 
classified as “isodense” and hence be of a very similar density to underlying grey and white 
matter. Very high density areas can also represent either acute haemorrhage or membranes, 
which can also appear white, but usually have more of a “trabecular” pattern, as seen in 






Table 1.2; density of white matter, grey matter and haematoma on CT. 
Substance Mean x-ray absorption density 
(HU) 
Reference 
White matter 28 - 30  (Cala et al., 1981; Nowinski et 
al., 2014)  
Grey matter 33 - 37 (Cala et al., 1981; Nowinski et 
al., 2014) 
IVH/ICH in acute stroke 
patients 
59  (Range 25-88); 
60 day one to 53 day eight+ 
Nowinski et al. 2014 
CSDH 15 - 50  (Ito et al., 1984) 
(IVH = intraventricular haemorrhage, ICH = intracerebral haemorrhage). 
 
Several previous studies have described how the pattern of density within a CSDH on CT 
relates to different stages of pathological growth and therefore recurrence risk (Huang, Lin, 
Lu, & Chen, 2014; Jack, O'Kelly, McDougall, & Findlay, 2015; Nakaguchi et al., 2001; 
Ohba, Kinoshita, Nakagawa, & Murakami, 2013; Stanisic & Pripp, 2017; Yamamoto et al., 
2003; Yan, Yang, & Huang, 2018). However, the classification of density patterns is entirely 
subjective and varied between published studies making comparison of the findings 
challenging, and at times causing conflicting results. With a large cohort of patients recruited 
to the Dex-CSDH study with CT imaging available, this provided the opportunity to assess 
density patterns in detail and relate the findings to an objective computed-automated 
quantification of density. This is discussed in further detail in Chapter seven.  
 
Imaging findings can also reflect the histology of CSDH membranes and relate to the clinical 
state of the patient at presentation. One study showed how more mature membranes (with 
scarring) correlated with hypodense haematomas, whilst immature membranes had more 
acute bleeding (hyperdensity) and was associated with a worse clinical state (Gandhoke et al., 
2013).  The authors postulated that more immature membranes represented an earlier stage in 
the inflammatory cycle which was more rapidly expanding, hence the associated worse 
clinical presentation (Gandhoke et al., 2013).  
 
Finally, imaging is necessary to diagnose reaccumulation, or recurrence, of a CSDH, rates of 
which have been reported to range from 6.1% - 22%, (Baechli et al., 2004; Berghauser Pont, 
Dammers, Schouten, Lingsma, & Dirven, 2012; Brennan et al., 2017; Gelabert-Gonzalez et 
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al., 2005; Goto et al., 2015; Santarius & Hutchinson, 2009; Stroobandt et al., 1995), with an 
average time period to recurrence around 35 days in one series on 414 patients (Goto et al., 
2015). Application of a post-operative subdural drainage has been a significant factor in 
reducing recurrence rates in the last decade, reducing them to an average of 9% from a recent 
national UK audit (Almenawer et al., 2014; Brennan et al., 2017; Liu et al., 2014; Santarius 
& Hutchinson, 2009). Several studies have shown a higher recurrence rate in older patients 
(i.e >70 years old) compared with younger patients (Gelabert-Gonzalez et al., 2005; 
Stroobandt et al., 1995). The cause of this is not well defined but may be related to poorer 
brain re-expansion in the elderly. Certainly, higher residual post-operative volumes, which 
could be considered a corollary of poor brain re-expansion, have been linked to a higher 
recurrence risk (Stavrinou et al., 2017; Yan et al., 2018).  
 
There is some debate about whether routine post-operative imaging is helpful in predicting 
CSDH recurrence. Some clinicians advocate a routine post-operative CT to get a baseline 
understanding of the extent of CSDH evacuation and rule-out complications, whilst others 
suggest that it is unnecessary radiation with no practical implications unless the patient has 
clinically deteriorated. Residual CSDH on post-operative imaging is common place, seen in 
43-78% of patients, is normally resolved by day 40 post-operatively, and is not correlated 

















1.4 Pharmacological treatments and CSDH 
For patients who become symptomatic from CSDH, which can range from headaches, to 
neurological deficits and finally coma, surgery is often considered the mainstay of treatment. 
In cases where patients are critically unwell they require emergency evacuation of the CSDH 
to resolve the acute decompensation due to raised intracranial pressure. However, there is a 
large cohort of patients who are clinically stable with appearances of CSDH found on 
imaging who would be appropriate for a more conservative treatment pathway, such as a drug 
therapy. There is also the risk of CSDH recurrence in the surgically treated patients, and 
therefore the opportunity to implement additional peri-operative therapies targeted at 
preventing recurrence and further surgery. Scientists have sought to discover drugs which 
influence the inflammatory pathophysiological processes involved in CSDH discussed 
earlier, in the hope that they can provide a conservative and potentially preventative 
treatment option for CSDH. These therapies will be further discussed further here.  
 
1.4.1 Dexamethasone 
Steroids have long been used in the context of CSDH, and in 1974 it was summarised that 
steroids aid the resolution of CSDH, supporting medical management rather than surgery in 
some cases (Bender, 1974). Dexamethasone is a synthetic version of naturally-occurring 
corticosteroid hormone, and was first made in 1958 and heralded as a potent anti-
inflammatory drug (Arth et al., 1958). In 1976 Glover and Labadie used an experimental rat 
model of CSDH to show that dexamethasone could inhibit the formation of an expanding 
encapsulated haematoma from implanted blood clot, which did form in 47% of the untreated 
rats (Glover & Labadie, 1976). They suggested that dexamethasone inhibited the 
inflammatory response and hence the process driving membrane development, the latter of 
which was an essential source of continued haemorrhage allowing CSDH growth.  
 
In 2005, Sun. et al showed that dexamethasone could be successfully employed as a 
conservative treatment option, with 25/26 patients who received dexamethasone and no 
surgery experiencing complete CSDH resolution (Sun, Boet, & Poon, 2005). Several other 
studies have supported these findings of successful conservative management but also shown 
reductions in recurrence in surgical patients treated additionally with dexamethasone 
(Berghauser Pont, Dammers, et al., 2012; Delgado-Lopez et al., 2009; Dran, Berthier, 
Fontaine, Rasenrarijao, & Paquis, 2007; Qian, Yang, Sun, & Sun, 2017; Thotakura & 
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Marabathina, 2015). However, further level one evidence is still needed to support the 
implementation of dexamethasone in improving long term outcome for CSDH patients 
(Berghauser Pont, Dirven, Dippel, Verweij, & Dammers, 2012).  
 
It is well recognised that the anti-inflammatory effect of corticosteroids is mediated through 
gene expression, altering transcription of inflammatory proteins such as cytokines and 
chemokines (Barnes, 1998; Czock, Keller, Rasche, & Haussler, 2005; Dietrich, Rao, 
Pastorino, & Kesari, 2011; Dinarello, 2010). Other signaling pathways involved in 
inflammation and membrane function are also targeted and there is a significant effect on 
differentiation and function of immune cells, such as B and T cells, dendritic cells and 
macrophages (Coutinho & Chapman, 2011; Czock et al., 2005; Dietrich et al., 2011). Some 
clinical studies have identified mediators that reflect the anti-inflammatory mechanisms of 
steroids in the brain, such as tuberculous meningitis patients showing decreased MMP-9 
levels in CSF following administration of corticosteroids (Green et al., 2009). Cerebral 
extracellular fluid (brain microdialysate) in brain tumour patients receiving dexamethasone 
has also shown significantly increased concentrations of anti-inflammatory mediators such as 
IL-1ra and tissue inhibitor of metalloproteinase-1 (TIMP-1) (Marcus, Carpenter, Price, & 
Hutchinson, 2010). 
 
Despite the role of dexamethasone as an anti-inflammatory, since the 1960s its primary 
application in neurosurgery has been in the treatment of cerebral oedema (Maxwell RE, 
1972). Originally the focus was on cerebral oedema secondary to brain tumours but also 
included oedema following TBI or haemorrhage (French, 1966; Maxwell RE, 1972). Whilst 
its efficacy in improving oedema related to tumours has remained, it benefits vary depending 
on the underlying pathology and it is now considered harmful in the context of TBI (Edwards 
et al., 2005). Steroids continue to be used to reduce oedema in other conditions such as spinal 
cord compression and high-altitude pulmonary and cerebral oedema (Siegal, 1995; Stream & 
Grissom, 2008).  
 
The suggested mechanism of action of dexamethasone in reducing cerebral oedema is a 
reduction in vascular permeability at the BBB through modification of capillary endothelial 
cells and regulation of tight junctions via expression of the occludin gene (Andersen, 
Haselgrove, Doenstrup, Astrup, & Gyldensted, 1993; Andersen & Jensen, 1998; Forster et 
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al., 2005; Ostergaard et al., 1999). This all leads to “tightening” of the BBB and hence 
difficulty for fluid, but also other inflammatory cells such as leucocytes, to enter the brain. It 
is plausible that dexamethasone has the same effect on the vascular endothelium of the 
“leaky” blood vessels seen in CSDH membranes, thereby reducing fluid exudation and 
bleeding and allowing resolution of the collection. The anti-inflammatory effect of 
dexamethasone is a more commonly accepted explanation for its role in CSDH, but as this 
has never been tested at a molecular level, the true mechanism remains unknown.  
 
One of the major drawbacks of steroid therapy is the significant side-effect profile seen with 
systemic application, a challenge which may out-weigh the benefits of its use (Prud'homme, 
Mathieu, Marcotte, & Cottin, 2016; Weissman, Dufer, Vogel, & Abeloff, 1987). Brain 
tumour studies have shown that the toxic effects of dexamethasone are dose-related, and 
lower daily doses (4 mg compared to 16 mg) and courses shorter than 28 days reduce this risk 
significantly (Vecht, Hovestadt, Verbiest, van Vliet, & van Putten, 1994). Dosing must also 
take into consideration the pharmacokinetic and dynamic properties of dexamethasone. It has 
very good oral bioavailability (76-90%) and high potency but a relatively short plasma half-
life of 4-4.7 hours (Czock et al., 2005; Meikle & Tyler, 1977). It only takes 1-1.5 hours to 
reach its peak plasma concentration, hence the rapid clinical effect, but is considered a long-
acting steroid with a biological half-life of 36-54 hours (Czock et al., 2005; Nicolaides NC, 
2018). Several trials to establish the evidence for dexamethasone efficacy, and appropriate 
administration and dosing, for CSDH treatment are on-going throughout the world, including 
that which is discussed throughout this PhD; the Dex-CSDH trial (Emich et al., 2014; 
Henaux, Le Reste, Laviolle, & Morandi, 2017; Kolias et al., 2018; Miah et al., 2018). 
 
1.4.2 Other drugs investigated as CSDH therapies 
Dexamethasone is not the only drug that has been used as a treatment for CSDH, and several 
others are currently under investigation but are yet to show as much promise. These are not 
investigated in this thesis, but the data on inflammatory pathways may be useful in 
understanding the mechanisms of actions of these alternative drugs. 
 
Atorvastatin, classically known as a cholesterol-lowering drug, has been suggested to have a 
range of properties relevant to CSDH such as anti-angiogenesis (inhibiting VEGF and IL-8), 
anti-inflammatory (reducing TNF-a and MCP-1) and even fibrogenic effects by reducing 
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collagen deposition (Araujo, Rocha, Mendes, & Andrade, 2010; Dulak et al., 2005). Recent 
publication of a large study on 196 Chinese patients randomised to 20mg atorvastatin or 
placebo found reduced haematoma size and surgical intervention rates in the atorvastatin arm 
(Jiang et al., 2018). This study was limited by a large list of exclusions and only recruited 
patients with a mild-moderate CSDH from out-patient clinics, many of whom would never 
have needed any treatment, as exemplified by only a 23.5% surgical intervention rate in the 
placebo arm. A further retrospective, observational study has suggested that peri-operative 
administration of atorvastatin may reduce recurrence (Tang et al., 2018), but well-designed 
randomised studies are needed to fully understand if atorvastin if useful in large, 
symptomatic CSDH.  
 
Angiotensin Converting Enzyme (ACE) inhibitors may also help regulate some inflammatory 
markers as part of their primary application in coronary artery disease, where inflammation is 
involved in plaque rupture (da Silva, Fraga-Silva, Stergiopulos, Montecucco, & Mach, 2015). 
One early study suggested this could lead to lower recurrence rates in CSDH, possibly 
through reduction in VEGF (Weigel, Hohenstein, Schlickum, Weiss, & Schilling, 2007). 
However, several further studies have reported contradictory findings with similar or even 
increased recurrence rates in patients on ACE inhibitors (Bartek et al., 2018; Neidert et al., 
2016; Poulsen, Munthe, Soe, & Halle, 2014)  
 
Finally, the anti-fibrinolytic drug tranexamic acid has been shown to reduce death due to 
haemorrhage in acute trauma patients, and therefore may also be relevant to CSDH (Shakur 
et al., 2010). One small study reviewed 21 CSDH patients treated with tranexamic acid, 
where only three patients required surgery, and all had complete resolution of the CSDH 
(Kageyama, Toyooka, Tsuzuki, & Oka, 2013). Currently there is an on-going prospective 
trial assessing tranexamic acid in CSDH management and the results of this are keenly 
awaited (Iorio-Morin, Blanchard, Richer, & Mathieu, 2016).  
 
1.4.3 Anti-aggregant and anti-coagulant drugs 
The use of anti-aggregant (AA) medications, such as aspirin and clopidogrel, and anti-
coagulant (AC) medications, such as warfarin and novel oral anti-coagulants (NOACs) are 




Some studies report that AA/ACs do not increase the likelihood of an ASDH transforming 
into a CSDH, especially if coagulation is corrected at the time of ASDH (J. J. Lee, Won, Y., 
Yang, T., Kim, S., Choi, C. S., Yang, J., 2015; Lucke-Wold et al., 2016). Although patients 
given prothrombin complex concentrate do show faster resolution of their ASDH (Lucke-
Wold et al., 2016). However, other studies suggest that AA and ACs are risk factors for 
CSDH development and can increased haematoma growth in both ASDHs and CSDHs 
(Asan, 2018; Laviv, 2014; Yang & Huang, 2017). Interestingly, the risk of CSDH appears to 
be lower for aspirin, which has some anti-inflammatory function as a cyclooxygenase 
inhibitor, compared with other AAs (clopidogrel) and ACs (De Bonis et al., 2013). 
 
Whether AA and ACs increase the likelihood of CSDH recurrence and when they should be 
restarted is much debated, and a randomised trial in this area is needed (Aspegren, Astrand, 
Lundgren, & Romner, 2013; Fornebo et al., 2017; Gonugunta & Buxton, 2001; Nathan, 
Goodarzi, Jette, Gallagher, & Holroyd-Leduc, 2017; Poon & Al-Shahi Salman, 2018; Wang 
et al., 2017). The use of these mediations is reported in all patients recruited to the Dex-
CSDH trial, and this data is referred to throughout the sub-study analyses to assess their role 
















1.5 The Dex-CSDH trial 
The lack of high-quality, robust data to determine whether dexamethasone is an efficacious 
treatment for CSDH has led to wide variations in practice. As with all pharmacological 
therapies, one must weigh up the risks of the treatment with the potential benefits, and 
although the former are well known for steroids, the latter have not been well-established. 
Therefore, the Dex-CSDH trial was designed by a panel of experts to answer the question of 
whether giving dexamethasone to patients with a CSDH would improve their outcome at 6-
months. The details of the trial are discussed at length in chapter eight, but in essence it is a 
randomised, placebo-controlled trial of dexamethasone for patients admitted to a 
neurosurgical unit with a CSDH. The investigational medicinal product (IMP), 
dexamethasone or placebo, would be given as a weaning course over two weeks and the 
patients monitored closely for 30 days for potential side-effects (electronic Medicines 
Compendium). The trial was not prescriptive other treatment for the CSDH; therefore, the 
IMP could be given as either a stand-alone treatment or in combination with surgery. The 
inclusion criteria were deliberately broad to allow maximum inclusion of CSDH patients, 
unlike many CSDH trials which appear to have long exclusion lists and thus suffer with 
selection bias. The aim was for the trial to be pragmatic and therefore highly relevant and 
translatable to neurosurgical clinical practice.  
 
Many specialists contributed to the design and approval of this trial, and my role was to 
establish and run the trial throughout my PhD. As the Dex-CSDH trial research fellow I have 
been intimately involved in the day-to-day running of the trial, including site initiations, site 
queries, local recruitment, safety reporting and trial oversight. However, the clinical data 
produced from patients recruited to the trial is not a product of my own work, but rather that 
of the many clinical research nurses, neurosurgeons and other clinical trials staff involved at 
multiple sites across the UK. The final results of the trial are not presented here as the study 
will not complete until May 2019; although some blinded pilot data is discussed in chapter 
eight. During the running of the trial I established some independent sub-studies which ran at 
the sponsor site only (Cambridge). These sub-studies were my own design, with the support 
of supervisors, and were ethically approved to run in parallel with the main study. The 
findings from these sub-studies are the main focus of this thesis, and it is hoped that they will 




1.6 Thesis outline 
 
This thesis combines neurochemical analysis, imaging and clinical data to build a picture of 
the true pathophysiological events that take place during the development of CSDH. The 
purpose of this is to aid scientific understanding of the condition such that identification of 
primary and recurrent CSDH is more efficient, treatment options are better applied 
(particularly pharmacological agents such as dexamethasone) and ultimately patient 
outcomes improved.  
 
Chapter two explores the theory of two different developmental origins of CSDH, a 
distinction which is increasingly apparent with frequent imaging of elderly patients following 
head trauma. These different origins may have implications for the natural history of each 
CSDH and guide our understanding of the underlying biological processes occurring. Chapter 
three details the specific components within a CSDH, attempting to understand the age of the 
blood present and how this can be used to predict outcome following surgical drainage.  
 
Chapter four is primarily a methodological chapter which involved developing a process for 
analysing CSDH for the presence of dexamethasone to determine whether it enters the 
subdural space.  
 
In chapter five the primary hypothesis underlying the pathophysiology of CSDH is explored 
through examination of inflammatory markers within CSDH fluid. Intra-operative and post-
operative CSDH samples are interrogated for their inflammatory profiles and how this relates 
to CSDH recurrence. This links in closely to the findings discussed in chapter six, which 
relate the inflammatory profiles to dexamethasone exposure and other clinical factors.  
 
Chapter seven is an extensive review of the CT imaging characteristics of CSDH, how they 
are best defined, measured and what clinical relevance they have.  
 
Chapter eight includes my own reflections on the design and methodology related to the Dex-




Finally, chapter nine concludes the findings from all the chapters, bringing together an 
overarching theory on how CSDH forms, recurs and can be treated. This involves 
considerations for future research on CSDH and how both clinical and research practice can 
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Many people believe that trauma, resulting in a small acute subdural haematoma (ASDH), 
occurs at the start of all CSDHs and is simply forgotten. However, widespread access to 
computed tomography (CT) imaging has provided evidence against this and anecdotal 
clinical experience has demonstrated that some patients with normal imaging at the time of 
trauma can still develop a CSDH. This led to the hypothesis that a CSDH is the end-point of 
two distinct pathophysiological processes defined as; 
 
1. Acute transformed chronic subdural haematoma (CSDH-AT); patients where an ASDH 
precedes the formation of a CSDH, usually, but not exclusively, subsequent to trauma, as 
evidenced by serial post-traumatic imaging. 
2. De-Novo chronic subdural haemtoma (CSDH-DN); patients who develop a CSDH 
without evidence of a preceding ASDH on serial post-traumatic imaging. 
 
To prove this hypothesis, baseline imaging is required, and this is nearly always done in the 
context of recent trauma. It is conceivable that patients without reported trauma, and 
therefore no reason to have an ASDH, develop a CSDH through the “de-novo” route.  
Pathophysiologically, either delamination of the dural border cell layer or some kind of local 
shear forces are likely to be necessary to initiate the inflammatory cascade resulting in a 
CSDH. If acute haemorrhage is not necessarily present when this occurs, then this suggests 
relatively minor injury can be the trigger. This may mean that the dural border cells can also 
be injured by non-traumatic, seemingly innocuous stimuli, such as sudden brief changes in 
intra-cranial pressure (ICP) or CSF dynamics. This could include the combined effects of 
progressive cerebral atrophy, and movement (e.g. bending) causing strain on this important 
layer of cells. There are currently no studies assessing ways in which the dural border cells 
can be injured other than via a trauma, but this should be a focus for future research. 
Currently it is impossible to ascertain the initiating pathophysiology of a CSDH in non-
trauma patients as they have no prior imaging for interrogation, however by evidencing that 
CSDH-DN exists, this alternative pathway for CSDH development can be investigated.  
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Understanding the exact chain of events that occurs between normal trauma imaging and the 
development of a CSDH-DN is also challenging and can only occur through serial imaging of 
such patients. As discussed in chapter one, CSF leakage and subdural hygroma have been 
implicated in CSDH pathophysiology, therefore careful review of “normal” baseline imaging 
in CSDH-DN patients is necessary. Careful analysis of baseline cerebral atrophy may also be 
valuable in improving understanding on the degree to which this contributes to CSDH-DN 
formation.  
 
Understanding of these two pathophysiology sub-types may be important in guiding 
diagnosis, treatment and prediction of outcome in a heterogeneous CSDH population. This 
chapter will review the imaging from a sub-group of patients recruited to the Dex-CSDH 
study, in whom baseline imaging was available. This allows categorisation into the two 
CSDH sub-types and review of factors leading to this, such as atrophy and anti-coagulant 
exposure. It is hypothesised that as the pathophysiology differs, so might the natural course 
of the CSDH sub-types, thus enabling better prediction for the timing of development, 
recovery and even risk of recurrence from the differing sub-types. 
 
Finally, the diagnostic CSDH imaging of the two sub-types will be compared to identify 
whether there are distinguishing features of each sub-type, and thus if they can be categorised 
without the benefit of the baseline imaging. This would enable differences between the sub-
types to be investigated on a larger scale, in all patients with a CSDH who haven’t had the 









Out of 205 patients recruited to the Dex-CSDH study in Cambridge between 2015-2017, 46 
(22%) had cranial imaging prior to their CSDH diagnosis. This so called “baseline” imaging 
was undertaken due to minor head injury (within 10 days) or in one case, presentation with 
spontaneous headache. Subsequent CSDH diagnosis was within five months in all cases. The 
baseline imaging was not available for review in five cases therefore these patients were 
excluded and the remaining 41 patients comprised the study group for analysis. 
Demographics, baseline data and modified Rankin scale (mRS) scores dichotomised into 
favourable (0-3) and unfavourable (4-6) outcome at three and six months were collected for 
all patients in the study group. Breakdown of all mRS scores can be seen in chapter eight, this 
is a continuous assessment scale grading patients from asymptomatic (0) to dead (6) by 
increasing levels of disability. Dichotamising changes this binary categoriee, thereby making 
the comparison of groups easier, particularly when there are such small numbers of patients 
distributed among the categories. However, statistically there are also well-recognised 
drawbacks of dichotamising, as a great deal of information is lost and the assumption that 
there is a difference between the groups closet to the cut-off point (e.g. score 3 and 4) may 
not be correct, as it relies on there being a linear relationship between variables and outcome. 
It is important to consider this when looking at the final dichotamised groups. 
 
All baseline imaging was analysed for presence of ASDH ipsilateral to subsequent CSDH 
development, and if present, the patient was classified as a CSDH-AT, otherwise they were 
classified as a CSDH-DN.  
 
All scans containing an ASDH or a CSDH were measured using a by computer-assisted 
technique for total volume and mean density (see imaging chapter seven for methods). Any 
associated mid-line shift (MLS) was measured as the greatest distance from a central line 
dividing the cranium to the septum pellucidum (Figure 2.1). All CSDH scans were also 
classified by observation into either homogenous or mixed density (see imaging chapter 




Figure 2.1; example of midline shift measurement (red line). 
 
Baseline imaging for CSDH-DN patients was assessed for three measures of atrophy; 
bicaudate ratio (BCR), cortical atrophy scale (CAS) and subdural space depth (SSD). Further 
to this, each scan was classified for presence or absence of a subdural hygroma (SDG), and 
whether this was unilateral or bilateral. 
 
The bicaudate ratio (BCR) is an indirect measure of cerebral atrophy, which has been shown 
to have excellent interobserver agreement (van Zagtan, Kessels, Boiten, & Lodder, 1999). 
Whilst it correlates significantly with volumetric measures of brain atrophy, it may be a 
stronger measure of ventricular volume than overall atrophy per se (Jeong et al., 2016).  The 
BCR is calculated as the distance between the two caudate nuclei apices at the level they 
make the greatest indentation on the lateral ventricles, and dividing by the maximum width of 
the skull at the same level (Figure 2.2).  
 
 
Figure 2.2; example of bicaudate ratio measurements: (A) yellow line = distance between two 
caudate nuclei, (B) yellow line = maximum skull width at same level.  
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The cortical atrophy scale (CAS) is a descriptive scale of brain atrophy, with higher scores 
(moderate-severe atrophy) correlated to an increased risk of CSDH following head injury 
(Jeong et al., 2016). Examples of scoring from A to D in patients from this study can be seen 
in Figure 2.3; there was only one patient classed as A and this patient has frontal hygromas.  
 
 
Figure 2.3; example of images assessed with cortical atrophy scale: (A) none (but this patient does 
have bilateral frontal subdural hygroma), (B) mild, (C) moderate, (D) severe. 
 
An enlarged subdural space has also previously been associated with an increased risk of 
CSDH formation (Han et al., 2014; Ju et al., 2015). Therefore, the subdural space depth 
(SSD) was measured as the maximum distance from the cortex to the inner skull on any slice, 
as shown in Figure 2.4.  
 
 
Figure 2.4; example of bilateral subdural space depth measurements (blue lines in frontal region) 
 
Finally, the presence or absence of a SDG was made by blinded observer assessment. A SDG 
was considered present if the cortical surface was flattened and sulci obliterated, or if there 




Figure 2.5; (A) example of left subdural hygroma present at baseline and left CSDH-DN on day 61, 
(B) example of no subdural hygroma at baseline and left CSDH-DN on day 45.  
 
All linear and descriptive measurements (BCR, CAS, SSD, MLS, density) were undertaken 
using a Navigatium DICOM viewer by a single assessor (E Edlmann), as they have been 
previously validated. The volumetric analyses were undertaken using ITK-snap software 
(Yushkevich et al., 2006) also by a single assessor (E Edlmann), but validated by multiple 
assessors (results in chapter seven). 
  
Statistical analysis 
GraphPad Prism 7 was used for all statistical analysis. P values of <0.05 were considered 
significant. Continuous data (e.g. age) were compared using an unpaired t test if likely to 
results from a normal distribution and Mann-Whitney if not. Categorical data (e.g. gender) 
were tested with Fishers exact or Chi squared test, and Chi squared test for trend was used for 
multiple categories (such as GCS and mRS). Marginal significance is considered carefully, as 





2.3.1 Classifying CSDH-AT and CSDH-DN 
In 40/41 patients the baseline CSDH imaging was performed following head trauma. One 
patient experienced severe, sudden-onset headache prompting hospital attendance and 
baseline imaging revealed an idiopathic spontaneous ASDH.  
 
In 26/41 patients (63%), there was no blood, acute or chronic, ipsilateral to the side of 
subsequent CSDH development; these patients were classified as having a CSDH-DN. In 
15/41 patients (37%) there was presence of ASDH ipsilateral to the side of subsequent CSDH 
development; these patients were classified as having a CSDH-AT. 31/41 (76%) patients 
were scanned on the same day as the trauma/spontaneous ASDH, whilst the remaining 10 
patients had a delayed scan within 10 days of trauma (Table 2.1). Two of the 41 patients 
underwent initial magnetic resonance imaging (MRI) rather than CT, both of these cases 
were in the CSDH-DN group. 
 
Table 2.1: CSDH sub-types and timing of pre-CSDH imaging. 
No. of days from trauma  
(or spontaneous ASDH): 
All patients CSDH-DN CSDH-AT 
All patients 41 26 15 
Day 0 (same day) 31 19 12 
Day 1 (next day)  2 1 1 
Day 2 - 5 2 1 (D5) 1 (D2) 
Day 7 - 10 6 5 (D7 x2, D10 x 3) 1 
(D=day) 
 
Several case examples of CSDH-DN and CSDH-AT can be seen in Figures 2.6 & 2.7. One 
case of CSDH-DN had serial imaging displaying the phases in CSDH formation from a 
normal baseline CT 10 days after initial trauma (Figure 2.6C), to bilateral hygromas on day 
30, an isodense left subdural collection on day 51, to a symptomatic left-sided CSDH on day 
76. This appears to support the theory of hygroma in the early stages, followed by isodense 
expansion, presumably secondary to repeated haemorrhage and finally continued expansion 
into a larger CSDH. This reflects the process previously described, where numerous fragile 
capillaries in the CSDH membrane contribute to repeated micro-haemorrhage, rather than 
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one single haemorrhage as seen with an ASDH (Moskala et al., 2007). It also exemplifies 
how although the injury may be widespread, causing bilateral hygromas, only one side 
progressed to CSDH, suggesting a specific process or level of dural border cell injury is 
required to initiate the inflammatory processes leading to CSDH membrane formation. 
 
 
Figure 2.6; CSDH-DN case examples: (A) trauma scan normal day 0 and R CSDH day 112, (B) 
trauma scan bilateral frontal enlarged CSDH spaces, classified as atrophy, day 0 and L CSDH day 47, 
(C) trauma scan normal day 10, interval MRI small bilateral hygromas  day 30, interval CT 





Figure 2.7; CSDH-AT case examples: (A) trauma scan R ASDH day 0, R CSDH day 18; (B) Trauma 
scan L ASDH day 0, interval scan day 6 and large L CSDH day 13, (C) trauma scan L ASDH day 0, 
mixed density L CSDH with increased shift day 7, (D) trauma scan L ASDH day 0, Interval scan day 
14, repeat scan with larger L CSDH and increased shift day 17, (L = left, R = right). 
 
 
2.3.2 Baseline data 
There were no significant differences between the demographics for the CSDH sub-types, 
including age, gender and anti-platelet or anti-coagulant use (Table 2.2). However, the 
median time interval from trauma (or spontaneous ASDH, in one case) to CSDH diagnosis 
was significantly longer for CSDH-DN (median 57 days) than CSDH-AT (median 16 days) 
(Table 2.2).  
 
Table 2.2; summary of baseline characteristics and time from trauma  
 CSDH-DN CSDH-AT p value (significance) 
Total no. of patients 26 (63%) 15 (37%)  
Mean age 78 75 p = 0.2836 (NS) 
Gender 20 Male   (77%) 
6  Female (23%) 
8 Male    (53%) 
7 Female (47%) 
p = 0.4818 (NS) 
Patients on AP or AC 14 (54%) 9 (60%) p = 0.7021 (NS) 
Median time interval 
to CSDH diagnosis 
57 days 
(range 32-145 days) 
16 days 
(range 7-45 days) 
p < 0.0001 (S) 
 
(AP = anti-platelet, AC = anti-coagulant, NS = not significant, S = significant) 
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The distribution of time intervals can be seen in Figure 2.8, with all CSDH-ATs occurring 
between one and three weeks (21 days), apart from one outlier who was diagnosed 45 days 
later. This outlier was also the smallest ASDH, only 20cm3 which may go some way to 
explaining the prolonged time interval. The CSDH-DNs occurred up to 20 weeks (145 days) 
after trauma, and none before four weeks (32 days). This data is comparable to the literature 
regarding a CSDH transformed from an ASDH, with means of 15.3 to 23.3 days (Izumihara, 
Yamashita, & Murakami, 2013; Laviv, 2014). It is also logical that a CSDH-AT forms more 
rapidly as there is potentially greater disruption of the dural border cells layer with a volume 
of acute blood to both contribute to the CSDH volume and act as a constant stimulus for 
inflammation. Whereas in a CSDH-DN the entire collection must form from scratch and it 
may take longer for the inflammatory response to escalate. 
 
 
Figure 2.8; time from trauma (or spontaneous ASDH) in CSDH-DN and CSDH-AT. Line (median), 
bars (IQR), statistically significant differences denoted as P £ 0.0001 (****). 
 
 
2.3.3 Baseline imaging characteristics 
There were significantly more patients with bilateral CSDH-DN (9/26) than CSDH-AT 
(0/15) (p=0.0154, Table 2.3). However, in only five of the bilateral CSDH-DNs were both 
sides treated, with the other four having only the larger CSDH treated. Volumes were 
compared between sub-types for all treated CSDHs, excluding the untreated side of bilateral 
CSDHs and combining the volumes from each side if both sides were treated (see Table 2.3). 
This showed CSDH-DNs were significantly larger in volume than CSDH-ATs (p = 0.0111), 


















Table 2.3: diagnostic CSDH imaging  
 All 
CSDHs 
CSDH-DN CSDH-AT P value 
(significance) 
Laterality; all patients (n) 
i. Patients with unilateral CSDH 
ii. Patients with bilateral CSDH 
n = 41 
32 
9 
n = 26 
17 
9 




p = 0.0154 (S) 
 
















p = 0.0111 (S) 
 















p = 0.05 (S) 
 
















p = 0.4968 (NS) 
 




n = 26 
40.5 
n = 15 
43.1 
 
p = 0.3239 (NS) 













p > 0.9999 (NS) 
 







Figure 2.9; comparison of volume between CSDH-DN and CSDH-AT: (A) all CSDHs, (B) 
Unilateral CSDHs only. Line (median), bars (IQR), statistically significant differences denoted as P £ 
0.05 (*). 
 
All bilateral cases were excluded from MLS assessments due to the potential interaction 
between sides. There was very little difference in the mean midline shift between the CSDH 
sub-types (Figure 2.10). This suggests that although CSDH-DNs are significantly larger, they 
do not have an associated increase in MLS, either because they have more baseline atrophy to 
tolerate a greater CSDH volume, or because the longer time it takes to develop a CSDH-DN 
allows for better cerebral compensation and thus less MLS. Baseline atrophy cannot be 
compared between groups as it is too difficult to assess atrophy in the CSDH-AT who already 
have ASDH present on their baseline imaging.  
 
 



















































There was no significant difference in the mean density between CSDH-DN and CSDH-AT, 
and the grouping by density into homogenous or mixed density was almost the same for both 
sub-types (Table 2.3 and Figure 2.11). This suggests although they may have different 
pathological beginnings, both type of CSDH can similar patterns of either homogenous or 
mixed density by the time of diagnosis. 
 
 
Figure 2.11; comparison of CSDH density between subtypes, as per Table 3. 
 
ASDH imaging 
The majority of patients who developed a CSDH-AT had an isolated ASDH (13/15) on the 
baseline imaging, which was most commonly homogenous (Table 2.4). Two patients had 
mixed density ASDHs, both of which had much greater volumes and MLS than all the other 
ASDHs. Counter-intuitively the presence of low density in the acute setting can represent 
hyper-acute blood, thus these mixed density ASDHs may be continuing to bleed, resulting in 
larger ASDHs with more associated MLS. Alternatively, the mixed-density may suggest that 
there was pre-existing CSDH present and there has been a large bleed within this. As all the 
mixed density ASDHs were following significant trauma and contained the vast majority of 
acute blood they continue to be classified as CSDH-AT, with the caveat that it is possible 
there was pre-existing blood there. The presence of underlying brain injury (contusions and 
traumatic subarachnoid blood, as seen in Figure 2.7D), is also associated with greater MLS, 
despite similar volumes.  This is as expected, as the underlying parenchymal injury 
















Table 2.4; data on ASDHs from baseline imaging  
 No. of 
patients 
Mean MLS in mm 
 
Median ASDH volume 
in cm3 
All ASDHs 15 5.18 
(range 0 - 11.6) 
60.7 
(range 21.5 - 107.2) 
Homogenous ASDH 11 3.78 59.6 
Mixed density ASDH  2 11.5 110.1 
ASDH + underlying brain injury 2 6.51 53.7 
(ASDH = acute subdural haematoma, MLS = midline shift) 
 
ASDH volume and time to CSDH-AT diagnosis had a significant negative correlation 
(Spearman r = -0.6811, p = 0.0174, Figure 2.12A), which remains significant, but weaker 
with removal of an obvious outlier (Spearman r = -0.5386, p = 0.0493, Figure 2.12B). 
Therefore, larger volume ASDHs have a shorter time interval to CSDH-AT development than 
smaller ones, which is logical. However, there was no significant correlation between ASDH 
volume and subsequent CSDH-AT volume (Spearman r = 0.3536, p = 0.1964), therefore 
larger ASDHs do not necessarily form larger CSDHs. Again, this is logical, as although they 
are forming more rapidly, you would expect most patients to be diagnosed with a similar 




Figure 2.12; (A) correlation between ASDH volume and time interval to diagnosis, linear regression 
line y = -0.1492x + 25.17, (B) correlation between ASDH volume and time interval to diagnosis with 
removal of outlier, linear regression line y = -0.0729x + 18.62. 
 
 






































CSDH-DN and the subdural space  
The baseline imaging was assessed in 25/26 CSDH-DN patients, with one patient excluded 
due to the abnormal gantry prohibiting BCR calculation. The BCR, CAS, SSD and presence 
or absence of SDG was assessed in all remaining 25 patients, with results summarised in 
Table 2.5.  
 
An SDG was reported as present on baseline imaging in 14/26 (54%) CSDH-DN patients. In 
four patients this was unilateral, all of which correlated with the side of subsequent CSDH-
DN development. The remaining 10 SDGs were bilateral; five developed only a unilateral 
CSDH-DN, three developed a bilateral CSDH but only one side needed treating, and two 
developed a bilateral CSDH-DN where both sides were treated. Therefore, counting all sides 
individually, two-thirds of SDGs (16/24) developed into a CSDH-DN which required 
treatment, making a strong case for their role in CSDH-DN pathophysiology. 
 
Table 2.5; baseline trauma imaging measurement for CSDH-DN patients. 
 All 
CSDH-DNs 
No SDG SDG 
present 
p value comparing 
SDG and no SDG 
(significance) 
No. of patients  25 11 14  








p = 0.6867 (NS) 
Mean unilateral SSD (mm) 8.3 4.6 9.1 p < 0.0001 (S) 
Mean time from trauma to 







p = 0.0451 (S) 
Median CSDH-DN volume 
(cm3)* 
104.7 116.8 103.6 No (p = 0.5196) 




The SSD was significantly higher on sides that had an SDG present than those that didn’t (p 
< 0.0001) (Figure 2.13A). This suggests the SSD is a good objective measure of SDG 
presence. The limitation to this is the degree of pre-existing cerebral atrophy, as it is more 
difficult to measure an SDG in an already atrophic brain with large CSF spaces. This is 
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exemplified by Figure 2.13B which excludes all patients with the greatest degree of atrophy, 
CAS D, and shows a more obvious difference in the SSD between the SDG groups. 
 
  
Figure 2.13; (A) Subdural space depth (SSD) in patients with and without subdural hygroma (SDG) 
(B) as per A, with CAS D patients excluded. Line (mean), bars (S.D.), statistically significant 
differences denoted as P £ 0.0001 (****). 
 
The time delay from trauma to baseline imaging was significantly longer in patients who had 
an SDG diagnosed (mean 3.2 days versus 0.5 days, p = 0.0451). This suggests that SDGs 
may take >24 hours to develop, and therefore immediate imaging misses them.   
 
There was no significant difference in the CSDH-DN volume between those that had a prior 
SDG reported and those that did not (p = 0.5125). There was also no correlation between the 
final CSDH-DN volume and the time interval from initial trauma, Figure 2.14 (r = -0.0835, p 
= 0.6552), unlike with CSDH-AT.  
 
 














































The median BCR for all patients was 0.14 and there was no difference in BCR between 
patients with an SDG present or absent, suggesting increased atrophy doesn’t necessarily 
increase the risk of an SDG (p = 0.6867). No correlation was found between the BCR and the 
total SSD, an alternative measure of atrophy (Spearman’s r = 0.07043, p = 0.7436). However, 
the BCR did match well with the CAS grade, with significant differences in BCR between 
the four grades (One-way ANOVA, p = 0.0018) (Figure 2.15A). The BCR also showed a 
trend towards correlation with CSDH-DN volume, although this was weak (Spearman r = 
0.3176, p 0.0931) (Figure 2.15B). This may be due to the increased space available for 
CSDH expansion in patients with a more atrophic brain, and hence higher BCR. 
 
  
Figure 2.15; (A) comparison of bicaudate ratio (BCR) and cortical atrophy scale, line (median), bars 




2.3.4 Outcome data 
CSDH-AT patients had significantly lower GCS scores on their date of admission to the NSU 
compared with CSDH-DN patients (p = 0.0358) (Figure 2.16A). The “GCS £12” group 
included GCS’s of 7, 8 and 9 in the CSDH-AT group, whereas the lowest GCS in the CSDH-
DN group was 12, in only one patient. This difference in GCS had resolved by the time of 
discharge from NSU, with no significant difference between the sub-types, and the lowest 
GCS score was 13 (Figure 2.16B). Although not significant, it is interesting that despite 
having lower GCS scores to start with, the CSDH-AT group had better overall GCS scores at 
discharge. Perhaps suggesting the recovery is slower in the more long-standing CSDH-DNs. 
 


























Figure 2.16; (A) GCS on admission to neurosurgical unit, (B) GCS on discharge from neurosurgical 
unit. CSDH-AT n = 15, CSDH-DN n = 26, (GCS = Glasgow coma score).  
 
Two patients were managed conservatively with medical treatment only; both CSDH-DNs. 
The remaining 39 CSDHs were treated surgically, at a median of two days (range 0-12 days) 
from the diagnostic CSDH imaging. There were two recurrences, one was a CSDH-DN and 
the other CSDH-AT. There was no significant difference between the dichotomised 3-month 
or 6-month mRS scores for the CSDH sub-types (Figure 2.17).  
 
 
Figure 2.17; outcome with dichotamised mRS scores at: (A) three months, (B) six months. CSDH-





































In this study 41 CSDH patients had baseline imaging around the time of head injury or, in 
one case, unprovoked headache. Perhaps surprisingly, the baseline imaging was more 
commonly normal (63%), than showing ASDH (37%), and normal images were observed up 
to 10 days after traumatic injury. This evidences the hypothesis that whilst some patients 
undergo a transformational process from ASDH to CSDH (CSDH-AT), even more common 
is the de-novo development of CSDH (CSDH-DN) following trauma with no acute 
haemorrhage. 
 
The main limitation is that only 46/205 patients had baseline imaging, therefore ideally large-
scale studies are needed to get more numbers for statistical power. Time intervals were also 
calculated using the date of CSDH diagnostic imaging, rather than symptom onset, since the 
latter is much more difficult to define. This could potentially introduce bias, as patients with 
an ASDH on original imaging may be more likely to present earlier for follow-up imaging 
than those who have been told they have a normal original scan. However, the highly 
significant difference in time interval between CSDH-AT and CSDH-DN diagnosis, suggests 
the timeline of the pathophysiological processes is truly different.  
 
As well as taking longer to present following trauma, CSDH-DN were also significantly 
larger than CSDH-AT. The volume difference was not simply a product of the longer time 
interval, as CSDH-DN volume was not correlated to time, and two of the largest CSDH-DNs 
formed in the shortest time interval. Therefore, time to develop a CSDH after trauma and 
volume of final CSDH appear to be independent factors, this may mean that the CSDH 
expansion rate is more related to variations in inflammation than time, and will be assessed in 
more detail in chapter six.  
 
The size of ASDHs that become CSDHs appears to be small, with a mean volume of 61.5 cm3 
and mean MLS of 5.18 mm, compared to a mean volume of 146.1 cm3 and MLS of 14.4mm 
in operated ASDHs in patients over 70 (Benedetto, Gambacciani, Montemurro, Morganti, & 
Perrini, 2017). Notably, Benedetto reported that 85.7% of patients with an ASDH volume 
over 200 cm3 died within 10 days, thus there is a pre-selection of smaller ASDHs in those that 
survive long enough to have an CSDH-AT. However, there is also evidence that thicker 
ASDHs are more likely to develop a CSDH requiring surgical treatment (Benedetto et al., 
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2017; Laviv, 2014). In our study the mean increase in MLS from ASDH to CSDH-AT was 
5.52 mm, with volume increasing by over a third from a median of 60.7 cm3 to 85.5 cm3. This 
demonstrates reasonably rapid growth in a mean time-period of only 16 days. There was a 
significant inverse correlation between the volume of ASDH and the time interval to CSDH-
AT diagnosis (Figure 2.12A). Thus, larger volume ASDHs transformed into symptomatic 
CSDHs more quickly, suggesting either a larger original blood load, or perhaps a more 
significant trauma, provides a greater stimulus for rapid conversion to CSDH. However, the 
CSDH-AT volume is not correlated to the original ASDH volume, therefore although 
forming more slowly, small ASDHs have the capacity to expand to the same extent as larger 
ASDHs. 
  
Some authors believe that all CSDHs which do not form from an ASDH must involve an 
SDG (Lee, 2004; Nakaguchi, Tanishima, & Yoshimasu, 2001; Park et al., 2008). This study 
found significantly more bilateral CSDH-DN’s (9/26) compared with CSDH-AT (0/15), and 
as SDGs are more commonly bilateral that unilateral, this adds some support to the theory of 
SDGs in CSDH-DN evolution (Ahn et al., 2016). Analysis of the baseline imaging 
specifically for SDG showed that 54% (14/26) of CSDH-DN patients had evidence of SDG, 
although those with SDG also had a significantly longer time interval from trauma to baseline 
imaging. This may mean that SDG occurs in all patients with CSDH-DN, but is only 
observed if the imaging is delayed following trauma, allowing time for CSF to accumulate. 
Only 1/7 patients with delayed imaging (at day five post-trauma) had no SDG reported, and 
all images performed after seven days had an SDG.  
 
The subdural space depth (SSD) was significantly higher on the side of the cranium where an 
SDG was reported, compared to no SDG. Therefore, SSD could be used as a useful objective 
measure of the presence of SDG, which is often under-reported. This might help highlight 
patients who are more likely to develop a CSDH-DN following head trauma with a “normal” 
CT, however it is likely to be more challenging to diagnose these in patients with severe 
grades of atrophy. The bicaudate ratio (BCR) appeared to be a good reflection of 
observational assessments of atrophy, such as the cortical atrophy scale (CAS). However 
there was only a weak trend between BCR and CSDH-DN volume. Therefore, whilst brain 
atrophy is a well-recognised risk factor for CSDH, it only seems to have a small impact on 
the final volume of CSDH that forms. Van Gijn reported the upper limit of normal BCR in 
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patients as 0.21 in those under 80, therefore the measurements in these patients (mean 0.14) 
appear well within the normal range for a population of patients with a mean age of 78 (van 
Gijn, Hijdra, Wijdicks, Vermeulen, & van Crevel, 1985). To understand the role of atrophy 
further it would be useful to assess BCR measurements in all elderly patients with trauma to 
assess their predictive value in CSDH formation. 
 
The low number of recurrences (two, with one in each CSDH sub-type) mean that no 
inferences can be made about CSDH pathophysiology with respect to this. It has been 
suggested that recurrence is higher in patients who present fewer than 60 days after trauma 
compared to after 60 days (Nakaguchi et al., 2001). This would indicate a higher recurrence 
rate for the CSDH-ATs, which tend to form more rapidly after trauma, but insufficient data is 
available to support this. Closer observation of patients with known CSDH-AT in the future 
may help elucidate whether this is a factor.  
 
The GCS on admission to the neurosurgical unit was significantly lower in CSDH-AT 
patients than CSDH-DN, although this had resolved by discharge and there were no 
differences in three and six month mRS. The caveat to this is that the mRS was dichotomised, 
and is therefore only measuring the functional outcome in terms of patients that are 
independently mobile compared to those that are not, and will not be sensitive to more subtle 
differences. Further to this, with such a high good outcome rate in CSDH patients overall 
(80-85% at six months, see chapter 8), much larger patient numbers would be needed to see 
any significant differences. Longer and more detailed follow-up on these patients would be 
valuable to discern whether there are more subtle differences between the CSDH pathological 
sub-types.  
 
There is already evidence of widespread brain tissue volume loss over a one year period in 
the chronic phase after moderate to severe TBI, unrelated to time since injury (Cole et al., 
2018). This has not been studied in CSDH patients specifically but is likely to impact this 
population of patients, many of whom already have a significant degree of cerebral atrophy 
(6/25 CSDH-DN had grade D on CAS). Increased global cerebral atrophy may have 
implications for increased long-term dementia risk, as is seen in patients who develop 
dementia post-stroke (Leys, Henon, Mackowiak-Cordoliani, & Pasquier, 2005).  
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The different sub-types of CSDH may represent different severity of injury, with CSDH-AT 
more likely to have sustained a higher impact trauma causing ASDH, and thus potentially 
prone to long-term degenerative effects. Alternatively, it may be that the prolonged exposure 
to inflammation around the brain impacts future neurodegeneration and therefore CSDH-DN 
patients would be at greater risk due to the longer delay from trauma to CSDH diagnosis. 
Either way long-term follow-up studies on CSDH patients with a known pathophysiological 
process will be valuable to understand these risks and what factors contribute to possible 
secondary neurodegeneration. 
 
Increased uptake of CSDH sub-categorisation such as de-novo and acute-transformed, where 
possible, may help increase understanding of some of the differences seen in this very 
heterogeneous condition. This is of particularly relevance to the assessment of new 
treatments such as dexamethasone, where understanding the pathophysiological sub-type or 
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Spectrophotometry is the quantitative measurement of the light transmission properties of a 
material, as a function of wavelength. By comparing the percentage of light that passes 
through a test solution (CSDH sample) in comparison to a reference solution (saline), the 
absorbance (also termed optical density) of the test solution can be quantified at each 
wavelength. 
 
Ultraviolet-visible spectrophotometry (UV-Vis) has been used to characterise the constituents 
of blood, primarily determined by red blood cells (RBCs), which are approximately 99% of 
the cells present (Nonoyama, 2004), see Table 3.1. Haemoglobin (Hb) makes up 97% of the 
total protein in RBCs, and is therefore the dominant chromophore molecule which is used to 
estimate quantities of haemorrhage within a sample.  
 
Table 3.1; components of blood 
Blood component Blood content Size 
55% Plasma  
 
 proteins, lipids, amino acids <<< 1 µm 
45% Cells Red blood cells (40-45%) 6-8 µm 
White blood cells (1%) 
 
neutrophils 12-15 µm  
lymphocyte 7-20 µm 
Platelets (<1%) 2- 4 µm 
 
This study will compare the UV-Vis spectrum of whole blood with CSDH, in order to 
estimate the relative quantity of Hb in each. CSDH composition is similar to blood, with a 
cellular predominance of RBCs contained within an exudate (similar to plasma). A previous 
study utilising Cr-labelled RBCs showed that CSDHs contain, on average, 6.7% acute 
haemorrhage, and that all CSDHs contain at least some active haemorrhage (Ito, Yamamoto, 
Saito, Ikeda, & Hisada, 1987). RBCs have been evidenced to enter CSDH fluid by leaking 
through endothelial gap junctions of highly permeable CSDH outer membrane 
macrocapillaries, as seen in Figure 3.1 (Sato & Suzuki, 1975; Yamashima, Yamamoto, & 
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Friede, 1983). This bleeding is also promoted by impaired coagulation and hyperfibrinolysis, 
mediated by high levels of thrombin and tPA (tissue plasminogen activator) released from 
CSDH neomembranes (Shim, Park, Hyun, Park, & Yoon, 2007; Suzuki et al., 1998). Some of 
the Hb within the CSDH will also be “free” Hb, following breakdown of RBCs, and has been 
shown to be present at between 1-3 g/dL in CSDH fluid (Labadie & Glover, 1976; Weir & 
Gordon, 1983).  
 
 
Figure 3.1; electron micrograph of two RBCs squeezing through an endothelial gap junction, out of a 
macrocapillary of the outer membrane of a CSDH, reproduced from (Yamashima et al., 1983). 
 
The macrocapillary gap junctions in CSDH membranes also allow leakage of other blood 
components, such as the smaller platelets and plasma proteins (see Table 3.1), which forms 
the CSDH exudate (Fujisawa, Nomura, Tsuchida, & Ito, 1998; Tokmak, Iplikcioglu, Bek, 
Gokduman, & Erdal, 2007; Yamashima et al., 1983). Originally it was thought that plasma 
protein leakage into the subdural space would cause an oncotic gradient which would drive 
fluid expansion of CSDHs, however this theory was displaced by studies that clearly showed 
a lower oncotic and similar osmotic pressure within CSDH compared to venous blood 
(Labadie & Glover, 1976; Weir, 1980). The rate of protein exudation varies between CSDHs, 
and has been correlated with different sub-types of CSDH seen on imaging (Tokmak et al., 
2007). This may reflect the different stages of membrane development and thus leakiness of 
capillaries, resulting in varying patterns of bleeding and fluid accumulation that appear 
differently on imaging. Finally, WBCs are clearly present in CSDH membranes and 
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important sources of inflammatory mediators, but it is less clear whether they actually enter 
the subdural space themselves, given their larger size (Moskala et al., 2007; Shono et al., 
2001). 
 
A complicating factor in UV-Vis spectroscopy is that particles, particularly large cells (e.g. 
RBCs and WBCs), cause light scattering. This means that some of the light that should reach 
the detector, is instead scattered by the cells, thus over-estimating the final absorption 
reading. To account for scattering, theoretical modelling (Mie theory) and complex 
mathematics can be applied, but is outside the scope of this thesis, and indeed the subject of 
an entire thesis already published (Nonoyama, 2004). There are also instruments which can 
be used to modify for scattering, such as an integrating sphere, however these have also been 
shown to have the adverse effect of under-estimating absorption peaks. Therefore, in this 
study a standard spectrophotometer was used with no re-modelling for scatter but an 
acceptance that the values of absorption are not exact, but the peak wavelengths and trends in 
absorption changes still meaningful. Another potential con-founding factor is pH, however 
the reported effects of pH on the UV-Vis spectra of human oxy-Hb is minimal, and therefore 
this was not considered to be a significant factor (Wimberley, Fogh-Andersen, Siggaard-
Andersen, Lundsgaard, & Zijlstra, 1988).  
 
Experiment Aim and hypotheses 
The aim of this study is to compare the UV-Vis spectrum between paired venous whole blood 
and CSDH fluid to enable a relative quantification of Hb, and thus haemorrhage, within each 
CSDH.  
 
Histological analysis of CSDH membranes show that they mature over time and that more 
mature membranes allow increased CSDH growth due to higher haemorrhage rates from 
macrocapillaries (Gandhoke, Kaif, Choi, Williamson, & Nakaji, 2013). Therefore, it is 
hypothesised that higher Hb levels measured with UV-Vis will be correlated to larger, and 
thus generally older, CSDHs (see chapter seven). It is also hypothesised that higher Hb will 
be related to CSDHs with higher imaging mean density, as higher density is considered to 
reflect fresh bleeding on imaging (see chapter seven).  
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As RBCs and their breakdown products have been previously implicated as drivers of the 
inflammatory response in CSDH (Labadie & Glover, 1976), it is also hypothesised that 
increased Hb will correlated with increased levels of inflammatory markers (see chapter five 
for full details on markers analysed). Further to this, it is hypothesised that this increased 





52 patients were consented and recruited to the Dex-CSDH neurochemistry sub-study and 
had venous whole blood and intra-operative CSDH samples collected during their procedure. 
From these, 44 patients had UV-Vis spec performed, as either the primary investigator 
(E.Edlmann) or in some cases the laboratory post-doc (S. Giorgi-Coll), were available to 
process the samples immediately. 
  
Samples were collected in 2.2 mL EDTA tubes and refrigerated immediately after collection 
at 5 °C until analysed. For the UV-Vis spec analysis, 5 µL of whole blood or CSDH was 
pipetted into 1000 µL of 0.9% saline solution in a 1.5 mL Eppendorf tube and inverted a few 
times for homogenous distribution of cells. The entire volume was then pipetted into a 1.5 
mL quartz cuvette, with 1000 µL of 0.9% saline used as the reference sample, prior to 
analysis by UV-Vis at room temperature. 
 
The CSDH samples only were then centrifuged for 10 minutes at 4,000 rpm. Following this 
the colour of the supernatant was categorised as either black/brown, dark-brown, dark-red, 
brown, light-brown, light-red or light-orange or yellow. The cell layer size was also recorded 
as either large, small or no cell layer (see examples in Figure 3.2). These subjective 
recordings of colour and cell layer size were performed by the same two people (E.Edlmann 
and S.Giorgi-Coll).  
 
 
Figure 3.2; examples of cell layers in CSDH post-centrifugation; left shows a large cell layer and 
right shows no cell layer. Both supernatants are light red.  
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A Hitachi U-3900H spectrophotometer was used for UV-Vis analysis. This has a double light 
beam and monochromator; one beam for the reference sample and the other for test sample. 
There are two lamps; WI lamp (visible range) and Deuterium lamp (ultraviolet range). A 
spectral range of 200-700nm; a 1cm pathlength was used. The wavelength accuracy is +/- 
0.1nm. 
 
The results from the UV-Vis are displayed in spectral graphs depicting absorbance (in 
arbitrary units) and wavelength (nm). The software automatically fits the curve and provides 
values for the wavelengths of maximum absorption (i.e. the top of the peaks in the spectra), 
which are described as lambda-maximum (lmax).  
 
All statistical analysis was performed using Graphpad Prism 7 (GraphPad Software, La Jolla, 
CA, USA), with either paired/unpaired T-tests in the case of parametric data or Mann-





3.3.1 UV-Vis spectrophotometry of CSDH fluid and blood 
One patient was excluded from the UV-vis analysis as the spectrum was flat, with no peaks. 
As discussed later in this chapter, it was determined that this was a subdural hygroma rather 
haematoma and therefore contained no RBCs and such minimal levels of any other cells or 
proteins that they were not detectable after the dilution method used. The UV-Vis spectra for 
the remaining 50 CSDH fluid samples from 43 patients (seven had bilateral CSDHs) and 
paired venous blood samples are shown in Figure 3.3. The pattern of peaks in the venous 
blood, are congruent with those previously reported and the representative constituents are 
seen in Table 3.2.  
 
Table 3.2; UV-Vis spectra lmax for blood and CSDH fluid 
Peak 
(P) 




CSDH lmax (nm) Constituent of peak 
P1 210 212 210 Amide chains of proteins 
P2 278 277 278 Protein peak   
(Tyrosine and tryptophan) 
P3 344 345 351 NADH, NADPH 
P4 416-7 417 410 Oxy-Haemoglobin 
P5 540-7 543 542 Oxy-Haemoglobin 
P6 575-8 577 577 Oxy-Haemoglobin 







Figure 3.3; UV-Vis absorbance spectra of: (A) all venous whole blood samples, highlighting lmax of 6 













































Peaks four to six are relevant to understanding the degree of haemorrhage within the CSDH 
as they relate to oxy-haemoglobin. Peak four is the only peak which shows a difference 
between CSDH fluid and venous blood, where a left-shift is observed from a mean 
wavelength of 417nm to 410nm, and is seen in more detail in individual patient number 08 in 




Figure 3.4; paired samples from patient 08 showing clear left shift of peak four in the CSDH fluid 
(λ(max) = 408) compared to blood (λ(max) = 417). 
 
The mean absorbance of all the CSDH samples was approximately 25-30% of that seen in 
venous whole blood, as shown by the comparative absorbance maxima (Figure 3.5). This 
includes the main protein peak, which includes albumin (peak two), and corroborates the 
previous literature that there is lower protein in CSDH compared to venous blood (Labadie & 
Glover, 1976; Sizer & Peacock, 1947; Weir, 1980). The reduced heights of the remaining 
peaks suggest that all other blood components, especially RBCs, are found at lower levels in 
CSDH fluid compared to venous blood. This is either because they do not pass through 
freely, or because they are broken down once they have entered the CSDH cavity. These 
comparisons are only estimations as it must also be considered that the blood cell content 
may vary depending on the haematocrit, and could be diluted by the use of intra-operative 
fluids. 
















Figure 3.5; mean results of all blood and CSDH samples (n = 50), with boxes displaying mean 
absorbance at each peak λ(max), as per the wavelengths highlighted in Figure 3.1.  
 
The UV-vis spectrum in Figures 3.3 and 3.5 show an elevated baseline above 600 nm despite 
no absorbance being expected in this range, and likely represents the increased absorbance 
secondary to Rayleigh light scattering by the high cell content discussed previously. To help 
overcome the effects of scattering the spectrum could be zeroed at the highest wavelength, 
although it is the lmax rather than the peak height which is important. To avoid using absolute 
measurements, due to the confounding caused by scattering, the relative amount of RBCs in 
the paired CSDH and blood samples for each patient was determined. This was done by 
taking each CSDH fluid absorbance spectrum and converting it into a percentage of the 
paired venous blood sample absorbance, named the “blood fraction” (Figure 3.6). This shows 
a large range from just above 0% to over 100%, with higher values relating to CSDH with a 
larger fraction of haemorrhage within the CSDH compared to the venous blood. The highest 
four lines in Figure 3.6, all over 100%, are from bilateral CSDH samples in two patients (47 
and 50). The abnormal spectra seen for these two patients is likely due to the fact that the 
CSDHs were much darker than blood, causing a large amount of scattering, and thus 
extremely high perceived absorbance in the CSDH samples.  
 














































Figure 3.6; percentage difference between venous blood and CSDH fluid in UV-Vis absorbance. N = 
50, patients 47 and 50 highlighted in boxes (R = right, L = left).  
 
As highlighted previously, the main difference observed between the CSDH and venous 
blood samples was the wavelength of peak four. This peak is helpful in understanding the 
status of RBCs and type of haemoglobin, or its derivative, that is present in CSDH fluid. 
Kidwell et al. has shown that breakdown of intracranial haemorrhage occurs by oxidative 
denaturation, as the original oxy-haemoglobin becomes deoxy-haemoglobin and then 
methaemoglobin, which is eventually phagocytosed by macrophages (Kidwell & 
Wintermark, 2008). Figure 3.7 shows the formula for the dioxygenation reaction, which 
occurs when oxygenated Hb reacts with Nitric Oxide (NO) to form methemoglobin (FeIII) 




Figure 3.7; dioxygenation reaction for conversion of haemoglobin to methaemoglobin.  
 
Whilst oxyhaemoglobin (oxyHb) has a characteristic peak at 417nm, methaemoglobin 
(metHb) has been shown to be left-shifted with a peak at 400nm and loss of peaks five and 
six (Nonoyama, 2004). Previous analysis of subarachnoid haemorrhage in cerebrospinal fluid 
(CSF) showed that if this peak is below 410nm, it is unequivocally suggestive of the presence 























HbFe II - O2 + NO à HbFe III + 
NO3- 
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of metHb (Beetham, Fahie-Wilson, & Park, 1998)., Formation of metHb occurs more rapidly 
when Hb is free (i.e. following haemolysis of red blood cells), thus it was hypothesised that 
higher proportions of metHb, as seen with left shift of the peak to around 410nm, would 
represent greater RBC breakdown, and possibly an older CSDH.  
 
MetHb has also been correlated with imaging findings, causing hyperintensity on T1 MRI 
(Senturk et al., 2010). It has been suggested that this hyperintensity is reduced by absorption 
or degradation of metHb (Fobben et al., 1989). Therefore, persistent hyperintensity probably 
represents repeated haemorrhage and transformation to metHb, and has been reported in 67 - 
79% of CSDHs (Hosoda, Tamaki, Masumura, Matsumoto, & Maeda, 1987; Senturk et al., 
2010; Tsutsumi et al., 1997). The imaging collected in this study was all CT, therefore 
hyperintensity cannot be assessed, however the mean density, with a higher density 
suggesting more acute blood, is compared to the UV-Vis findings in section 3.3.5 below. 
  
The mean wavelength at peak four across all samples was significantly lower in the CSDH 
fluid compared to venous blood (Mann-Whitney, p < 0.0001) (Figure 3.8A). This highlights 
the left-shift (or blue-shift) in the CSDH samples, where the lower wavelengths are at the 
bluer end of the spectrum and are consistent with a higher metHb/oxyHb ratio. There was 
also a wider spread of λ(max)  at peak four in the CSDH samples (405.5 - 420 nm, see Figure 
3.8B) compared to venous blood (415-418.5 nm). This highlights the variation in the balance 
between oxy and met-Hb in CSDH fluid, unlike blood which only contains oxyHb. 
 
 
Figure 3.8; (A) peak four λ(max)  in all CSDH and blood samples, CSDH n = 50, blood n = 43, line 
(mean) and bars (S.D), statistically significant differences denoted as p <0.0001 = ****. (B) variation 
in peak four in all CSDH samples, n = 50.  
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The shoulder of peak four was also analysed closely, as bilirubin can appear in this location, 
with a peak around 450-460nm (University of Birmingham). Bilirubin is another derivative 
of Hb formed by a rate-limited enzymatic reaction, and is often used as a diagnostic marker 
of subarachnoid haemorrhage (SAH) if found in the cerebrospinal fluid (CSF) (Tallur, 
Belton, Stephen, & Minns, 2005). There are two reports confirming the presence of bilirubin, 
alongside methaemoglobin, in subdural collections (Tallur et al., 2005; Wahlgren & 
Lindquist, 1988). However, Wahlgren et al. suggest that when the Hb concentration is low it 
is primarily converted in bilirubin, whilst higher Hb concentrations result in formation of 
methaemoglobin, due to the limited capacity of the haem oxygenase system required for 
bilirubin formation. Our analysis found no clearly identifiable separate bilirubin peaks, which 
may suggest that the CSDHs contain a large amount of Hb which exceeds the capacity of the 
oxygenase system to form bilirubin. Indeed, Tallur et al. report that bilirubin is correlated to 
bleeding in the last 24-72 hours, and therefore is less relevant to CSDH as it is to the more 
acute SAH (Tallur et al., 2005). However, it is likely that there is at least some bilirubin 
present, which may be hiding within the shoulder of peak 4, as many of the shoulders are 
broad and extend into the region of a bilirubin peak. 
 
 
3.3.2 Methaemoglobin and CSDH fluid observations 
Samples with a large “cell level” observed in the CSDH fluid had a significantly higher 
blood-fraction, than those with no or a small cell level (Unpaired T test, p > 0.0001) (Figure 
3.9A). Due to the extremely high blood fraction in patient 50’s bilateral samples (Figure 3.6), 
a further analysis was done excluding this patient, as it appeared as if it may be skewing the 
results. However, the difference remained at the same significance (Figure 3.9B). The high 
blood fraction in the CSDHs with a large cell level suggests that there is a larger volume of 




Figure 3.9; peak four blood fraction in relation to observed cell level in fluid: (A) all patients n = 49, 
(B) outliers excluded, n = 47. Line (mean), bars (S.D.), statistically significant differences denoted as 
p <0.01 = **. 
 
When observing the colour spectrum of CSDH samples, those with the largest blood fraction 
(and hence also high cell level), were usually black-brown, followed by dark red-brown 
(Figure 3.10). The lower blood fraction correlated to dark brown and light red-brown or 
orange, suggesting these colours form when the RBCs have broken down and there are fewer 
cells left.  When the colours were grouped into darker (black-brown and dark red-brown) and 
lighter colours (brown, light red/orange), there was a significant difference in blood fraction 
(unpaired T test, p = 0.0065). This gives the operative surgeon a good indication of the recent 
bleeding rate just by observing the CDSH fluid colour and cell level after centrifugation, or 
can also be seen if the sample is left undisturbed for a few hours in a test tube. The one 
patient with no peaks on the UV-Vis spectrum (who was excluded from all other analysis), 
was observed to be translucent fluid with slight yellow colouring and no cell level following 
centrifugation. This is in-keeping with a subdural hygroma, which are usually found to 
contain no Hb (Weir & Gordon, 1983).  
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Figure 3.10; peak four blood fraction in relation to CSDH fluid colour, n = 51, bars (mean), lines 
(S.D.) statistically significant differences denoted as p <0.01 = **. 
 
CSDHs with a large cell level also had a significantly higher λ(max) with a median of 414 nm 
compared to 408 nm in CSDHs with small/no cell level. This supports the theory that the 
large cell level indicates more recent bleeding, as a higher wavelength is essentially a red-
shift (i.e. more red than blue) on the UV-Vis spectra, and is similar to the wavelength of the 
Hb peak in venous blood (417nm). CSDHs with “small” or “no” cell level appear to contain 
older haemorrhage, which has formed metHb following RBC breakdown, and shifted the 


















































Figure 3.11; CSDH fluid peak four λ(max) in relation to observed cell level, n = 49 (one patient had no 
cell level recorded), line (median), box (IQR), bar (range), statistically significant differences denoted 
as p £ 0.005 = **. 
 
There was no significant difference in the peak four λ(max) on each side of a bilateral CSDH 
(paired T test, p > 0.999), with 4/7 cases showing very similar results on each side, whilst the 
other three did show variation (Figure 3.12A). There was a significant difference between the 
λ(max) of peak 4 between sides (paired T test, p = 0.0245), suggesting that there isn’t always the 
same rate of haemorrhage or blood breakdown in co-existent, bilateral CSDHs.  
 
 
Figure 3.12; bilateral paired samples compared for: (A) peak four λ(max), (B) peak four maximum 
absorbance, n = 7, statistically significant differences denoted as p £ 0.05 = *. 
 
3.3.3 Methaemoglobin and inflammatory markers 
It was hypothesised that an increase in Hb breakdown could act as a stimulus for 
inflammation, thus increasing the inflammatory markers in patients with higher proportions 
of metHb. The inflammatory profiles for a selection of markers (see details in chapter five) 
were compared to the λ(max) of peak four.  















































There were no correlations between peak four height, or blood fraction, and the concentration 
of any of the inflammatory markers. The only significant correlation found between peak 
four λ(max) and any of the inflammatory markers was a weak negative correlation with; MIP-1a 
(Spearman r = -0.484, p = 0.0004) and IL-1a (Spearman r = -0.3577, p = 0.0108) (Figure 
3.13). This provides limited support for the hypothesis of higher levels of inflammation (with 
only two significant markers) in samples with lower Hb λ(max), and hence more metHb.  
 
 
Figure 3.13; λ(max) correlated with: (A) IL-1a, (B) MIP-1a, n = 50.  
 
A further analysis was performed by grouping all samples into those with a λ(max) equal to or 
below 410 nm, and those with a λ(max) above 410 nm; as the median λ(max) across all CSDH 
samples was approximately 410 nm. Again, only MIP-1a was significant increased in 
CSDHs with a low λ(max), and hence more metHb (p = 0.0028) (Figure 3.14).  
 
Figure 3.14; MIP-1a grouped by wavelength. £ 410 n = 25, >410 n = 25, statistically significant 
difference denoted as p £ 0.005 = **, line (median) and bars (IQR). 
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Overall, there is limited evidence to suggest that the inflammatory profile is related to the 
ratio of metHb or indeed overall amount of fresh blood (blood fraction) in CSDH fluid. 
Therefore, on the basis of this evidence, the hypothesis of bleeding rate and metHb content 
being correlated to the inflammatory response appears not to be true in established CSDHs. 
However, an alternative hypothesis is that Hb and/or metHb are important in the early stages 
of establishing CSDH but are less significant by the time of operation. 
 
3.3.4 Methaemoglobin and imaging findings 
49 CSDHs had both imaging and UV-vis data available for comparison, five of which were 
recurrent CSDHs.  
 
It has already been established above that the cell level appears to reflect the amount of 
recent haemorrhage within the CSDH, therefore it is not surprising that there is a significant 
difference in the mean density on CT imaging between CSDHs with no (n=22), small (n=13) 
or large (n=13) cell levels (One-way ANOVA, p = 0.0007) (Figure 3.15A). Thus, those 
CSDHs with higher mean densities show more recent haemorrhage (which is hyperdense), as 
expected. When assessing CSDH volume, there was a trend for CDSHs with no evident cell 
level after centrifugation to be larger than those with small or large cell volumes as a group 
(Mann-Whitney, p = 0.0879) (Figure 3.15B), suggesting the largest CSDHs tend to contain 
less recent bleeding.  
 
 
Figure 3.15; cell level by: (A) mean density, line (mean), bars (S.D.), (B) CSDH volume, line 








































The mean density was also assessed in CSDHs with high or low levels of metHb, as 
measured by peak four λ(max) £ 410 and > 410 nm respectively. This correlated well with the 
data in Figures 3.11 and 3.15A, as CSDHs with a higher mean density (and therefore a larger 
cell level), were also significantly more likely to have a wavelength >410 nm, corresponding 
to more recent haemorrhage (Unpaired T test, p = 0.0026) (Figure 3.16A). The CSDHs with a 
λ(max) £ 410 nm had lower mean densities, and thus CSDHs with more metHb, and less recent 
haemorrhage, are more likely to appear hypodense on imaging. This can also be seen with a 




Figure 3.16; (A) CSDH mean density on CT in relation to peak 4 λ(max), line (mean), bars (S.D.). 
Statistical significance shown as p<0.005 = **, (B) correlation between peak 4 λ(max) and mean density 
on CT.  
 
 
3.3.6 Methaemoglobin and recurrence risk 
When comparing primary CSDHs samples from those that went on to recur (n = 5) with those 
with no recurrence (n = 37), there was a significantly higher peak four λ(max) in the recurrent 
group (Mann Whitney p = 0.0237) (Figure 3.17). Although the numbers of recurrences are 
small, there is a clear difference in wavelengths in all but one of the CSDHs in the recurrent 
group, suggesting that CSDHs that go on to recur have more recent acute haemorrhage at the 
time of primary surgery than those without this complication. This may explain part of the 
driving force of recurrence, as the CSDH is already in a cycle of active bleeding, and thus if 
this continues post-operatively, it is more likely to lead to recurrence than a more “dormant” 








































Figure 3.17; peak four λ(max) in primary CSDHs with no recurrence (NR) or recurrence (Recur), line 
(median), bars (IQR), statistically significant differences denoted as p < 0.05 = *. 
 
When comparing the primary CSDH samples (n = 42) with the recurrent samples (n = 5), 
there was no significant difference in peak four λ(max) (Figure 3.18). Suggesting at the time of 
































In conclusion, the spectroscopy findings support the hypotheses that both protein exudation 
and haemorrhage contribute to the growth of CSDH. Whilst proteins appears to cross into the 
CSDH, they accumulates at lower levels than in venous blood, supporting the notion that 
oncotic gradient is not the source of CSDH expansion.  
 
Overall, the RBC content in all 50 CSDHs is approximately 25-30% that of venous blood, but 
ranges from just over 0% to nearer to 100% of the RBC content within the paired blood 
sample. However, the latter samples are likely to have exaggerated levels due to the artifact 
of scattering, which increases exponentially with the number of cells within a sample, thus 
still highlighting that there is a very high RBC cell count within these samples.  
 
The median λ(max of peak four is 410 nm in CSDH fluid, compared to 417 nm in venous blood, 
representing the left (or blue-shift) seen with presence of metHb, a breakdown product of Hb 
which has previously been recognised to accumulate in old cerebral haemorrhage. Therefore, 
the this peak informs on the ratio of old to new haemorrhage within CSDHs and a higher λ(max), 
associated with more acute haemorrhage, is also more likely to appear dark in colour 
(black/dark red-brown) and have a large cell level. The latter of which also correlates with a 
higher mean density on CT (as occurs with acute bleeding) and a lower volume. Conversely 
older CSDHs, with lower λ(max), representing more metHb, tend to be more low density and 
larger in volume on CT.  
 
Perhaps the most significant finding is that CSDHs that go on to recur have significantly 
higher λ(max) at their original operation, and thus more recent acute haemorrhage than those that 
don’t recur. Therefore, recent haemorrhage may be a driver of recurrence, and patients at 
high risk can be identified by high density on CT or simply observing a high cell-level in the 
drained CSDH fluid. Surprisingly, patients on anti-coagulants and anti-platelets do not have 
higher mean density on CT (see chapter 7), therefore the bleeding rate in CSDHs at diagnosis 
does not seem to be directly related to these drugs. However, there is still a perception that 
these medications increase the overall risk of CSDH, this is discussed further in chapter 8. 
 
There is limited evidence that metHb or bleeding is a stimulus for inflammation, therefore 
they may be independent processes involved in CSDH evolution. 
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Dexamethasone is a synthetic version of naturally-occurring corticosteroid hormone (Figure 
4.1). This hormone is made by the adrenal glands in response to adrenocorticotropic hormone 
(ACTH) from the adenohypophysis, and has a primary role in regulating the metabolism of 
carbohydrates, proteins and fats (Woodbury, 1958). Chemical manipulation of this hormone 
in 1958 led to the first production of dexamethasone, known chemically as 9α-fluoro-16α-
methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione (Arth et al., 1958; Buavari. S., 
1996; Hart, 1960).  
 
 
Figure 4.1; (A) naturally occurring hormone cortisol, (B) synthetic drug dexamethasone with 
additional fluoride (F) and methyl group (CH3) indicated with green circles. 
 
Dexamethasone has a potent anti-inflammatory effect without the salt and water retaining 
properties seen with other corticosteroid hormones (Arth et al., 1958). It therefore became a 
popular therapy for conditions such as rheumatoid arthritis, asthma, pemphigus and ulcerative 
colitis (Boland, 1958; Hart, 1960). In 1961 Galicich and French published the first work on 
the use of dexamethasone in humans to treat cerebral oedema (Maxwell RE, 1972). They 
reported dramatic relief of the signs and symptoms of raised ICP secondary to brain-tumour 
associated cerebral oedema. This was supported by histological analysis, which showed that 
dexamethasone was able to effectively reverse all the changes observed in oedematous tissue, 
short of necrosis (French, 1966). Following this, dexamethasone became widely used for a 
variety of neurosurgical conditions, including tumours, head injury, abscesses and 
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intracranial haemorrhage (French, 1966; Maxwell RE, 1972).  The first report of its 
application in CSDH came in 1974, when it was proposed as an effective treatment by 
reducing cerebral oedema related to the haematoma (Bender, 1974). More recent theories 
suggest that it is the anti-inflammatory properties of dexamethasone that may be of benefit in 
promoting resolution of CSDH, although this is yet to be proven.   
 
 
4.1.1 Understanding the anti-inflammatory role of dexamethasone role in CNS 
Glucocorticoids, such as dexamethasone, have been shown to have extensive anti-
inflammatory actions through up-regulating the gene transcription of anti-inflammatory 
cytokines such as IL-10, and down-regulating expression of inflammatory cytokines, 
chemokines, adhesion molecules and nitric oxide (Barnes, 1998; Cosio, Torrego, & Adcock, 
2005; Czock, Keller, Rasche, & Haussler, 2005).  
 
In relation to the central nervous system (CNS) specifically, the anti-inflammatory effects of 
dexamethasone have been interrogated in only a few cases, and mostly in animal models. A 
good example is Lyme disease of the CNS, where an inflammatory leptomeningitis occurs 
and treatment with oral dexamethasone results in significantly lower CSF white cell counts, 
IL-6, IL-8, MCP-1 and B-lymphocyte chemoattractant concentrations in macaques (Ramesh 
et al., 2015). Further to this, when post-mortem macaque frontal cortex tissue was exposed to 
live Lyme disease infection, pre-incubation with dexamethasone led to significantly lower 
levels of IL-6, IL-8, MCP-1, IL-1b, IL-18, TNF-a, VEGF and granulocyte-colony 
stimulating factor (Ramesh, Martinez, Martin, & Philipp, 2017). This is important as it shows 
the potential mechanism for dexamethasone to down-regulate molecules such as VEGF and 
ILs, which are suspected to be highly relevant in CSDH pathophysiology (Hara, Tamaki, 
Aoyagi, & Ohno, 2009; Hohenstein, Erber, Schilling, & Weigel, 2005; Hong et al., 2009; 
Hua et al., 2016; Kalamatianos et al., 2013; Nanko et al., 2009; Shono et al., 2001; Weigel, 
Schilling, & Schmiedek, 2001).  
 
Astrocyte cell cultures from rat brains incubated with mycoplasma, to induce an exaggerated 
inflammatory response, showed that pre-incubation with dexamethasone almost completely 
suppressed any TNF-a production and markedly reduced that of prostaglandin E (Brenner, 
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Yamin, Abramsky, & Gallily, 1993). The latter is also implicated in CSDH pathophysiology 
and so another potential target for dexamethasone in this context (Hara et al., 2009).  
 
The beneficial effects of dexamethasone in reducing morbidity and mortality in meningitis 
are well recognised, but despite this there is still significant debate regarding the mechanism 
by which this occurs (Fitch & van de Beek, 2008).  Human cases of tuberculous meningitis 
treated with intra-venous dexamethasone have shown reduced early CSF concentrations of 
MMP-9, which was suggested to be a product of altered neutrophil function (Green et al., 
2009). This mechanism may also apply to CSDH, where MMP-9 has been highlight as a 
potential marker of interest in aiding infiltration of inflammatory cells and increasing 
vascular permeability (Hua et al., 2016; Manicone & McGuire, 2008; Nakagawa, Kodera, & 
Kubota, 2000).  
 
Finally, the role of dexamethasone in reducing cerebral oedema related to brain tumours may 
also involve inflammatory molecules, such as the down-regulation of VEGF and up-
regulation of Angiopoetin-1 transcription resulting in decreased BBB permeability (Kim et 
al., 2008; Lewis, Harford-Wright, Vink, & Ghabriel, 2012). Increases in anti-inflammatory 
molecules IL-1ra and tissue inhibitor of metalloproteinases (TIMP-1) have also been shown 
in the cerebral extra-cellular fluid of brain tumour patients following dexamethasone 
treatment (Marcus, Carpenter, Price, & Hutchinson, 2010).   
 
 
4.1.2 Dexamethasone pharmacokinetics and dynamics 
Given its widespread use in neurological and neurosurgical conditions, there is surprisingly 
limited data available on the pharmacokinetics and dynamics of dexamethasone in relation to 
the CNS. It is also unknown whether dexamethasone penetrates the subdural space. 
 
The oral bioavailability of dexamethasone is very high, around 78% (Duggan, Yeh, Matalia, 
Ditzler, & McMahon, 1975). It also reaches its peak plasma concentration very quickly 
within 1-1.5 hrs, and has a short terminal half-life of less than 4 hrs (Czock et al., 2005; 
Meikle & Tyler, 1977; Queckenberg et al., 2011). Although the biological half-life, and 
hence time period it is clinically effective, is much longer, at around 36-54 hrs (electronic 
Medicines Compendium). In 1987, Balis reported a study comparing intravenous (IV) and 
intra-thecal (IT) dexamethasone and prednisolone administration in monkeys (Balis, Lester, 
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Chrousos, Heideman, & Poplack, 1987). The high protein-binding of both steroids (around 
70%), is the main limitation to its movement, but Balis showed that unbound or “free” steroid 
diffused rapidly into the intrathecal (IT) space following intra-venous (IV) administration. 
The peak IT concentrations were the same for both steroids, but dexamethasone had a longer 
half-life in the CSF, thus explaining why it is the preferred steroid for use in neurological 
conditions. There are no equivalent studies in humans, however the high level of protein 
binding of dexamethasone (75-77%) is well accepted and therefore a potential barrier to its 
ability to penetrate other spaces (Cummings, Larijani, Conner, Ferguson, & Rocci, 1990; 
electronic Medicines Compendium).  
 
 
4.1.3 Hypothesis and aims 
Part of understanding why dexamethasone may work as a treatment in CSDH is to 
understand the site and mechanism of action. Later chapters (five and six) will investigate the 
molecules involved in inflammation in CSDH and how these are altered by dexamethasone. 
The aim of this chapter is to assess whether dexamethasone penetrates the subdural space, 
working directly on the locally inflamed fluid, or rather whether it remains only in the 
peripheral blood and has downstream effects on inflammation.  
 
There are two potential routes for dexamethasone to pass from the peripheral circulation into 
the CSDH cavity. The first route is via the internal surface of the CSDH, which is separated 
from CSF by the inner CSDH membrane and the arachnoid mater. The inner membrane 
rarely contains any blood vessels, therefore for dexamethasone to enter the subdural space by 
this route, it would need to pass from the circulation into the CSF and then through the 
basement membrane of the arachnoid mater and inner CSDH membrane (Haines, 1991; 
Moskala et al., 2007). This is a rather circuitous route, therefore the alternative, of entering 
via the outer CSDH membrane, appears more likely. The outer membrane is recognised to be 
well-vascularised by macrocapillaries (Yamashima, Yamamoto, & Friede, 1983), and 
therefore has its own peripheral blood supply through which dexamethasone could enter 
directly. As the blood vessels within the outer membrane are also known to be highly 
permeable, it is hypothesised that dexamethasone will be able to pass freely into the subdural 
cavity. Once inside the cavity it will be incorporated into the expanded mass of haematoma, 
fluid and inflammatory cells; where it can have a direct anti-inflammatory effect. Once it has 
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entered the subdural space, dexamethasone will not be eliminated as it would from the 
peripheral circulation, and therefore may accumulate within this space, enabling a prolonged 
anti-inflammatory action. This is necessary for the many weeks it would take for a CSDH to 
be absorbed.  
 
The hypothesis that dexamethasone can enter and accumulate within the subdural space will 
be tested by analysing plasma and subdural fluid in patients treated with either 
dexamethasone or placebo as part of the Dex-CSDH trial. This chapter describes the 
development and validation of an appropriate technique for doing this in addition to the 
findings of this analysis. 
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4.2 Materials and methods  
Previous reports analysing dexamethasone presence in human plasma, urine and saliva have 
used the technique High Performance Liquid Chromatography (HPLC) (Difrancesco et al., 
2007; Djedovic & Rainbow, 2011; Frerichs & Tornatore, 2004; Kovarik et al., 1998; Kumar, 
Mostafa, Kayo, Goldberg, & Derendorf, 2006; Lamiable et al., 1986; Lariya, 2015; 
McWhinney, Ward, & Hickman, 1996; Song, Kim, & Kim, 2004; Tsuei, Moore, Ashley, & 
McBride, 1979). HPLC is a technique which enables separation and quantifications of 
components from a liquid sample. The HPLC instrument continuously pumps a solvent 
(called the mobile phase) through a column (stationary phase) at relatively high speed (hence 
high performance). A tiny volume of the sample being investigated is added to the mobile 
phase and pumped through the column, where its component parts interact differently with 
the porous media inside the column so that some flow through more quickly than others and 
they become separated from one another (Fornstedt, 2015).  
 
In early HPLC methods the stationary phase would be a hydrophilic surface, used with a 
hydrophobic mobile phase (Kazakevich, 2006). However more recently reverse-phase (RP)-
HPLC is more common, where the stationary phase is hydrophobic (usually porous silica 
with the addition of hydrocarbons) and the mobile phase is hydrophilic (Kazakevich, 2006). 
This RP-HPLC relies on dispersive forces to partition the sample between the mobile phase 
and the stationary phase (or column) and is able to discriminate very closely between related 
compounds. As constituents are separated and eluted from the column they need to be 
detected and quantified, this is usually done by an ultra-violet-visible (UV-Vis) absorption 
detector (Dong, 2006). The UV-Vis detector passes light through the fluid path and detects 
how much is absorbed by each compound eluted. This is transmitted as an output signal 
proportional to absorbance which is represented as a chromatographic “peak” for that 
molecule (Dong, 2006). How long it takes these peaks to elute from the column after 
injection is called the retention time; this time should be consistent for each molecular 
species (Riley, 1996). The area under the curve is proportional to the concentration of the 
compound in the sample (Riley, 1996). Therefore, once a calibration curve for a specific drug 
has been created the concentration of drug in any given sample can be determined. The UV-
Visible wavelength at which the detector is measuring can also be adapted to best suit the 




CSDH fluid contains similar components to blood but also includes blood breakdown 
products (as seen in chapter three) and other cellular debris due to its chronic nature. It also 
shares some similarities with CSF, which some consider to be the main fluid source for a 
CSDH (Kristof, Grimm, & Stoffel-Wagner, 2008). Whilst there are many studies using 
HPLC on blood, there is only one report of a HPLC method for dexamethasone in CSF, 
which was performed on rabbits (Lamiable, Vistelle, Nguyen-Khac, & Millart, 1988). Other 
substances within the brain, such as glycine, histamine and brain neurotransmitters, have also 
been studied with HPLC, but only using animal CSF or brain extracellular fluid (Bergh, 
Bogen, Lundanes, & Oiestad, 2016; Gonzalez, Fernandez, Vidal, Frenich, & Perez, 2011; 
Voehringer, Fuertig, & Ferger, 2013; Wang, Wu, Wu, & Bao, 2013). There is one study in 
the HPLC literature reporting a method for human CSDH fluid, but this was applied to 
identifying a type of bile acid (Nagata et al., 1992). Therefore, a novel method for 
dexamethasone analysis in human plasma and CSDH fluid using RP-HPLC with UV-Vis 
absorbance detection was designed for this study. 
 
 
4.2.1 HPLC conditions 
Chemicals and reagents 
All chemicals used were of HPLC grade and purchase from Sigma Aldrich (Gillingham, UK) 
unless specified. Ultrapure water of HPLC-grade was used throughout (18.2 MΩ.cm-1, 
Millipore Direct Q5 UV water purification system with LC-Pak polisher).  
 
Dexamethasone standard (Cerilliant reference standard; 1.0 mg/mL in methanol) and 
Flumethasone pivalate standard (European Pharmacopoeia (EP) Reference Standard, 100mg 
neat) were purchase from Sigma-Aldrich (Gillingham, UK). A 1:100 dilution of the 
dexamethasone standard in methanol was prepared to create a working solution of 100 
µg/mL, and this was stored at -20 °C. The internal standard (Flumethasone), was diluted in 
methanol to a working solution of 150 µg/mL and stored at -20 °C. The mobile phase was 
made using Ammonium acetate buffer (5mM, pH 3.5). The buffer was prepared by 
dissolving ammonium acetate in ultrapure water to 5mM, and adjusting with acetic acid to 
pH 3.5. Mobile phase A was 70:30 ammonium acetate buffer to methanol and mobile phase 
B 30:70 ammonium acetate buffer to methanol. Mobiles phases were vacuum filtered through 
Whatman 0.45 µm membrane filters (Sigma-Aldrich; Gillingham, UK) before use. 
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Chromatographic conditions 
An Agilent 1100 series HPLC (Agilent Technologies, Waldbronn, Germany) comprising of a 
binary pump, refrigerated autosampler (set to 5 °C) and a UV-Visible (UV-Vis) variable 
wavelength detector was used with a ChemStation data system. A C-18 Phenomenex Luna 
ODS2 (100 x 2 mm, particle size 3 µm, pore size 100 A; Phenomenex, Torrance, CA, USA) 
column was used and fitted with a Phenomenex SecurityGuard ODS guard cartridge. The 
UV-Vis detector was set at 238 nm for optimal dexamethasone detection (Buavari. S., 1996). 
The mobile phase was continuously vacuum-degassed (with a Cambridge Scientific 
Instruments vacuum degasser) and the column temperature maintained at 40 °C (with a Jones 
Chromatography column heater/chiller) (Figure 4.2).  
 
 
Figure 4.2; example set-up for HPLC  
 
Prior to sample analysis, a wash-programme was run at the beginning of the day using 100% 
methanol for 30 min followed by 50:50 of 100% methanol to 50% methanol/50% water for 
10 min, then back to 100% methanol for 10 min. Following this mobile phases A and B were 
run 50:50 for 30 min, then finally 100% mobile phase A for 10 min. This allowed the HPLC 
machine to be run through with both mobile phases and led to serial elution of any substances 
still residing on the column. Four blank samples were also run prior to sample analysis to 
ensure that no new contaminants were present. 
 
A standard sample injection volume of 10 µL was used and the flow rate was maintained at 
0.4 mL/min. A gradient method was used starting with 2 min of 100% mobile phase A, 
transitioning to 100% mobile phase B over 15 min and remaining stable for 7 min. Finally, 
the gradient returned to 100% mobile phase A over 1 min which continued for 5 min to 













150 µL of each sample was pipetted into a 1.5 mL Eppendorf tube and spiked with 10 µL of 
I.S (150 µg/mL in methanol). In the case of assay validation, the appropriate volume of 
dexamethasone working solution was also added to the sample. The extraction was then 
undertaken by adding 0.5 mL of ethyl acetate and vortex-mixing for 30 s followed by 
centrifugation at 10,000 rpm for 10 min. The supernatant was then transferred to a glass vial 
for drying on a heated block at 40 °C under a gentle stream of nitrogen gas for 10 min. The 
dry samples were reconstituted in 150 µL of mobile phase A, vortex-mixed and centrifuged 




4.2.2 HPLC method development 
Table 4.1 summarises previous HPLC methods used to aid the method development. As 
several papers reported success with isocratic methods, this method was tested first 
(McWhinney et al., 1996). However, despite using four different mobile phase constituents, 
no adequate elution of the dexamethasone was achieved with an isocratic method and 
therefore a gradient method was used instead.  
 
Optimisation of sample extraction was also reviewed and a solid phase-based extraction 
process, referenced in the literature, was trialed on our blank plasma samples spiked with 
dexamethasone (Difrancesco et al., 2007).  However, we found this method to be inferior to 
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(MeOH = methanol, MPA = mobile phase A, MPB = mobile phase B, LOD = limit of detection, LOQ 
= limit of quantification) 
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4.2.3 HPLC method validation 
 
Specificity 
Human plasma samples were spiked first with the internal standard only, which displayed a 
retention time (RT) of 13.64 min (Figure 4.3A). Then the plasma samples were spiked with a 
standard stock solution of dexamethasone (concentrations ranging from 0.375 – 6 µg/mL), 
and a mean RT of 14.3 min was determined (Figure 4.3B, Table 4.3). There was no 
interference at the dexamethasone RT in the plasma spiked with only the internal standard. 
 
 
Figure 4.3; chromatogram of a dexamethasone quality control sample: (A) blank plasma spiked with 
internal standard only (RT 13.6), (B) blank plasma spiked with internal standard (RT 13.89) and 6 
µg/mL dexamethasone (RT 14.36). Axes are not visible, as images cut and enlarged to focus on 
relevant peaks; X-axis = time (min) with retention time (RT) written above each peak, y-axis = scale 









Linearity was tested using multiple dilutions of standard stock dexamethasone. A target 
concentration 3 µg/mL dexamethasone was used and a range of 12.5% - 200% tested (Table 
4.2).  Repeats were performed over 3 different days. 
 
Table 4.2; linearity test of dexamethasone concentrations tested. 
Concentration 
(µg/mL) 
Concentration as % 
of 3 µg/mL  
Mean Dex peak 
area 
CV for peak area 
(%) 
0.375 (n=3) 12.5% 62.273 10.37 
0.75 (n=3) 25% 83.67 6.78 
1.5 (n=3) 50% 120.11 5.80 
3 (n=3) 100% 182.80 8.47 
6 (n=3) 200% 294.59 3.21 
  Mean CV: 6.926 
(CV =  coefficient of variation, dex=dexamethasone).  
 




Figure 4.4; linear regression with the ratio of dexamethasone mean peak area to dexamethasone 
concentration. Correlation co-efficient: r2 = 0.997; equation for regression line: y = 40.8x + 53.83. 
Error bars represent the standard deviation. 
 
Precision 
Precision, described as the coefficient of variation (CV) was assessed by repeatability (inta-
assay precision) and intermediate precision by analysing three repeats of three different 


















dexamethasone concentrations in human plasma. The CV was within the acceptable limit of 
<15% for all concentrations (Table 4.3). 
 
Table 4.3; repeatability tests 
Concentration Mean Peak height (CV%) Mean Peak Area  
(CV%) 
Mean RT (CV%) 
0.375 (n=3) 5.30 (8.01) 10.37 14.27 (1.09) 
0.75 (n=3) 6.92 (6.76) 6.78 14.28 (1.03) 
1.5 (n=3) 10.55 (5.17) 5.80 14.28 (1.02) 
3 (n=3) 17.67 (3.63) 8.47 14.28 (1.03) 
6 (n=3)  30.49 (0.45) 3.21 14.28 (0.99) 
Mean CV 4.80 6.926 1.03 
 
Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD was calculated as 3.3 times the standard deviation (S.D.) of the y-intercept of 
regression line / slope of calibration line, and the LOQ as 10 times the S.D, as shown below 
(Shrivastava & Gupta, 2011). 
 
LOD = 3.3 x 4.049 / 40.61 = 0.329 
LOQ = 10 x 4.049 / 40.61  = 0.997 
 
Absolute recovery 
The absolute recovery of dexamethasone was determined by comparing the dexamethasone 
peak area in a non-extracted saline sample (blank), which is assumed to represent 100% 
recovery, with an extracted plasma sample (matrix), both spiked with 6 µg/mL 
dexamethasone. The dexamethasone peak area was 300.21 in the blank and 294.59 in the 




4.2.4 Patient sampling procedure 
Paired blood and CSDH samples were collected from 34 patients and analysed with HPLC. 
The mean age of patients sampled was 74.5 years (range 34-93 years) and there were 11 
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females and 23 males. This reflects the normal age and gender distribution of patients 
affected by CSDH. 
 
Blood and CSDH samples were collected from patients in 2.2 mL EDTA tubes and 
centrifuged for 10 min at 2,500 rpm at 4 °C. The blood plasma and CSDH supernatant were 
transferred to 2 ml Eppendorf tubes and pipetted into 0.4 mL aliquots for freezing at - 75 °C 
until ready for batch extraction and immediate HPLC analysis. 
 
All samples analysed only underwent a maximum of one freeze/thaw cycle. There is 
evidence in the literature that several freeze-thaw cycles can occur without degradation of 
dexamethasone (Ray, Kushnir, Rockwood, & Meikle, 2011).  
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4.3 Results  
There were 28 placebo patients, with no dexamethasone exposure within at least 1 month of 
sampling, which were used as controls. Oral dexamethasone was given to six patients within 
24 hrs of sampling. The mean time from the last dexamethasone administration to sampling 
was 6.2 hrs (range 2.7 - 15.5 hrs), which is outside the normal half-life of dexamethasone. 
Only the patient with the shortest time-window from last dexamethasone dosing to sampling 
(2.7 hrs) had a very small dexamethasone peak identified in plasma (Figure 4.5). This was 
below the LOQ but still detectable and therefore corresponds to a concentration of 
dexamethasone in the range 0.3 - 1 µg/mL. There was no peak in the intra-operative CSDH 
fluid in this patient. 
 
No dexamethasone peaks were identified in plasma, intra-operative or post-operative CSDH 
drain fluid for any other treatment or control patients. Internal standard peaks were seen in all 
samples as expected.  
 
Table 4.4; dexamethasone dosing and sampling time in all patients 
 No. of patients 
(M:F) 
Mean total dex 
dose pre-op* 
(range) 
Mean time from dex 




Control group 28 (7:21) N/A N/A None 
Dex Treatment 
group 
6 (4:2) 40 mg (8 - 72 mg) 6.2 hrs  
(2.7 - 15.5 hrs) 
1 in plasma 
*= cumulative dex dose given over several days, with a maximum of 16 mg per day, (F = female, 









Figure 4.5; HPLC trace of plasma in patient sampled 2.7 hrs after dexamethasone dosing. Internal 
standard retention time (RT) = 13.748, dexamethasone RT = 14.209. X-axis = time (min) with 
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This HPLC method was designed to determine the presence of dexamethasone in CSDH fluid 
samples compared with serum. The method proved successful at identifying dexamethasone 
in both spiked plasma and CSDH fluid samples. Due to the nature of the trial, despite 
obtaining samples for 34 patients, only 6 patients had received the active treatment, 
dexamethasone, prior to sampling. One small dexamethasone peak was identified in the 
plasma of one patient, and none in the CSDH samples.   
 
Dexamethasone is known to have a short terminal half-life of around 2.5-3.5 hrs when 
assessed in both controls and neurosurgical patients (McCafferty et al., 1981; Tsuei et al., 
1979). The limit of detection and quantification is also higher with HPLC methods compared 
to tandem mass spectrometry (Difrancesco et al., 2007).  These factors limit the ability to 
detect dexamethasone in clinical samples. The short terminal half-life is a particular problem 
in this patient cohort where the majority of CSDH operations take place in the evening, at the 
end of operative lists, whereas dexamethasone administration is normally with breakfast and 
lunch (to avoid the side-effect of insomnia). This led to a mean time from medication dosing 
to sampling of 7.2 hrs, with only two samples taken within 3.5 hrs and dexamethasone only 
detectable in that taken in the shortest time of 2.7 hrs. As the biological half-life of 
dexamethasone has been reported as being around 36-54 hrs, it is much easier to measure the 
clinical effects than the absolute values in any given biological sample (electronic Medicines 
Compendium). 
 
The patient with detectable dexamethasone in the plasma had no detectable dexamethasone in 
the CSDH fluid. This suggests that either does not immediately cross-over into the CSDH 
fluid or if it does so then it is at reduced concentration compared to plasma. Patients received 
regular dexamethasone dosing, with a maximum cumulative dose of 72 mg given pre-
operatively. Despite this, no dexamethasone was detected in any of the CSDH fluid samples, 
where it might be expected to accumulate should it to pass freely into the subdural space and 
remain there. However, as dexamethasone is lipophilic and has high levels of protein binding 
(over 70%) the volume of distribution is very large and therefore there is a very limited 
amount of free dexamethasone able to pass into the subdural space (Cummings et al., 1990; 
Meikle & Tyler, 1977). Furthermore, it is well established that dexamethasone diffuses easily 
 116 
into cells where it binds to its cytoplasmic receptor to induce alterations in transcription of 
inflammatory molecules and related proteins (Barnes, 1998; Dietrich, Rao, Pastorino, & 
Kesari, 2011; Nicolaides, Galata, Kino, Chrousos, & Charmandari, 2010). Thus, it is likely 
that rather than infiltrating the CSDH fluid, its effector cells are located outside the fluid, for 
example within the subdural membranes. 
 
Experimental studies have shown glucocorticoids can induce morphological changes in 
endothelial cells and expression of tight junctions, such that they reduce the permeability of a 
membrane (Forster et al., 2005). This relates to its clinical use in brain tumour patients, where 
it has been shown to reduce the permeability of the endothelium in blood vessels supplying 
the tumour (Heiss et al., 1996; Ostergaard et al., 1999). Therefore, it is possible that 
dexamethasone does not need to enter the subdural space per se as its primary action may be 
on the endothelium of the CSDH membrane blood vessels themselves. As these vessels are 
the source of bleeding resulting in CSDH expansion, modification of the vessel wall to 
prevent further fluid, blood and inflammatory cells infiltration into the subdural space could 
be important in treating CSDH. The on-going process of forming new blood vessels within 
the membrane, angiogenesis, may also be targeted by dexamethasone, as other 
glucocorticoids have been shown to inhibit tumour angiogenesis in animal models (Tamargo, 
Leong, & Brem, 1990). This theory could be further investigated with histological analysis of 
CSDH membranes in patients treated with dexamethasone.   
 
In conclusion, a suitable sampling, extraction and RP-HPLC method has been determined for 
dexamethasone in CSDH samples. However, the hypothesis that dexamethasone would 
accumulate within the subdural space over serial dosing has not been shown, with the caveat 
that the very short half-life is a severe limitation in clinical studies such as this. Surrogate 
markers of the biological action of dexamethasone, as will be explored in chapters five and 
six, may be more suitable targets for analysis. Furthermore, analysis of CSDH membranes 
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Previous studies have indicated a role of for inflammatory pathway modulation in CSDH 
pathophysiology, but the key factors involved in growth and recurrence of a CSDH remain 
unknown. The purpose of this chapter is to increase the understanding of the inflammatory 
composition of CSDH fluid both intra-operatively and post-operatively. 
 
A Dex-CSDH neurochemistry sub-study was designed as part of the Dex-CSDH trial, with 
ethical approval and a separate consent form. All patients recruited into the sub-study 
underwent surgical drainage of their CSDH. Paired intra-operative blood and CSDH fluid 
samples were collected for the sub-study, but otherwise the surgery was performed in line 
with standard clinical practice. In the case of bilateral CSDH, separate samples were 
collected from each side, if possible. Patients who had a routine post-operative subdural drain 
left in-situ had CSDH drainage samples collected after surgery. These drains are normally 
removed after approximately 48 hrs, in some cases they were left up to 72 hrs. All patients 
included in this study were randomised to dexamethasone or placebo as part of the Dex-
CSDH trial and the effect of dexamethasone and other clinical factors on the inflammatory 
markers are discussed in the chapter six.  
 
Hypothesis and aims 
Many of the inflammatory markers assessed in this study have been previously highlighted as 
relevant in CSDH, but the literature is limited and in some cases conflicting. This study aims 
to clarify the inflammatory marker patterns, highlighting those most relevant to CSDH 
pathophysiology, and include analysis of some novel markers. The first hypothesis is that 
VEGF will be the primary marker in driving the inflammatory response in CSDH, as shown 
in previous studies, and that this will correlate with raised levels of other inflammatory 
markers.  
 
There is very limited data on whether concentrations of markers can be used to predict 
recurrence or poor outcome in relation to CSDH, and there are no published studies assessing 
what happens to the inflammatory marker profiles post-operatively. The second hypothesis is 
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that recurrent CSDH samples will contain significantly higher concentrations of VEGF, and 
possibly other inflammatory markers, due to escalating inflammation acting as a stimulus for 
the recurrence. Finally, it is hypothesised that post-operative CSDH samples will contain 
reduced levels of all inflammatory markers, as these have been “washed out” during the 
surgery. The exception to this may be primary CSDHs that develop subsequent recurrent 
CSDH, where higher residual levels of inflammatory markers are expected in the post-




























5.2 Neurochemistry methods 
52 patients were consented and recruited to the neurochemistry sub-study. The mean age was 
76 years and 14 (27%) were women; these reflect the normal demographics of CSDH.  
 
Sampling protocol 
Blood and CSDH samples were collected intra-operatively. Blood was sampled by the 
anaesthetist either during cannulation, or from an arterial line once the patient was 
anaesthetised.  CSDH fluid was collected by the operating surgeon once the subdural space 
was accessed, and prior to any irrigation being used. A 10 ml syringe was used to collect 
CSDH fluid, with care taken not to aspirate any blood from the surrounding surgical wound. 
All samples were then immediately dispensed into pre-labelled ethylenediamine tetra-acetic 
acid (EDTA) tubes (approximately 5 mL) to prevent blood clotting. Samples were either 
transferred immediately to the neurochemistry lab following collection, or stored at 4 °C in 
the theatre fridge prior to transfer.  
 
Post-operative drain samples were collected daily from the subdural drainage bag, between 8 
and 72 hrs post-operatively. Following each sampling, the drainage bag was completely 
emptied, so that subsequent sampling would include freshly drained fluid only. The time of 
sampling and total volume of fluid emptied were recorded on the biochemistry log. All blood 
and CSDH samples were transferred to the neurochemistry lab within 72 hrs of collection and 
registered with a unique lab identifier. Some samples were analysed by UV-Vis spectroscopy 
(see chapter three) prior to centrifugation (10,000 rpm, 10 min, at room temperature) and 
discarding of cells. The plasma or CSDH supernatant was divided into 0.4 mL aliquots in 1.5 
mL Eppendorf tubes, and stored at -75 °C (+/- 10 °C) prior to analysis. 
 
Sample analysis 
After thawing, all samples were analysed using a magnetic bead-based immunoassay on a 
Luminex 200 analyser (Luminex Corporation, Austin, TX, USA). Analyses were performed 
using custom 12-plex ProcartaPlex human cytokine and chemokine magnetic bead-based 
assay kits (Affymetrix eBioscience, Thermo Fisher Scientific; Paisley, UK) for the selected 
panel of inflammatory markers (Table 5.1), following the manufacturers’ instructions. This 
involved quantifying all 12 markers simultaneously, in the same assay well. Analyses were 
done in batches, once there were sufficient samples collected to fill a 96-well assay plate. All 
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standards and samples were analysed in duplicate.  The micro-beads in each well were 
covered with the mix of all 12 marker antibodies and a detection antibody before adding the 
samples. This was then incubated overnight at 5 °C for optimised binding. Any unbound 
substance was removed by washing, and streptavidin-phycoerythrin conjugate was added to 
each well to bind to the detection antibody, before washing and re-suspending the microbeads 
in a buffer for analysis. The concentrations of each marker were obtained from the standard 
curve using Luminex eXPONENT software.  
 
Table 5.1; panel of inflammatory molecules analysed. 
Cytokines Interleukins; IL-1a, IL-1b, IL- 6, IL- 8, IL-10 
tumour necrosis factor; TNF-a 
Chemokines macrophage inflammatory proteins; MIP-1a, MIP-1b 
monocyte chemoattractant protein; MCP-1 
interferon gamma-induced protein; IP-10 
Other inflammatory 
molecules 
vascular endothelial growth factor; VEGF 




Statistical analysis was performed using Graphpad Prism 7 (GraphPad Software, La Jolla, 
CA, USA). As the inflammatory profiles all followed a non-parametric pattern, the 
differences between paired samples (e.g. plasma and CSDH) were assessed using the 
Wilcoxon signed rank test. Unpaired samples (e.g. all primary CSDHs versus all recurrent 
CSDHs) were assessed using the Mann-Whitney Test. Spearman’s rank correlation 
coefficient (Spearman’s rho) was used to display the relationship between any two analytes. 
Any other statistical tests have been described throughout the results. All statistical analysis 












5.3 Intra-operative analyte concentrations in primary and recurrent CSDH 
Paired samples were collected from 57 operations in 52 patients. A single primary CSDH 
operation was sampled in 47 patients, whilst five patients had recurrent operations sampled. 
Of the five recurrence patients, one patient had only the recurrent CSDH sampled (with no 
sample from the primary operation), three patients had the primary and recurrent CSDH 
sampled and one patient had a primary CSDH and two recurrences sampled.  
 
Of the 57 operations, 68 paired plasma and CSDH samples were collected. A single CSDH 
sample was collected in 46 CSDHs, whilst 11 patients had dual-sampling from the same 
operation; 10 from bilateral CSDHs and one with both the anterior and posterior parts of a 
unilateral CSDH sampled. Of the 68 samples, 61 were primary CSDHs and seven from the 
five patients with recurrent CSDH (one bilateral and one patient with two recurrences). 




Figure 5.1; distribution of all 68 intra-operative paired CSDH samples in 52 patients. *one primary 
bilateral sample represents anterior and posterior parts of a unilateral CSDH. 
 
The concentrations of inflammatory markers in all intra-operative plasma and CSDH samples 
are summarised in Figure 5.2. Vascular Endothelial Growth Factor (VEGF) was identified as 
the marker with the highest median concentration in the CSDHs at 9594 pg/mL, and the 
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largest difference in comparison to plasma (approximately 168 times higher). The next 
highest median concentrations of inflammatory markers seen in CSDH fluid were IL-6 (1600 
pg/mL), MCP-1 (1500 pg/mL), IL-8 (433 pg/mL) and IP-10 (254 pg/mL). In plasma, the 
highest median concentration of any inflammatory marker was VEGF (57 pg/mL). 
 
 
Figure 5.2; intra-operative inflammatory marker concentrations detected in: (A) plasma, (B) CSDH. 
All values are the mean of two replicates, n = 68 from 52 patients (as per Figure 5.1). Line (median), 
bars (IQR), for detailed results and statistics see Figure 5.3.  
 
The significant differences found between the concentration of each analyte in plasma and 
CSDH can be seen more completely in Figure 5.3. MMP-9 was the only analyte with a 
median plasma concentration that was significantly higher than CSDH (Figure 5.3H). The 
plasma and CSDH concentrations of all analytes were compared with the literature on healthy 
controls and previous CSDH patients (Table 5.2). The challenge to the healthy control 
literature is that the collection, analytical processes and even statistical analysis are varied 
and poorly reported, thus there is a wide range of what can be considered “normal”. This is 
exemplified by one meta-analysis, where the healthy controls from each study had a mean IL-
8 concentration ranging from 0.91 pg/mL to 60 pg/mL (Dowlati et al., 2010). Other studies in 
the literature have reported median IL-8 values of 4.22 and 29.3 in healthy controls (Dahl et 
al., 2014; Kleiner, Marcuzzi, Zanin, Monasta, & Zauli, 2013). Thus, the overall values from 
the normal literature can only be used as a vague guideline, with the comparative plasma and 

































































































considered that many studies report mean values, whereas median values are more 
appropriate for non-normal data as is seen with the inflammatory markers assessed in this 
study. With these caveats, the cytokine plasma levels were comparable or lower than the 
control literature for all analytes apart from MMP-9, IL-6 and to a lesser extent VEGF, where 
there was a possible trend to higher plasma concentrations in CSDH patients.  
 
 
Figure 5.3; comparison between intra-operative CSDH and plasma concentrations of all 12 analytes. 
Values are the mean of two replicates, n = 68 from 52 patients, as per Figure 5.1. Line (median), bars 


























































































































































































































Table 5.2; plasma and CSDH analyte concentrations in control literature and previous CSDH studies. 
All values are in pg/mL unless stated as ng/mL (ng), means unless stated as median (Md) and plasma 
unless stated as serum. 













(0.5 - 0.5) 




(2.5 - 44.5) 











Di Iorio, 2003 
Dahl, 2014 
Dowlati, 2010 
Pripp* , 2014 
Stanisic, 2012 
907 controls (R 0.1-0.8 in 1292 controls).  
34 controls. (IQR 0.28-0.95) 
246 controls (R 0.67- 17.68) 
51 CSDH patients. 




(0.8 - 2.7) 
20  
607  
Pripp* , 2014 
Stanisic, 2012 
43 CSDHs 















Pripp* , 2014 
67 controls. 
35 controls; serum. 
34 controls. (IQR 1.28-6.28)  
400 controls (R 0.74- 5.35)  














Pripp* , 2014 
35 CSDHs; 1870 in NR, 3450 in recur  
64 CSDHs; 1980 in 52 NR, 2411 in 14 recur 
34 CSDH patients 















Pripp* , 2014 
Stanisic, 2012a 
35 controls; serum (IQR 24.4 - 35.9) 
34 controls. (IQR 2.95-7.04) 
77 controls (R 0.91-60). 
52 CSDH patients. 















56 CSDH patients 
35 CSDH patients; 1170 NR, 2674 in recur 
34 CSDH patients 













Pripp* , 2014 
Stanisic, 2012a 
35 controls; serum (IQR 8.5-16.7) 
34 controls (IQR 0.97-6.03). 
200 controls (R0.7 - 542.32). 
57 CSDH patients 










Pripp* , 2014 
Wada, 2006 
Stanisic, 2012a 
56 CSDH patients  
34 CSDH patients  

















16 controls (IQR 16-113) 
25 controls (IQR 35-71) 
35 controls; serum (IQR 32-118.9) 















11 CSDH patients (R 5,400 - 59,300)  
20 CSDH patients 
19 CSDH patients (R 1,255- 29,908) 
76 CSDH patients 
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Pripp* , 2014 
Stanisic, 2012 
35 controls; serum 
34 controls (IQR 4.92-22.65) 
360 controls (R 0.37 -36.04) 
41 CSDH patients. 




(5.5 - 38.7) 
3.2  
3  
Pripp* , 2014 
Stanisic, 2012 
38 CSDH patients. 













88 controls; serum 
65 controls 




(2.9 - 28.1) 











van B’man 2007 
35 controls; serum (IQR 6.2-9). 





(9.0 - 18.5) 




(3.3 - 5.0) 

















Pripp* , 2014 
Stanisic, 2012a 
35 controls; serum (IQR 20.1 - 78.9). 
56 CSDH patients. 








Pripp* , 2014 
Stanisic, 2012a 
53 CSDH patients. 











Pripp* , 2014 
Stanisic, 2012a 
35 controls; serum (IQR 368.5 - 808.5). 
57 CSDH patients  








Pripp* , 2014 
Stanisic, 2012a 
51 CSDH patients 
73 CSDH patients  
* derived values from reverse log calculation of the results reported (Conc = concentration, IQR = 
interquartile range, Md = median, NR = non-recurrent CSDH, Recur = recurrent CSDH, R = range). 
References; (Dahl et al., 2014; Di Iorio, 2003; Dowlati et al., 2010; Frati et al., 2004; Hohenstein, 
Erber, Schilling, & Weigel, 2005; Hong et al., 2009; Hua et al., 2016; Jonsson, Hjalmarsson, Falk, & 
Ivarsson, 2016; Kleiner et al., 2013; Kut, Mac Gabhann, & Popel, 2007; Li et al., 2018; Lip et al., 
2000; Nanko et al., 2009; Pripp & Stanisic, 2014; Salvi et al., 2000; Shoab, Scurr, & Coleridge-
Smith, 1998; Shono et al., 2001; Stanisic, Aasen, et al., 2012; Stanisic, Lyngstadaas, et al., 2012a; 
van Breemen et al., 2007; Wada et al., 2006; Weigel, Schilling, & Schmiedek, 2001). 
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5.3.1 Vascular Endothelial Growth Factor   
Significantly raised blood VEGF levels have been previously linked to diabetic vascular 
insufficiency (Kusumanto, Meijer, Dam, Mulder, & Hospers, 2007) and chronic venous 
disease (Shoab et al., 1998). VEGF has also been implicated in the neovascularization that 
occurs in diabetic retinopathy, which is characterised by a pre-retinal neovascular membrane, 
not dissimilar to the CSDH neomembranes, with a network of highly permeable vessels 
surrounded by fibroblasts and macrophages (Malecaze et al., 1994). Patients with such 
proliferative retinopathy have higher circulating plasma VEGF which have shown trends of 
decline following laser treatment and resolution of neovascularization (Lip et al., 2000). This 
data supports the role of VEGF in other similar neovascular-related diseases and even has 
potential as monitoring for disease activity and response to treatment.  
 
VEGF was the marker with the highest difference in concentration between CSDH and 
plasma, with a median concentration in CSDH 168 times that of plasma. This suggests it 
plays a critical role in CSDH pathophysiology, as has been highlighted by several other 
studies (Hohenstein et al., 2005; Hong et al., 2009; Nanko et al., 2009; Shono et al., 2001; 
Weigel et al., 2001). Nanko et al. have previously reported no difference in VEGF 
concentrations between 65 non-recurrent and 11 recurrent CSDH samples, with almost 
identical mean levels (Nanko et al., 2009). However, this study shows contrasting data, with 
significantly higher VEGF concentrations in the seven recurrent CSDH samples (median 
11987 pg/mL) compared to the 61 primary CSDH samples (median 8443 pg/mL) (p= 0.05) 
(Figure 5.4). This may suggest a role for VEGF in driving CSDH recurrence, however low 
numbers of recurrent samples make assessment of significance difficult, and the VEGF 
concentrations were highly varied amongst these seven patients. To analyse this further, only 
the paired primary and recurrent CSDH samples were assessed, excluding the patient where 
the primary CSDH was not sampled (also the highest outlier). The remaining six paired 
samples (one patient had two recurrences, each paired to the primary CSDH) showed no 
significant difference but a trend to higher VEGF concentration in the recurrent samples (p = 
0.0938) (Figure 5.5A). Perhaps surprisingly the plasma VEGF showed the opposite trend, 
with lower concentrations in plasma at recurrence, compared to time of primary surgery (p = 
0.0625) (Figure 5.5B). As the plasma VEGF at primary surgery is at the higher end of the 
range in normal literature (Table 5.2), this may indicate there is a mild peripheral 
inflammatory response in CSDH, which is lower following primary treatment, even in the 
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case of recurrence.  To validate this theory, it would be helpful to assess follow-up plasma 
samples in all CSDH patients, not just the recurrent cases, to look for systemic reductions in 
VEGF after surgical treatment of CSDH. No such data has been published, and therefore this 
should be considered in future studies.  
 
Figure 5.4; VEGF concentration in all CSDH and plasma samples (n = 68), primary CSDH (n = 61) 
and recurrent CSDH (n = 7) samples. Line (median), bars (IQR), statistically significant differences 
denoted as P £ 0.05 (*), (Recur = recurrence). 
 
 
Figure 5.5; VEGF concentration in patients with recurrent CSDH in: (A) CSDH, (B) plasma. N=6, 
line (median), bars (IQR), (Recur = recurrence). 
 
To help elucidate whether CSDH recurrence could be predicted from the primary surgical 
samples, comparison was made between patients who went on to have a recurrence and those 
who did not. Six primary CSDH samples were available in patients who went on to have a 
recurrence, with little difference in the VEGF concentration compared to the remaining 55 
primary samples (p = 0.3117, Figure 5.6).  The same was seen with plasma VEGF 
concentrations (p = 0.4442, data not shown).   


























































Figure 5.6; VEGF concentration in primary CSDH samples for non-recurrent (non-recur) and 
recurrent (recur) cases in CSDH. Non-Recur n = 55, Recur n = 6, line (median), bars (IQR). 
 
CSDH concentrations of VEGF in all 68 samples showed a moderate positive correlation 
with IL-6 (Spearman r = 0.5846, p < 0.0001) and MIP-1b (Spearman r = 0.5575, p < 0.0001), 
and a weaker correlation with IL-8 (Spearman r = 0.4178, p = 0.0004) and MMP-9 
(Spearman r = 0.3425, p = 0.0043) (Figure 5.7). This is supportive of synergistic action 
between some of the inflammatory markers. 
 
Figure 5.7; significant correlations between VEGF and other markers: (A) IL-6, linear regression line 
y = 0.2929x - 788.6, r2 = 0.3242, (B) MIP-1b, linear regression line y = 191.7x + 6760.6, r2 = 0.2928, 
(C) IL-8, linear regression line y = 3.561x - 2536, r2 = 0.2972, (D) MMP-9, linear regression line y = 



















5.3.2     IL-6, IL-8 and IL-10 
IL-6 and IL-8, both considered pro-inflammatory cytokines, had the second and fourth 
highest concentrations in the CSDH samples. IL-10 was the sixth highest, but is conversely 
considered an anti-inflammatory cytokine, although previous literature has shown that 
patients with high IL-10 also have higher levels of IL-6 and IL-8 (Wada et al., 2006). It is 
suggested that this shows there is some balance of pro- and anti-inflammatory cytokine 
activation, attempting to modulate the inflammatory response. However, no correlation 
between the three markers was found in this study, and IL-6, IL-8 and IL-10 were 
significantly different from one another (Friedman test, p<0.0001) (Figure 5.8).  
 
 
Figure 5.8; concentrations of IL-6, IL-8 and IL-10 in CSDH. N = 68. Line (median), bars (IQR), 
statistically significant differences denoted as P £ 0.0001 (****). 
 
Co-ordinated production of IL-6 and IL-8 is often observed in inflammatory conditions 
(Kishimoto, Akira, & Taga, 1992), and a significant moderate correlation was observed in 
this study (Spearman correlation r = 0.6314, p<0.0001) (Figure 5.9A). The correlation was 
repeated with the largest value excluded, as it appeared as if this may have a large influence 
on the correlation, but there was little change (Spearman correlation r = 0.6147, p<0.0001) 
(Figure 5. 9B).  
 
















Figure 5.9; correlation between IL-6 and IL-8: (A) all samples (N = 68), linear regression line y = 
0.2774x - 20.6, r2 = 0.869, (B) largest outlier excluded (N = 67), linear regression line y = 0.2034x + 
133.6, r2 = 0.381. 
 
IL-6 and IL-8 have previously been shown to be significantly higher in recurrent CSDH 
compared with primary CSDH (Frati et al., 2004), a finding also seen in this study; IL-6 
primary CSDH median 1569 pg/mL versus recurrence median 4294 pg/mL (p = 0.0008); IL-
8 primary CSDH median 396 pg/mL versus recurrence median 911 pg/mL (p = 0.0179) 
(Figure 5.10A&B). Again, this was repeated with largest outlier excluded (which was a 
recurrence sample for which no primary sample had been collected), maintaining significance 
for IL-6 (p = 0.0041), but just missing it for IL-8 (p = 0.0625) (Figure 5.10C&D).  
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Figure 5.10; concentrations in all primary and recurrent CSDHs for: (A) IL-6, (B) IL-8, Primary n = 
61, recurrence n = 7, (C) IL-6 excluding outlier, (D) IL-8 excluding outlier, Primary n = 61, 
recurrence n = 6. Line (median), bars (IQR), statistically significant differences denoted as; P £ 0.05 
(*), P £ 0.005 (**), P £ 0.001 (***), (Recur = recurrence). 
 
IL-10 showed no significant difference in CSDH concentration relating to recurrence (p = 
0.3610) and there was no difference in the plasma levels of IL-6, IL-8 or IL-10 in recurrent or 
primary samples (data not shown). Analysis of the six, paired primary and recurrent CSDH 
samples showed a significant difference with IL-8 (p = 0.0312) and a non-significant trend to 
higher IL-6 (p = 0.0625) and IL-10 (p = 0.0625) in the recurrence samples (Figure 5.11).    
 
 
Figure 5.11; primary and recurrent CSDH paired samples: (A) IL-8, (B) IL-6, (C) IL-10. N = 6. Line 



























































































































When assessing primary CSDH samples to see whether they were predictive of recurrence, 
no significant difference was seen for IL-6 or IL-8 (data not shown). However, IL-10 was 
significantly lower in the recurrent primaries (p = 0.0015) (Figure 5.12), which remained 
significant with removal of outliers (p = 0.0020). Lower concentrations of IL-10 may 
increase the risk of recurrence by reducing the normal anti-inflammatory response needed to 




Figure 5.12; IL-10 in primary CSDH samples for non-recurrent and recurrent cases. Non-recurrence 
n = 55, recurrence n = 6. Line (median), bars (IQR), statistically significant differences denoted as P £ 




Matrix Metalloprotease-9 (MMP-9) is the only marker with significantly higher 
concentrations in plasma than CSDH (p < 0.0001). There were no significant differences 
between primary and recurrent samples for CSDH (p = 0.2407) or plasma (p = 0.6458) 
(Figure 5.13A). However, paired primary and recurrent CSDH samples showed a strong trend 
towards higher MMP-9 in the recurrent samples (p = 0.0625, Figure 5.13B). When all the 
primary CSDH samples were compared, those that went on to recur were not significantly 




















Figure 5.13; MMP-9 concentration in primary and recurrent CSDH and plasma: (A) all samples, N = 
68, (B) paired primary and recurrent samples. N = 6. Line (median), bars (IQR), statistical significant 
differences denoted as P £ 0.0001 (****), (Prim = primary, Recur = recurrence).  
 
Interestingly MMP-9 was the only marker where the relationship between CSDH and plasma 
concentrations were not the same in all patients. There were three different patterns of MMP-
9 observed, and when analysing all the primary CSDH samples; in 68% (46/68) MMP-9 was 
higher in plasma (HP), in 20% (14/68) it was higher in CSDH (HC) and in 12% (8/68) it was 
comparable with CSDH concentrations (within 5 pg/mL, Figure 5.14A). The median 
differences between plasma and CSDH were 33pg/mL for HP and -15pg/mL for HC. A 
significant difference was found in these values between primary and recurrent CSDHs, with 
higher CSDH concentrations compared to plasma in the recurrent cases (p = 0.0241, data not 
shown). This is also reflected in reversal of the MMP-9 plasma/CSDH patterns in the 
recurrent samples, with 4/7 (57%) HC, 2/7 (29%) HP and 1/7 (14%) comparable (Figure 
5.14B). This increase in MMP-9 within the CSDH at recurrence (compared to plasma), 
suggests that MMP-9 is more active in recurrence than primary CSDH and may be because 
MMP-9 is important in the early stages of membrane formation, which has often long passed 
by the time of primary CSDH operation. However, recurrence could be partly driven by re-
activation of MMP-9 post-operatively, leading to further new membrane formation and 
bleeding.   
 





































Figure 5.14; (A) MMP-9 subgroups in primary CSDH. Conc. diff is the concentration difference as 
shown by plasma concentration minus CSDH concentration. N=68, (B) MMP-9 sub-groups in 
recurrent CSDH. N = 7. Box (median), whiskers (range), (HP = higher plasma, HC = Higher CSDH, 
Com = comparable). 
 
There was a moderate positive correlation between MMP-9 and MIP-1b (Spearman r = 
0.499, p < 0.0001) and a moderate negative correlation between MMP-9 and IL-1a 
(Spearman r = -0.455, p < 0.0001) (Figure 5.15). A positive correlation with VEGF is 
reported earlier (Figure 5.7D), but all remaining analytes were weakly or not significantly 
correlated with MMP-9 (data not shown). Previous reports have suggested that MMP-9 can 
have pro or anti-inflammatory actions (Manicone & McGuire, 2008), in general the positive 
correlation with VEGF and MIP-1b suggest it is pro-inflammatory, although it is not clear 
why there is a negative correlation with IL-1a, which is generally accepted as a “pro-
inflammatory” cytokine (Di Paolo & Shayakhmetov, 2016). 
 
 
Figure 5.15; correlations of MMP-9 with: (A) MIP-1b, linear regression y = 0.8043x + 1.454, r2 = 











































5.3.4 Other analytes 
The same analysis as shown in the above sections (3.3.1-3.3.3) was performed on all other 
analytes. Only the significant results are shown in this section with a summary of all findings. 
 
MIP-1b and TNF-a 
MIP-1b and TNF-a were significantly higher in recurrence samples compared with all 
primary samples (MIP-1b p = 0.02; TNF-a p = 0.0371) (Figure 5.16). However, significance 
was lost when comparing only the paired primary and recurrent samples and primary samples 
were not predictive of recurrence (data not shown).  
 
 
Figure 5.16; all primary and recurrent CSDH samples: (A) MIP-1b, (B) TNF-a. N = 68. Line 
(median), bars (IQR), statistically significant differences denoted as P £ 0.05 (*), (Recur = 
recurrence). 
 
IL-1a and IL-1b 
IL-1a and b are secreted by macrophages in the early stages of inflammation and can induce 
expression of pro-inflammatory genes for other cytokines and MMPs (Apte & Voronov, 
2008). Severe inflammation, with necrotizing cells, is required for IL-1a to become 
detectable, therefore it is not surprising that circulating plasma levels, as seen in Table 5.2 are 
very low (Apte & Voronov, 2008). However, there was a significant difference in IL-1a 
concentration between paired primary and recurrent CSDH samples (p = 0.0312), but only a 
trend comparing all primary with recurrent samples (p = 0.1075) (Figure 5.17A&B). For IL-
1b, there were significantly higher concentrations in all recurrence versus primary samples (p 






































Figure 5.17; primary and recurrent CSDH samples: (A) IL-1a in all samples (n = 68), (B) IL-1a in 
paired samples (n = 6), (C) IL-1b in all samples (n = 68), (D) IL-1b in paired samples, (n = 6). Line 
(median), bars (IQR), statistically significant differences denote as P £ 0.05 (*), P  £ 0.005, (Recur = 
recurrence). 
 
IL-1 and TNF-a are often considered to simulate each other’s production (Apte & Voronov, 
2008). This is seen with the moderate positive correlation between IL-1a and TNF-a 
(Spearman r = 0.5341, p < 0.0001, Figure 5.18), although interestingly IL-1b was not 
significantly correlated to TNF-a nor to IL-1a (data not shown). IL-1a also has significant 
moderate positive correlation with IL-8 (r = 0.534, p < 0.0001), all other correlations were 
weak or non-significant.  
 
 
Figure 5.18; correlation of IL-1a with: (A) TNF-a (r2 = 0.2159, y = 0.4623x + 14.22), (B) IL-8 (r2 = 

























































































MCP-1, MIP-1a and IP-10 
No significant differences between primary, recurrent or paired samples were found for these 
markers. 
 
5.3.5 Bilateral CSDH 
There were 10 cases of bilateral CSDH with no significant differences between the paired 
sides, suggesting contralateral sides are comparable for inflammatory profiles within 
individual patients (Figure 5.19). This is further validated by significant correlations between 
sides for MCP-1, VEGF, TNF-a, IL-1a and IL-1b (Table 5.3 and Figure 5.20). Correlation 
was close to significance for the remaining markers, but some are skewed by one or two 
outlying patients with large differences between sides. To assess the difference further, the 
side with the larger value was taken as the “baseline” and the percentage decrease to the 
smaller value calculated, with an overall mean difference of 30% between sides. In general, 
despite the collections being considered individual due to division by the midline falx cerebri 
and each CSDH membrane, this suggests there is reasonable congruity between sides. This is 
much greater than that seen between individual patients, as seen with large coefficients of 
variation (Table 5.3). The explanation for this is either the CSDH fluid can communicate 
across the membranes and falx cerebri, or that each patient mounts a similar level of 
inflammatory response on contralateral sides despite each CSDH being self-contained. 
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Figure 5.19; analyte concentrations for individual patients with bilateral CSDH for all analytes: (A) 
IL-1a, (B) IL-1b, (C) IL-6, (D) IL-8, (E) IL-10, (F) VEGF, (G) TNF- a, (H) MMP-9, (I) MIP-1a, 









Table 5.3: correlation of analyte concentrations and percentage difference between sides of bilateral 
CSDH. Rows highlighted in blue show significant correlation. 
Analyte Correlation between 
sides of bilateral CSDH 
Mean % decrease 
between sides  
Coefficient of variation 
in all samples 
IL-1a R = 0.930 (p = 0.0003) 30% 122% 
IL-1b R = 0.748 (p = 0.016) 33% 248% 
IL-6 R = 0.515 (p = 0.133) 30% 146% 
IL-8 R = 0.139 (p = 0.707) 46% 162% 
IL-10 R = 0.636 (p = 0.054) 47% 177% 
VEGF R = 0.733 (p = 0.020) 23% 64% 
TNF-a R = 0.891 (p = 0.001) 18% 124% 
MMP-9 R = 0.478 (p = 0.166) 46% 127% 
MIP-1a R = 0.418 (p = 0.233) 42% 63% 
MIP-1b R = 0.624 (p = 0.060) 40% 84% 
MCP-1 R = 0.879 (p = 0.002) 21% 45% 
IP-10 R = 0.479 (p = 0.166) 44% 67% 
Mean of all 
analytes 
N/A 35% 119% 
 
 
Figure 5.20; significant correlations for bilateral CSDH: (A) VEGF, (B) MCP-1, (C) TNF-a, (D) IL-
1a. N = 10. For R and p values see Table 5.3. 
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All individual bilateral CSDHs (including those where only one side was sampled) were 
compared to all the unilateral CSDHs to see whether they behaved differently. The unilateral 
CSDHs had significantly higher concentrations of VEGF (p = 0.0399) and MIP-1a (p = 
0.0386) (Figure 5.21). There was also a trend to higher concentration of IL-6 (p = 0.0616), 
but no difference for any other analyte (data not shown). One explanation for higher 
inflammatory markers in unilateral cases could be the dilution of the inflammatory markers in 
bilateral patients, were the body is required to mount an inflammatory response over a much 
larger surface area of brain (combined volumes of bilateral CSDHs are significantly more 
than unilateral, see imaging chapter seven). This might be particularly relevant if the pool of 
inflammatory cells is recruited locally from the skull bone marrow, as has been demonstrated 
in murine models, where the production per surface area of brain is potentially limited 
(Herisson et al., 2018).  
 
 
Figure 5.21; comparison between bilateral (B/L) and unilateral (U/L) CSDHs for: (A) VEGF, (B) 
MIP-1a, B/L n = 23, U/L n = 45. Line (median), bars (IQR), statistically significant differences 
denoted as P  £ 0.05 (*). 
 
In one patient two samples were taken from a unilateral CSDH; one from the anterior burr 
hole, the other from posterior burr hole. This was because the fluid in the collection looked 
very different between the anterior and posterior portions seen under each burr hole. This is 
usually due to different patterns of blood within the CSDH, which is discussed further in the 
imaging chapter (chapter seven). The posterior sample had higher concentrations of all 
analytes (shown by orange extension), apart from IL-1a and TNF-a, than the anterior sample 
(pink bar) (Figure 5.22). When all the markers were grouped and paired, there was a 
significant difference between the anterior and posterior concentrations (Wilcoxon test p = 






































two different CSDHs (as with each side of bilateral samples), as the samples were so 
different and it was not possibly to determine which was more representative. This raises the 
issue of regional CSDH inflammatory variation, which is unsurprising considering the 
different patterns of density seen within many CSDHs (see imaging chapter seven). The burr 
hole positioning could therefore have a significant influence on the inflammatory markers 
observed in the fluid collected. For future studies, it may be beneficial to take samples from 








5.3.6 Intra-operative data summary  
General findings from the intra-operative CSDH and plasma fluid data can be surmised as; 
i. All analytes were significantly elevated in CSDH compared to plasma, apart from 
MMP-9. This supports the established theory that the inflammatory response in 
CSDH is overwhelmingly a local phenomenon. 
ii. VEGF was the marker with the greatest concentration by far within CSDH, 
supporting the hypothesis that this is the primary mediator of inflammation. 
iii. MMP-9 had significantly higher plasma levels in the majority of primary CSDHs, 
however this was reversed for recurrent CSDH, and may indicate a role for MMP-
9 in the early development of CSDH which is re-activated during recurrence. 
iv. The majority of pro-inflammatory markers (IL-6, IL-8, IL-1a, IL-1b, MIP-1b, 
TNF-a and MMP-9) are elevated in CSDH recurrence samples suggesting that 
















































v. The only marker where concentrations at the primary operation could help predict 
recurrence was IL-10, where it was significantly lower in CSDHs that went on to 
recur. This suggests a poorly balanced anti-inflammatory response in CSDHs that 
recur. 
vi. Several of the pro-inflammatory cytokines are moderately well correlated, 
particularly VEGF, IL-6 and IL-8 suggesting they are working in synergistic 
cascades (see Table 5.4) 
vii. Bilateral CSDHs are more similar to one another than CSDHs between different 
patients, suggesting they either communicate or that each patient’s cellular 
inflammatory response is similar regardless of the collection being self-contained 
on the opposite side of brain. 
 
Table 5.4; summary of correlations between individual inflammatory markers 
 IL-1b VEGF IL-6 IL-8 IL-10 TNF-a MCP-1 IP-10 MIP-1a MIP-1b MMP-9 
IL-1a / / + ++ / ++ / / + / + 
IL-1b  / / / / / / + + + + 
VEGF   ++ + / / / / / ++ + 
IL-6     ++ / + / / + + / 
IL-8     / / + / + + / 
IL-10      + - / / / / 
TNF-a       / / / / / 
MCP-1        / / + + 
IP-10         + / / 
MIP-1a          + / 
MIP-1b           + 
R <0.3 no correlation (even if p significant) = / 
R = 0.30 - 0.49 and p<0.05; significant weak correlation = + (positive) or - (negative) 
R = 0.50 - 0.70 and p<0.05; significant moderate correlation = ++ (positive)  
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5.4 Post-operative CSDH drain samples 
Post-operative drain samples were collected from 28 CSDHs in 25 patients (three bilateral), 
with comparable demographic data to the patients who had intra-operative sampling (Figure 
5.23). 
 
Figure 5.23; demographic data on patients with drain samples collected compared to all patients: (A) 
gender distribution, (B) age distribution. Intra-op n = 68, post=op n = 25, line (mean), bars (S.D.), (op 
= operative). 
 
All 28 CSDHs had the drain sampled and emptied within 8-24hours of the operation, 10 of 
these drains were emptied and sampled again within the next 16-hour time window (25-40 
hours), four of whom were emptied and sampled in the final 24-hour time window (41-65 
hours). More drain samples were collected but were excluded if they were not sampled at all 
time-points, as this would allow accumulation of markers over multiple time points and skew 
the data. The drainage fluid contained, in differing ratios, a mixture of residual CSDH fluid, 
intra-operative irrigation fluid (0.9% normal saline), and fresh haemorrhage from the surgical 
wound. However, considering that the plasma concentrations were low for all analytes other 
than MMP-9, any increases in inflammatory markers is largely considered to be due to new, 
local production within the subdural space rather than from operative haemorrhage. This is 
further corroborated by the low-rate of acute bleeding seen on post-operative CT scans (see 
imaging chapter seven). The data in this chapter is also potentially limited by the variations in 
volume of fluid output for each drain. To get truly reliable readings the concentration of 






































The trend in the percentage-change in VEGF concentration from baseline (intra-operative) 
can be seen in Figure 5.24. The median percentage change was -33.5% (mean -23.6%) in 
samples collected at 8-24 hrs, although there was a wide range (-86% to +80%) with 71% 
(20/28) of CSDHs showing a drop from baseline. This exemplifies what was hypothesised to 
occur in the immediate post-operative period, as the majority of the VEGF should have been 
washed out during surgical evacuation of the CSDH, leading to a decrease in concentration. 
However, as the CSDH membranes remain in-situ, there will be on-going production of 
VEGF post-operatively and infiltrating inflammatory cells produced in response to the 
surgical trauma, explaining the positive trend seen in some patients. From 25-40 hrs the 
median percentage change was 22% (mean 15.5%), showing a significant shift from the 8-24 
hr values (unpaired t-test, p = 0.0176), to an increased production of VEGF. This time 70% 
(7/10) of samples showed an increase compared to baseline, suggesting this is the most 
reactive pro-inflammatory time period. Finally, between 41-65 hrs the median percentage 
change was -26% (mean -20.3%), with 75% (3/4) showing a negative trend once again. As 
post-operative drains are removed within 48-72 hrs it is impossible to assess the trend after 
this time point. Therefore, the levels of VEGF could be cyclical or more likely, levels are 
depleted during surgical evacuation but on-going production leads to an acuumulation of 
VEGF at around 25-40 hours post-operatively which then declines, presumably continually, 
until resolution of the CSDH occurs (unless there is a recurrence). 
 
 
Figure 5.24; percentage change in VEGF in post-operative drain samples. Line (median), box (IQR), 



















5.4.2 IL-6, IL-8 and IL-10 
No significant changes were seen at any of the post-operative time-points with regard to the 
percentage change in IL-6 or IL-8, although again the range of changes was wide. A few 
patients showed massive increases in IL-6/IL-8 production, again mostly at the 25-40 hr time 
point (Figure 5.25).  
 
 
Figure 5.25; percentage change in post-operative drain samples: (A) IL-6, (B) IL-8. Line (median), 
box (IQR), whiskers (range). 
 
No significant differences were seen at different time points post-operatively for the full IL-
10 data set, however there were six outliers at the 8-24 hr time point. This included a patient 
with an intra-operative IL-10 concentration of only 3.58 pg/mL which increased by a massive 
3714% to 136.57 pg/mL post-operatively. Interestingly, this was one side of a bilateral 
CSDH and the contralateral side also increased substantially, by 1282% from 9.81 pg/mL to 
135.69 pg/mL. Again, this suggests that either the fluid on both sides is in communication, or 
that the patient’s inflammatory response is mirrored on each side of the head. This is a 
surprising response as IL-10 is considered to primarily be anti-inflammatory, and such a huge 
surge of anti-inflammatory action would not be expected following an inflammatory stimulus 
such as surgery. Exclusion of the six outliers, makes it easier to observe the peak in 

































Figure 5.26; percentage changes in IL-10 in post-operative drain samples: (A) all data, (B) excluding 
outliers. Line (median), box (IQR), whiskers (range), statistically significant differences denoted as P 
£ 0.005 (**). 
 
In-keeping with the intra-operative samples, a significant positive correlation was found 
between the percentage changes in drain samples of IL-6 and IL-8 at 8-24 hrs (Pearson’s r = 
0.554, p = 0.0022) and 25-40 hrs (Pearson’s r = 0.8856, p = 0.0007). There were not enough 
time points at 41-65 hrs to assess correlation and there was no correlation with either marker 
and IL-10 or VEGF at any time point (Figure 5.27). 
 
 
Figure 5.27; correlation of IL-6 and IL-8 in post-operative drain samples at: (A) 8-24 hrs, linear 
regression line y = 1.115x + 15.21, (B) 25-40 hrs, linear regression line y = 2.309x - 88.98. 
 
5.4.3 MMP-9 
The drain samples showed escalating, and in some cases massive concentrations of MMP-9 
post-operatively, with 96% showing a positive change at 8-24 hours, but with wide ranges 
and no significant differences (Figure 5.28). This, to some extent, explains why MMP-9 was 
higher in CSDH than plasma in the recurrent samples, as clearly it is re-activated following 
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Figure 5.28; percentage change in MMP-9 in post-operative drain samples. Line (median), box 
(IQR), whiskers (range). 
 
5.4.4 Other analytes 
None of the remaining markers showed significant changes post-operatively, but the patient 
numbers are also small. Perhaps more informative are the patterns in mean percentage-
change post-operatively (Figure 5.29). VEGF and IP-10 were the only markers to show a 
majority decrease in concentration at 8-24 hrs, whilst all other markers showed a majority 
increase at the earliest time point. In some cases, this was extremely large, such as the MIP-
1b, where the mean increase was 4187%. This contradicts the hypothesis of surgery washing 
out and diluting all the inflammatory markers, and instead surgery appears to stimulate 
production of most markers. Several of the key markers such as VEGF, IL-6 and IL-8 
increase up to 25-40 hrs and then start to show a decline, although concentrations are still 
higher than the intra-operative values at 41-65 hrs for all markers except VEGF. Most of the 
remaining markers continue to increase up to 41-65 hrs, which may mean that they take 
longer to decline post-operatively or that it is the change in balance of pro- and anti-
inflammatory markers, rather than the absolute values, which switch the environment from 


















Figure 5.29; mean analyte percentage changes in post-operative drain samples. 
 
5.4.5 Post-operative drain samples and recurrence 
One might expect higher post-operative levels of inflammatory markers in patients that go on 
to develop a recurrence. However, a significant difference between recurrent (n=4) and non-
recurrent (n=22) primary post-operative samples at 8-24 hrs was seen for only one marker, 
MCP-1 (Unpaired t-test, p = 0.0092) (Figure 5.30). Only one patient who went on to have a 
recurrence was sampled after 24 hours, therefore no further comparisons could be made at the 
later time-points.  
 
Figure 5.30; percentage change in MCP-1 in post-operative drain samples at 8-24 hrs in primary 
CSDHs that lead to recurrence (n=4) or no recurrence (n=22). Line (median), box (IQR), whiskers 
















































































A panel of cytokines and chemokines was selected for assessment in CSDH pathophysiology. 
The selection was based on previous evidence of molecules that are likely to contribute to 
CSDH or have been shown to be involved in neuro-inflammatory processes in other types of 
head injury. The aim was to determine which factors are most significant in CSDH 
pathophysiology and recurrence, and thus could be potential targets for treatments such as 
dexamethasone. Only IL-10 was included as an anti-inflammatory marker, due to previous 
evidence of its role in predicting lower recurrence (Wada et al., 2006). MMP-9 has been 
shown to act in both pro- and anti-inflammatory roles but also has a key role in angiogenesis 
(Manicone & McGuire, 2008), a process essential to CSDH membrane formation. 
 
Limitations of work 
As only approximately 10% of CSDHs recur it is challenging to obtain sufficient patient 
numbers to make meaningful comparisons between recurrent and non-recurrent CSDH. 
CSDH collections can also be loculated and poorly mixed, meaning that the region of 
sampling might influence to some degree the inflammatory response observed, as seen in the 
case with anterior and posterior samples. Multi-regional sampling might help overcome this 
in future studies.  
 
Summary of findings 
Analysis of the intra-operative CSDH fluid led to findings agreeing with previous literature 
that VEGF, IL-6, IL-8, IL-10, IP-10, MCP-1 and IL-1b were significantly raised compared to 
plasma. Novel data showed that IL-1a, MIP-1a and MIP-1b were also raised, implying they 
contribute to the inflammatory cascade in CSDH. TNF-a levels were also found to be 
significantly higher in CSDH, whereas previous literature has suggested they are not raised 
(Pripp & Stanisic, 2014; Stanisic, Aasen, et al., 2012).  
 
MMP-9 was the only marker with overall significantly higher concentrations in plasma than 
CSDH, although this was not the case in all patients. This contradicts previous findings in the 
literature where consistently significantly higher levels of MMP-9 were found in CSDH 
compared to serum (Hua et al., 2016). Positive MMP-9 staining has also been displayed in 
CSDH outer membranes, suggesting it has a key role in CSDH pathophysiology (Nakagawa, 
Kodera, & Kubota, 2000). The percentage of patients with higher MMP-9 in CSDH 
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compared to plasma was greater in recurrent CSDHs (57%) compared to primary CSDH 
(20%). There were also huge increases in MMP-9 post-operatively for most patients (as high 
as 4000% increase), which continued to increase up to 65 hrs post-operatively. This has led to 
a new hypothesis that MMP-9 is important in the early stages of CSDH membrane 
development and angiogenesis and may have decreased (below plasma levels) by the time of 
primary surgery in most patients. However, surgery appears to “re-activate” MMP-9 which 
may be an important cause of further membrane/vessel development and subsequent 
recurrence. 
 
Higher concentrations of several other markers were also linked to recurrence; VEGF, IL-6, 
IL-8, IL-1a, IL-1b, MIP-1b, TNF-a, giving credence to the theory that on-going, 
uncontrolled inflammation drives CSDH recurrence. Indeed, post-operative drain samples 
suggest that rather than “washing” out these markers, most are increased by the stimulus of 
surgery. Unfortunately, the concentrations of most analytes at the time of primary CSDH 
surgery, and post-operatively, do not appear to be predictive of recurrence. Only a decreased 
level of IL-10 appeared to relate to a higher risk of recurrence, and therefore might be 
valuable for predicting high-risk patients.  
 
This is the first time that congruity in inflammatory response between sides of bilateral 
CSDHs has been shown, and is surprising since each side is often assumed to be an entirely 
independent collection. Either the inflammatory response from the body is co-ordinated in 
such a way that the response is the same on both sides, or possibly the fluid communicates 
across membranes and through CSF pathways, translating the inflammatory response from 
one side to the other. There was one clear outlier with highly different levels of IL-6, IL-8 
and IL-10 between sides, and there are often clinical cases where only one side of a bilateral 
CSDH needs treating, whilst the other is small and dormant, therefore clearly situations exist 
where the inflammatory response is not equivalent bilaterally. This could potentially relate to 
CSDHs which are more encapsulated or membranous. 
 
In summary, the hypotheses that VEGF would be the most significant marker, and that this, 
and other markers, would be further elevated in recurrent CSDH was confirmed. However, 
the hypothesis that surgery would result in significant dilution of markers was not confirmed, 
with all markers showing some elevation at one or more time-points post-operatively. VEGF 
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was the marker with the greatest overall decrease, although there was still a peak at 25-40 
hrs. Several of the other markers remained significantly elevated throughout the post-
operative period. This may indicate that the early post-operative period is an important target 
time for anti-inflammatory therapies such as dexamethasone, as there is actually an on-going 
and in some cases elevated inflammatory response following surgery. Dampening down this 
response may help to prevent an on-going tide of new inflammatory marker activation which 
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Firstly, this chapter will explore the hypothesis that dexamethasone aids resolution of CSDH 
through reducing inflammation within the subdural space. This will be investigated by 
comparing concentrations of the inflammatory markers discussed in chapter five in the intra-
operative and post-operative CSDH fluid samples from both placebo and dexamethasone-
treated patients. It is hypothesised that dexamethasone-treated patients will have lower 
concentrations of all inflammatory markers compared with placebo patients; particularly 
VEGF, the marker present in highest concentrations in CSDH. It is also anticipated that the 
concentration of inflammatory markers will be lower in the post-operative than the intra-
operative samples, due to the cumulative effect of dexamethasone dosing over time. 
Likewise, patients who have received higher doses of dexamethasone pre-operatively are 
expected to have lower concentrations of inflammatory markers than those with lower 
cumulative pre-operative dosing.  
 
The second main hypothesis of this chapter is that the level of inflammatory response within 
a CSDH correlates to both the time since traumatic injury and patient outcome. If the 
inflammatory response in CSDH continues to escalate over time, as is suspected, then those 
patients with the longest time delay from trauma to surgery should have the highest levels of 
inflammation. Similarly, those patients with higher levels of inflammation present are more 
likely to have a poorer outcome, as measure by GCS on discharge and mRS at three and six 
months. Further clinical data which may be relevant to the inflammatory response, such as 






All samples were collected as per the method reported in chapter five and the same 68 
samples from 52 patients are reviewed in this chapter. All patients recruited to the 
neurochemistry sub-study had been previously randomised to the study IMP (dexamethasone 
or placebo), and this allocation was blinded throughout the collection and analysis of all 
neurochemistry samples. Unblinding for final results analysis only occurred once all patients 
had completed their final study follow-up at six months, and this information was restricted 
to the neurochemistry team.  
 
At the time of inclusion in the neurochemistry study, details on how much trial medication 
was taken pre-operatively and post-operatively, during drainage sample collection, was 
recorded. Relevant demographic and clinical data was also collected on all patients. There 
was no significant difference between the treatment groups for time from randomisation to 
operation, with most patients operated on the same or following day. 
 
Of the 52 patients included in the neurochemistry study, 22 received dexamethasone and 30 
received placebo. Only 11 of the dexamethasone patients had received any IMP prior to 
surgery, with the remaining 11 patients starting it post-operatively (Table 6.1). Those patients 
who had not received any pre-operative IMP were grouped with the placebo patients into a 
“no dexamethasone” category for the intra-operative fluid analysis. 
 
Table 6.1; pre-operative doses of dexamethasone and recurrence  
No. of patients Dexamethasone dose pre-op  Recurrence 
11 0 mg 1 (Day 41 + 50) 
2 8 mg  0 
2 16 mg 0 
1 32 mg  1 (Day 14) 
1 40 mg  0 
1 48 mg  0 
1 54 mg 0 
1 60 mg 0 
1 72 mg 0 
1 124 mg (full course) 0 
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There were two recurrences in the 22 patients who were randomised to dexamethasone (9%), 
only one of which was sampled at the time of recurrence (the other only had sampling of the 
primary CSDH). There were four recurrences in the 30 patients on placebo (13%), all of 
which were sampled. One of the recurrence patients who was on dexamethasone, received no 
drug pre-operatively and stopped the course early on day seven (receiving a total of 92 mg). 
This patient was treated for recurrent CSDH 41 days after primary surgery, with a second 
recurrence a further nine days later. The second patient on dexamethasone with recurrence 
received two full days of pre-operative dexamethasone (total 32 mg) and was treated for 
recurrence 14 days after primary surgery, having completed the full dexamethasone course (a 
total of 124 mg). Of the four recurrence patients treated with placebo; one occurred eight 
days after primary surgery, one at 11 days, one at 13 days and one at 14 days. Therefore, the 
median time to recurrence was 14 days (mean 18.6 days) in all patients, but was later in the 
dexamethasone group due to the recurrence in one patient on day 41.  
 
A one-off intravenous dose of 6.6 mg intra-operative dexamethasone (IOD) was allowed in 
trial patients, as this was routine clinical practice before the trial commenced, for anti-emesis 
as part of the anaesthetic. There were eight patients who were given IOD; four from the 
dexamethasone treatment arm (two with bilateral CSDH, making a total of six samples) and 
four from the placebo treatment arm (one with bilateral CSDH, making a total of five 
samples). The potential impact of IOD on the inflammatory profiles of intra-operative CDSH 












6.3 Dexamethasone and the inflammatory profile results 
 
6.3.1 Intra-operative samples  
All primary CSDH samples were grouped into “no dexamethasone” (ND, n=49), where the 
patient was either on placebo or received no dexamethasone pre-operatively, and 
dexamethasone (Dex, n=12), where they received pre-operative dexamethasone. It was 
anticipated that dexamethasone worked as a treatment for CSDH by reducing the 
concentration of key inflammatory markers, particularly those previously identified as higher 
in recurrent CSDH (i.e. VEGF, IL-6, IL-8, MIP-1b, TNF-a, IL-1a, IL-1b). However, the 
opposite trend was seen for all these markers, with significantly higher levels in the 
dexamethasone treated group for IL-6 (p = 0.0107), IL-8 (p = 0.0041), MIP-1b (p = 0.0147), 
TNF-a (p = 0.0217) and IL-1a (p = 0.0274) and a non-significant trend to higher levels for 
VEGF (p = 0.2954) (Figure 6.1). Smaller, non-significant trends were seen for IL-10, MIP-
1a and IP-10 and no differences were seen for MCP-1, IL-1b and MMP-9 (data not shown).  
 
Figure 6.1; comparison inflammatory profiles in no-dexamethasone (ND) and dexamethasone (D) 
samples: (A) IL-6, (B) IL-8, (C) MIP-1b, (D) IL-1a, (E) TNF-a, (F) VEGF. ND = 49, Dex = 12. 










































































































Further analysis of the dexamethasone group, by total cumulative dose received pre-
operatively, was performed (Figure 6.2). One patient, who received 124 mg (the complete 
course) pre-operatively, was excluded, as the surgery was performed 44 days after 
completion of the course. This is a sufficient time-lag for any anti-inflammatory action of the 
dexamethasone to have resolved and the inflammatory profile to change significantly. 
 
VEGF, MMP-9 and to a lesser extent IL-6, all showed a continued rise in concentration with 
increasing doses of dexamethasone (Figure 6.2A-C). All other analytes generally showed an 
increase in concentration up to 48 mg dexamethasone, but a decrease when the maximum 
pre-operative dose of 54-72 mg had been given (equivalent to 4 or 5 days of treatment). This 
was most apparent for IP-10, TNF-a, IL-1a and IL-1b (Figure 6.2H-K). This may suggest 
that the effect of dexamethasone in reducing inflammation in CSDH only becomes apparent 
at higher (>48 mg) or longer (>3 days) dosing. It may be that the doses given were 
insufficient to see a change for the key markers such as VEGF and IL-6, as these were also 
the markers at the highest concentrations within the fluid. Alternatively it is possible that the 
markers only appear higher in concentration because there is less fluid, and that the 
dexamethasone is working to reduce fluid production resulting in less dilution of markers. 
Further work is needed sampling CSDH fluid in patients who have received longer course of 
dexamethasone to further clarify this.  
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Figure 6.2; analyte concentrations in relation to cumulative pre-operative dexamethasone dose: (A) 
VEGF, (B) MMP-9, (C) IL-6, (D) IL-8, (E) MIP-1a, (F) MIP-1b, (G) MCP-1, (H) IP-10, (I) TNF-a, 
(J) IL-1a, (K) IL-1b, (L) IL-10. Dexamethasone doses; 0 mg (n = 49), 8-16 mg (n = 4), 32-48 mg (n 
= 4), 54-72 mg (n = 3). Bar (median), line (IQR), (Dex = dexamethasone). 
 
Intra-operative dexamethasone 
Including only the “no-dexamethasone” patients, those given 6.6 mg of IOD were compared 
with the those given none (ND). IL-1a was the only analyte to show significantly higher 
concentrations in the IOD compared to ND group, but with such a wide range this is likely 


































































































































































































































































































no effect on the analyte concentration (Figure 6.3B-D), which is as expected with a small, 
one-off dose of dexamethasone given immediately prior to surgery. 
 
 
Figure 6.3; placebo patients given intra-operative dexamethasone (IOD) and no dexamethasone 
(ND): (A) IL-1a, (B) VEGF, (C) IL-6, (D) IL-8. ND (n = 29), IOD (n= 5). Line (median), bar (IQR), 
statistically significant difference denoted as P £ 0.05 (*).  
 
 
6.3.2    Post-operative drain samples  
Dexamethasone may be more active post-operatively once the large collection of 
inflammatory cells and fluid has been drained. This is supported by the data on post-operative 
drain samples for the majority of analytes. In the placebo samples, there is usually a peak in 
the inflammatory markers at 25-40 hours, this is significantly reduced in the dexamethasone 
group for VEGF (p = 0.0095), and shows a non-significant trend in reduction for IL-6, IL-8, 
IL-10, IL-1a, IL-1b, MIP-1a and MIP-1b (Figure 6.4). There are also reduced percentage 
increases in these inflammatory markers across all the time points, which gives an overall 
picture of a “dampening down” of the inflammatory response post-operatively. It may be this 
effect which is essential to promoting CSDH resolution, rather than the intra-operative 
changes discussed above. No significant differences or patterns were observed for MMP-9, 








































































Figure 6.4; percentage-change of analyte concentrations in post-operative drain samples by treatment 
group: (A) VEGF, (B) IL-6, (C) IL-8, (D) IL-10, (E) IL-1a, (F) IL-1b, (G) MIP-1a, (H) MIP-1b. 
Line (mean), box (IQR), whiskers (range), statistically significant differences denoted as P £ 0.005 












































































































































































































































6.3.3 Paired primary and recurrence samples 
The paired primary and recurrence samples were compared between the treatment groups. 
There were two paired samples in the dexamethasone arm; from the same patient who had 
two recurrences, both of which were paired to the primary CSDH sample. This patient had 
also not received any dexamethasone prior to the primary surgery and the recurrences were 
late (day 41 and 50). There were four paired samples from three patients (one bilateral 
CSDH) in the placebo arm. Due to these small patient numbers no statistical significance is 
assessed, but the patterns are shown below. 
 
VEGF, IL-6, IL-10 and IL-1b showed relatively stable concentrations between primary and 
recurrence samples in the dexamethasone patient compared to increases in most of the 
placebo samples at recurrence (Figure 6.5).  
 
 
Figure 6.5; paired primary and recurrence samples: (A) VEGF, (B) IL-6, (C) IL-10, (D) IL-1b. 
Placebo (blue, N = 4), dexamethasone (orange, N = 2), (2nd R = second recurrence, Recur = 
recurrence). 
 
IL-1a and TNF-a showed increases in concentration between primary and recurrence 
samples in the dexamethasone patient and increase or stability in the placebo samples (Figure 





























































































but decreased or stable levels in the second recurrence in the dexamethasone patient, whilst 
placebo patients increased in most apart from with MCP-1 (Figure 6.6B-G). MMP-9 was the 
only analyte to show a marked decrease in both dexamethasone recurrences, with varied 
responses in the placebo patients (Figure 6.6H). 
 
 
Figure 6.6; paired primary and recurrence samples: (A) IL-1a, (B) TNF-a, (C) MCP-1, (D) IP-10, 
(E) MIP-1a, (F) MIP-1b, (G) IL-8, (H) MMP-9. Placebo (blue, N = 4), dexamethasone (orange, N = 





















































































































































The change of each analyte from primary to recurrent CSDH is very different in each patient, 
regardless of treatment group. Therefore, it is difficult to identify any clear trends. This is 
exemplified by comparing the changes in IL-6 and IL-8, which are considered to work 
synergistically and concentrations normally correlate well to one another (see chapter five), 
but show very different patterns from primary to recurrent CSDH (Figure 6.7). In one patient 
(P1) there was a large increase in IL-8 at recurrence, but a simultaneous decrease in IL-6, 




Figure 6.7; percentage change between paired primary and recurrent CSDHs in placebo (P) and 





























6.4 Clinical correlations  
 
6.4.1 Trauma and time course  
Clinical data was available on all 52 CSDH patients, as reported in chapter five the mean age 
was 76 years and 27% were females. The inflammatory profiles for all markers were 
compared between primary CSDH samples from patients aged under 76 and those 76 and 
above, and no significant differences were found (data not shown). This suggests that age 
alone does not alter the inflammatory response.  
 
The patient and/or next-of-kin were asked whether there had been a recent history of head 
trauma within the past 6 months and this was reported as present in 32/52 (62%) patients. 
Although more male patients reported no history of trauma, there was no significant 
difference between genders (Fishers exact, p = 0.1978) (Figure 6.8).  
 
 
Figure 6.8; Gender and reported history of trauma, female n = 14, male n = 38. 
 
The time interval between trauma and CSDH diagnosis was known for 28/32 trauma patients, 
with the shortest interval of two weeks, and maximum 12 weeks (Figure 6.9A). The mean 
time interval from trauma to CSDH was five weeks (median four weeks) and three time-
periods were made to assist further analyses, dividing at the median of four weeks and with a 























Figure 6.9; (A) survival curve of time from trauma to CSDH diagnosis (N = 28), (B) Time-groups 
from trauma to CSDH diagnosis, <4 weeks (n = 16), 4-8 weeks (n = 8) and after 8-weeks (n =4).  
 
The 61 primary CSDH samples (counting each side of bilateral and anterior/posterior as 
individual CSDHs) were reviewed for each analyte, comparing those with a reported history 
of trauma (n = 36) and those without (n = 25). The only markers which showed a significant 
difference between these two groups were IL-1a (p = 0.0245) and TNF-a (p = 0.0263) 
(Figure 6.10). This suggests that the method of CSDH initiation (trauma or no trauma) makes 
little difference to the ensuing inflammatory reaction, as most of the key markers showed no 
differences. There is also possible bias from the fact that some patients cannot remember 
trauma despite it occurring. 
 
 
Figure 6.10; IL-1a and TNF-a in trauma and non-trauma patients. Trauma n = 36, Non-Trauma (NT) 
n = 25, statistically significant differences denoted as P £ 0.05 (*). 
 














































The time interval from trauma to CSDH diagnosis was known in 32/36 samples and grouped 
as per Figure 6.9B. A significant difference between the three time intervals was found for 
VEGF concentration (Kruskal-Wallis test, p = 0.0057), with a dip at 4-8weeks suggesting 
perhaps a more dormant period of inflammation with an early and late peak either side 
(Figure 6.11A).  A increase across the three time points, with a much higher peak at the latest 
time point, was seen for IL-6, IL-8, IL-1a and MIP-1a (Figure 6.11B-E). This supports the 
hypothesis of escalating inflammation over time following trauma. Only MMP-9 followed a 
similar trend to VEGF, with a peak in CSDHs diagnosed <4 weeks after trauma. This 
suggests that these two inflammatory markers may be important in the early stages of CSDH 
development, with VEGF re-activated later as well. No trends or significant differences were 
seen for the remaining markers (data not shown).   
 
  
Figure 6.11; Analyte concentrations at time intervals post-trauma: (A) VEGF, (B) IL-8, (C) MIP-1a, 
(D) IL-6, (E) IL-1a, (F) MMP-9, <4 weeks (n = 18), 4-8 weeks (n = 10), >8-weeks (n =4). Line 
(median), bar (IQR), statistically significant differences denoted as P £ 0.005 (**). 
 
The peak in VEGF in CSDHs diagnosed <4 weeks from trauma may also relate to the 
pathophysiological sub-type (as discussed in Chapter two). It has already been demonstrated 
that CSDHs transformed from acute subdural haematomas (acute transformed; CSDH-AT) 
present earlier following trauma than those that appear to form de-novo (CSDH-DN); with a 
mean of 16 days in the former versus 57 days in the latter. Thus, VEGF may be key in the 















































































































patients with imaging confirmation of CSDH-AT (n = 5) compared to CSDH-DN (n = 6), 
higher VEGF was seen in all but one outlying CSDH-AT patient (Figure 6.12). Excluding 
this outlier, a significant difference is seen between VEGF levels which are higher in CSDH-
AT than CSDH-DN (p = 0.0121). No differences were seen between the sub-types for any 
other marker, including MMP-9 (data not shown).  
 
 
Figure 6.12; difference in VEGF between CSDH sub-types. Median (line), IQR (bars), (AT = acute 
transformed, CSDH = chronic subdural haematoma, DN = De Novo, o = outlier excluded). 
 
 
6.4.2 Anti-platelet and anti-coagulant treatment 
Patient data on anti-coagulants and anti-platelets is shown in Table 6.2. There were not 
enough patients on aspirin or clopidogrel to compare these medications, therefore they are 
grouped together under anti-platelets despite their different mechanisms of action. Whether 
the patient was on anti-platelets or anti-coagulants prior to CSDH surgery appeared to have 
no effect on the inflammatory profile with no significant differences between the two groups 
for any marker. An example of the equal distribution is shown with VEGF in Figure 6.13. 
This is perhaps surprising, as both aspirin and clopidogrel have been shown to have anti-
inflammatory properties (Schrottmaier, Kral, Badrnya, & Assinger, 2015; Sternberg et al., 
2016; Thomas & Storey, 2015; Vane & Botting, 1998). However, there were several 
confounding factors including variation in the duration of time from stopping treatment to 
surgery and whether any reversal therapies (e.g. platelets, vitamin K) were given. 
Unfortunately, detailed data on this was not available to allow comparison. It is certainly an 
area for future research to look at the profiles more carefully in patients who are naïve to any 





























Table 6.2: anti-coagulant and anti-platelet data 
Type of treatment No. out of 61 primary samples (%) 


















Figure 6.13; VEGF and anti-platelet and anti-coagulant (anti-coag) treatments, n as per Table 6.2, 
line (median), bars (IQR). 
  
 
6.4.3 Admission and outcome data 
The Glasgow Coma Scale (GCS) is a universal measure of the degree of coma. It is made up 
of three component parts assessing response by eyes, verbal and motor function which are 


































Table 6.3; breakdown of GCS scoring (Teasdale) 
Eye response Verbal score Motor score 
4; spontaneously 5; orientated 6; obeys commands 
3; to verbal command 4; confused 5; localises to pain 
2; to pain 3; inappropriate words 4; flexion to pain 
1; no eye opening 2; incomprehensible sounds 3; abnormal flexion to pain 
 1; no verbal response 2; extension to pain 
  1; no motor response 
 
The GCS was assessed in all patients on admission and discharge from the neurosurgical unit 
and always either improved or stayed the same (if originally 14 or 15) (Figure 6.14A). The 
median GCS was 15 on admission and discharge (Figure 6.14B), exemplifying that all 
patients recruited to the neurochemistry sub-study were relatively well neurologically, 
probably because there is often not enough time to recruit the sickest patients due to delays 
with consent and the need for immediate surgery. 
 
 
Figure 6.14; Admission and discharge GCS: (A) paired admission and discharge GCS patterns, (B) 
individual patient numbers of GCS on admission and discharge, n = 52. 
 
One might expect more rapidly expanding CSDH to cause a lower GCS and be associated 
with a greater escalation of inflammatory markers. The limited number of patients with a low 
GCS make it difficult to determine this, but no significant differences were found in relation 
to GCS and any inflammatory marker. In fact, the pattern seen with some of the key 
inflammatory markers (e.g. VEGF, IL-6) showed the opposite, with similar, or lower, 
concentrations in the five samples from patients with the lowest GCS scores (12-13), see 





















Figure 6.15; GCS on admission related to: (A) VEGF, (B) IL-6. GCS 15 n = 46, GCS 14 n = 17, 
GCS 12-13 n = 5. Line (median), bars (IQR), f = outlier. 
 
Long-term outcome was assessed at three and six months with the modified Rankin Scale 
(mRS); dichotomised to good outcome (mRS 0-3) and poor outcome (mRS 4-6) (see chapter 
eight for more details). Two patients had follow-up missing at three months and one bilateral 
CSDH was lost-to follow-up at six months, leaving 66 CSDH samples with mRS outcomes at 
each time point. 
 
VEGF was significantly lower in patients with a poorer outcome at both three months (p = 
0.0224) and six months (p = 0.0031) (Figure 6.16A&B). A similar pattern was seen for IL-6 
at six months (p = 0.0181, Figure 6.16C) but not for any other analyte (data not shown). The 
data was also reviewed by individual ordinal mRS score, but this did not add any further 
insight to the dichotomisation of VEGF concentrations above and below mRS scores of three 
(Figure 6.16D). As there are very few patients with an mRS 4-6 it is difficult to make any 
definite conclusions about this. One possible explanation is that poor outcome from CSDH is 
higher in patients with co-morbidities and poorer health in general, such patients may not be 
capable of mounting a high immune response at the time of CSDH, thus resulting in the 











































Figure 6.16; (A) VEGF and mRS at 3 months, mRS 0-3 n = 61, mRS 4-6 n = 5, (B) VEGF and mRS 
at 6 months, mRS 0-3 n = 60, mRS 4-6 n = 6, (C) IL-6 and mRS at 6 months, n as per B, (D) VEGF 
and all mRS categories at 6 months. Line (median) and bar (IQR), statistically significant differences 




















































































The data on treatment groups shows a surprising elevation of several of the key inflammatory 
markers (although not significant for VEGF) in patients who have received dexamethasone 
compared to those that haven’t. This appears to continue despite higher cumulative pre-
operative dosing of dexamethasone for most markers. Some markers do appear to fall in 
patients who have received more than 48mg (or three days) of pre-operative dexamethasone, 
suggesting this may be the minimum dose required to initiate an effect on inflammation in 
CSDH. Overall, the findings contradict the original hypothesis that dexamethasone would 
result in reduced levels of inflammation in CSDH fluid. However, this is not to say that 
dexamethasone doesn’t have an anti-inflammatory effect, and timing of doses and sampling 
may be important.  
 
As the collection of subdural fluid is sufficiently large to require surgery, it provides a 
substantial pool of inflammatory cells and mediators. Chapter four evidences that 
dexamethasone does not accumulate within the subdural space and therefore its effects may 
occur from down-stream genomic effects on the cells in the subdural membranes. The 
combination of these two factors may mean that the pre-existing CSDH fluid collections take 
some time to change their inflammatory profile. The post-operative drain data does show 
reduced concentrations of most inflammatory markers across all time points in patients 
treated with dexamethasone, suggesting once the milieu of inflammation is removed with 
surgery, the drug has a more rapid effect. If the post-operative peak in inflammation is the 
driver to recurrence, this would explain how dexamethasone works to reduce post-operative 
recurrence. However, this does not explain why the levels of some markers, including IL-6 
and IL-8, are significantly higher in the intra-operative samples. It is possible that the anti-
inflammatory action of dexamethasone initially stimulates a rise in some markers, but that 
these are switching to a “reparative” role. 
 
Dexamethasone has also been reported to work successfully as a conservative treatment 
option for some patients with CSDH, therefore surgical drainage is not always necessary 
(Sun, Boet, & Poon, 2005). As some of the inflammatory markers showed a decline in the 
intra-operative CSDH fluid for patients who had received a minimum of 48mg (three days) of 
dexamethasone, this may indicate that inflammation can be controlled with sufficient 
cumulative dexamethasone treatment.  This is corroborated to some degree by Berghauser’s 
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study which found that the recurrence risk with CSDH was lower, the longer the pre-
operative course of dexamethasone given, with five days being the median duration in non-
recurrence patients (Berghauser Pont, Dammers, Schouten, Lingsma, & Dirven, 2012). 
Therefore, perhaps if a longer course of dexamethasone were given prior to surgery then 
different changes would have been observed. It may also be the case that surgery is more 
successful if performed once inflammation is already reducing, thus making the case for a 
more prolonged trial of dexamethasone treatment for CSDH prior to surgery, in patients that 
are neurologically stable.  
 
Finally, review of clinical data does appear to confirm the hypothesis that the inflammatory 
response escalates over time, with higher levels of most markers in patients who present the 
longest time-period after trauma. VEGF and MMP-9 appear particularly relevant in the early 
pathophysiological stages, which is interesting as both are also implicated in CSDH 
recurrence (see Chapter five). This may mean that recurrence occurs through a re-initiation of 
CSDH inflammatory cycle, similar to that which occurs at the very origin of the CSDH 
initially. VEGF was also significantly higher in acute transformed (CSDH-AT) compared to 
de-novo (CSDH-DN), the latter forming more insidiously over time.  
 
Contrary to expectations, patients with a worse outcome, as measured by the mRS, appear to 
have lower inflammatory profiles. This may be a reflection of the general immunosuppressed 
status of more unwell patients, who have poorer recovery in the long-term. This is also 
confounded by the small numbers of patients with a poor outcome, and therefore needs 
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Previous studies have shown some evidence that imaging characteristics of CSDH, such as 
the laterality, volume, mid-line shift and pattern of density, may be useful in predicting the 
risk of recurrence, however the data is conflicting. A sub-group of 164 patients recruited to 
the Dex-CSDH study, had baseline diagnostic computed tomography (CT) imaging available 
for analysis. Just over half of these patients (86/164) also had post-operative CT imaging 
available for comparison. Clinical data was available on all 164 patients, and all patients in 
the neurochemistry sub-study (discussed in chapters five and six) were also included for 
comparison of imaging to inflammatory profile data.  
 
The first aim of this chapter was to establish a reliable and accurate methodology for 
analysing CT imaging with regard to volume and density. Such that, this method could be 
applied to analysing all the CT imaging from patients in this study.  
 
The first hypothesis was that larger CSDHs would be more likely to recur and have a poorer 
outcome. This assumed that larger CSDHs are more likely to be incompletely evacuated and 
therefore residual inflammatory molecules could increase the risk of recurrence and poor 
outcome. Similarly, it was hypothesised that post-operative CT imaging would be useful in 
predicting recurrence, with higher recurrence rates in patients with larger residual volumes of 
pneumocephalus. This is based on the theory that pneumocephalus prevents adequate, timely 
brain re-expansion and thus allows a persistent space for re-accumulation of the CSDH to 
occur. Finally, it was hypothesised that CSDHs containing a density pattern suggesting recent 
new haemorrhage within the CSDH (i.e. high density) would also be more likely to recur. 
This is because haemorrhage from membranes may suggest a more “active” stage of 
inflammation and membrane development, and thus would also likely be correlated to higher 




7.2 Imaging Methods 
The first aim was to quantify the volume of all CSDHs in this study. Two different methods 
for calculating the volume of CSDHs and ASDHs are referred to in the literature and were 
assessed before designing the volume analysis method for all scans. The first method for 
assessing volume is the ABC/2 technique, and has been published as reliable for CSDH 
volume calculation when using the maximum width x maximum length (both on any slice) x 
depth (no. of slices x slice thickness) (Sucu, Gokmen, & Gelal, 2005). The second method, 
referred to here as slice-by-slice (SBS), involves calculating the volume by tracing the 
haemtoma on each slice (area) and multiplying by the slice thickness (Huang, Lin, Lu, & 
Chen, 2014; Yan, Yang, & Huang, 2018). This technique is used more commonly in the 
literature, as intuitively it would be more accurate, but it is also more time consuming. Thus, 
the ABC/2 technique would be more efficient for analysing large imaging data sets, such as 
in this study, as long as accuracy can be maintained. The methods were compared for 
accuracy and agreement on a sub-set of images before determining the imaging analysis 
protocol for the full CSDH data set.  
 
7.2.1 Semi-automated volume calculation 
 
To make the SBS volume calculation quicker and more efficient, a semi-automated computer 
programme was developed to aid the volume calculation. Images were downloaded into ITK-
snap (Yushkevich et al., 2006) and a newly developed programme called “watershed” was 
used to segment each scan into regions by density. Areas of different density could then be 
grouped together by point and click, thus only highlighting the area correlating to CSDH (not 
normal brain). This was done on each slice of the scan so that eventually the volume of area 
selected (i.e. CSDH) from each slice was combined to calculate the overall volume of the 




Figure 7.1; (A) Original CSDH scan, (B) Automated segmentation by software (red lines) with 
region of CSDH highlighted in green. 
 
The software can help delineate CSDHs that are isodense, where the user may have difficulty 
finding the distinction between brain and CSDH. The regions that are automatically 
segmented can also be manually edited by the user if needed. The programme is also able to 
assess the density within the highlighted area, and therefore can split the CSDH into areas of 
“high” (red) and “low” (green) density, giving an objective assessment of density (Figure 




Figure 7.2; (A) original CSDH scan, (B) automated segmentation with CSDH highlighted and areas 






7.2.2 Agreement between methods for volume calculation  
Agreement between the two different measurement methods (ABC/2 and SBS) for ASDH 
volume calculation (n = 15) were assessed by comparing the average volumes with the 
differences between them, as per Figure 7.3 (Bland & Altman, 1986). 
 
 
Figure 7.3; Bland-Altman plot of volume calculation with ABC/2 and SBS, upper and lower 95% 
confidence intervals shown with blue lines, n = 15. 
 
The bias, or mean difference, is only 0.879cm3 (S.D 10.53), with the ABC/2 tending to 
slightly overestimate. However, the 95% limits of agreement from -19.77 to 21.53 cm3 is 
wide, which can be particularly problematic for small ASDHs. This is exemplified by one 
patient in whom the ABC/2 method overestimated the volume by 130% (25.8cm3) compared 
to SBS (11.3cm3). With this in mind, the distribution of ASDH volume was plotted, with an 
obvious division between the smallest five ASDHs (all under 40cm3) and the larger 10 
CSDHs (Figure 7.4A). The percentage difference between the methods was significantly 
lower in the larger volume ASDHs (>40cm3) compared to smaller ASDHs (unpaired T test, p 
= 0.0188) (Figure 7.4B). Therefore, it would seem sensible not to apply the ABC/2 technique 



























Figure 7.4; (A) distribution of ASDHs by volume, n = 15, (B) comparison of percentage-difference in 
ASDHs below and above 40cm3 in volume on SBS, statistically significant differences denoted as p £ 
0.005 = **. 
 
Agreement between the two methods for calculating the CSDH volumes (n = 50) was 
assessed with the same method and showed a larger bias of 12.97 cm3 (S.D. 32.25), again 
with the ABC/2 method over-estimating (Figure 7.5). The CSDH volumes measured were 
often greater than the ASDHs and unlike the ASDHs, large and small volume CSDHs were 
equally poorly estimated with the ABC/2 method.  
 
Figure 7.5; Bland-Altman plot of volume calculation with ABC/2 and SBS. Upper and lower 95% 
confidence intervals shown with blue lines, n = 50. 
  
Intra- and Inter-rater reliability  
The intra-rater reliability for the SBS and ABC/2 methods was calculated by assessing five 
CSDH images (differing in density) and three ASDH images twice by a single rater (E 


























































Edlmann). The intra-class coefficients can be seen in Figure 7.6 and clearly show that the 
SBS method was more reliable than ABC/2 for both types of subdural, but particularly for 
CSDH volume calculation.  
 
Figure 7.6; intra-rater reliability for CSDH and ASDH volume assessment by SBS and ABC/2 
methods, as measured by intra-class correlation coefficient (ICC), bars = 95% confidence intervals. 
 
The inter-rater reliability of the both methods was also assessed with four different raters; one 
junior neurosurgeon, two senior neurosurgeons and one neuro-radiologist. Four different 
CSDH images (varying in density) and two ASDH images were assessed by all raters. The 
ICC for inter-rater variability was similar between the two methods; ABC/2 = 0.911 and SBS 
= 0.929. However, the SBS method was marginally superior, and this can be seen in the 
pattern of measurements displayed in Figure 7.7, with the ABC/2 method showing wider 
variation in readings, which often over-estimate the volume. 
 
  
Figure 7.7; inter-rater reliability for CSDH (C1-4) and ASDH (A1-2) test cases assessed by four 
raters with; (A) ABC/2 method, (B) slice-by-slice (SBS) method. 
 
 






























































Overall, although quicker, it was evident that only small changes in one measurement with 
the ABC/2 method could result in significant changes in volume. A single rater (E Edlmann) 
would be used to assess all images in this study, therefore the SBS technique was applied for 
its superior accuracy and repeatability.   
 
 
7.2.3 Methods for density assessment 
 
There is varying literature on different “types” of CSDH as classified on CT. The most 
common classification system referred to was first reported by Nakaguchi et al. and has seven 
categories within two main sub-types; homogenous (hyperdense, isodense and hypodense) 
and mixed (trabecular, laminar, gradation and separated) (Figure 7.8A-G) (Nakaguchi, 
Tanishima, & Yoshimasu, 2001). 
 
 
Figure 7.8; Nakaguchi classification: (A) homogenous hyperdense, (B) homogenous isodense, (C) 
homogenous hypodense, (D) mixed trabecular, (E) mixed laminar, (F) mixed gradation, (G) mixed 
separated, (H) mixed sub-type not described by Nakaguchi et al.  
 
Nakaguchi postulated that the sub-types represented different stages in CSDH evolution, each 
with varying bleeding tendencies. The homogenous types were considered the earliest stage, 
some of which are “laminar” with an inner layer of hyperdensity. The CSDH then progresses 
to the separated stage and finally the trabecular stage. The lowest recurrence, of 0%, was seen 
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in the latest stage (trabecular), which is considered a “resolution stage”. Higher recurrence 
was seen in the other stages; homogenous (15%) and laminar (19%), with the highest 
recurrence in separated CSDHs (36%), considered the most “active” period of bleeding. This 
was corroborated by Ohba et al. who found significantly higher recurrence in separated 
compared to trabecular CSDHs and Huang et al. who found higher recurrence with “layered” 
(or separated) CSDHs (Huang et al., 2014; Ohba, Kinoshita, Nakagawa, & Murakami, 2013). 
Yamamoto et al. used a slightly different classification, but also found lower recurrence rates 
in hematomas with “multiplicity” of density, most similar to the trabecular type (Yamamoto 
et al., 2003). However, conversely CSDH with septations (which could be considered 
trabecular) have been linked to a higher risk of recurrence (Jack, O'Kelly, McDougall, & 
Findlay, 2015), as have CSDHs categorised as “mixed density” (which also includes those 
that appear trabecular) (Yan et al., 2018). Some studies have also suggested that hyper- and 
isodense CSDHs, from the homogenous sub-group, have a higher risk of recurrence 
alongside the separated group (Stanisic & Pripp, 2017). 
 
Overall, density classifications are subjective and it is difficult to know how uniformly the 
definitions are applied, even when the same classification is referred to. A large degree of 
judgment is required as many CSDHs do not fit neatly into the pre-defined classification. For 
example, there are variations within the “mixed density” group that do not fit into any of the 
Nakaguchi categories (see Figure 7.8H), where there is some acute blood but with no pattern. 
There are also many CSDHs that could largely be considered homogenous but may have 
some areas of mixed or higher density around the skull base (the most dependent area), 
whether this is significant enough to change to a mixed category depends on the assessor.  
 
It was therefore anticipated that an objective measure of CSDH density would be a stronger 
predictor of the recurrence risk than the current subjective classifications. This was done 
using the same software as the volume calculation (Yushkevich et al., 2006), where the 
watershed programme automatically calculates the mean density of the area highlighted. It 
can also perform a density-split, where the exact volume of high and low density is 
calculated. This split was then converted into a percentage of high density (percentage-
hyperdense) with the formula; 
 
 % hyperdense = (volume of high density/total volume of CSDH) x 100 
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The main drawback to this technique is that the percentage of hyperdensity gives no 
indication about the distribution of the hyperdensity, as would be provided in the subjective 
descriptions (e.g. trabecular versus separated). Therefore, the percentage of hyperdensity 
could be the same for Figures 7.9A&B, despite different patterns of blood. 
  
 
Figure 7.9; CSDH scans with semi-automated segmentation and density split, high density areas 
shown in red and low density in green: (A) Trabecular CSDH, (B) Separated CSDH. 
 
 
7.2.4 Agreement between methods for density assessment 
 
To test inter-rater and intra-rater reliability, 50 CSDH patients were chosen at random for 
repeat assessment of the density category (as per Figure 7.8). Four patients had bilateral 
CSDHs, which made a total of 54 CSDHs analysed. Each CSDH was assessed as 
homogenous (H) or mixed (M) and then further sub-grouped as either hypodense (HYPO), 
isodense (ISO) or hyperdense (HYPER) in the homogenous group and laminar (LAM), 
trabecular (TRA), separated (SEP) or gradation (GRA) in the mixed group. 
 
The intra-rater reliability for density category was assessed twice by a single rater 
(E.Edlmann) at least seven days apart and with the same 54 CSDHs assessed in a different 
order. The classifications agreed in 44/54 CSDHs (Table 7.1; blue cells), giving Cohens 
kappa coefficient of 0.768 (standard error 0.064) showing reasonable agreement between the 
two ratings (where 1 is complete agreement). This was limited by assessing only one rater 
and this rater had experience in using the classification in CSDH, therefore one might expect 
less agreement with raters not experienced with it. Of the 10 ratings that did not agree these 
were most commonly in CSDHs classified as hyper or isodense on at least one of the ratings, 
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suggesting these are the most difficult sub-types to delineate. A case example of a CSDH 
initially classified as isodense and later classified as hyperdense can be seen in Figure 7.10.  
 
Table 7.1; intra-rater categorisations of density sub-types with pink boxes highlighting cases with 
disagreement between the two assessments. 
1st/2nd HYPO ISO HYPER TRA LAM GRAD SEP 
HYPO 13             
ISO 1 4 1         
HYPER   3 4     2   
TRA   1 1 15 1     
LAM         3     
GRAD           3   












Figure 7.10; CSDH case example classified as both hyperdense and isodense by the same rater. 
 
The inter-rater reliability was assessed using two raters, both neurosurgeons experienced with 
assessment of CSDH, on the same 54 CSDHs. The agreement between the two different 
raters was poor, with a Cohens kappa coefficient of 0.397 (standard error 0.75). This shows 
the significant limitation of applying the Nakaguchi classification, with different users 
interpreting it very differently. As there was reasonable intra-rater reliability with the single 
rater, all the images in this study were still grouped by the Nakaguchi classification in order 




7.3 Results on primary CSDH volume 
Diagnostic CT imaging was reviewed on 189 CSDHs in 164 patients recruited to the Dex-
CSDH trial. There were 25 patients with bilateral CSDHs and of the remaining 139 unilateral 
CSDHs, 65 were left-sided and 74 right-sided. Small contralateral CSDHs which did not 
require any treatment were not included in the analysis. 
 
7.3.1 CSDH volume in all patients 
The volumes for all 189 CSDHs can be seen in Figure 7.11, with a median volume of 103cm3 
(I.Q.R 69 - 138cm3). The volumes were not normally distributed; therefore, all statistical 
analyses used non-parametric tests. 
 
Surgery was performed as first-line treatment for 172/189 (91%) CSDHs in 149 patients (23 
bilateral CSDHs). First line conservative medical management was used for 17 CSDHs in 15 
patients (two bilateral CSDHs), of which four CSDHs in three patients (one bilateral) failed, 
requiring subsequent surgery at days 15, 28 and 36 after the original diagnosis. 
 
As one would expect, there was a significantly lower volume in the patients initially treated 
conservatively (median 74cm3) compared with those initially treated surgically (median 
106cm3), (Mann Whitney test, p = 0.0196), with one clear outlier in the conservative group. 
 
 
Figure 7.11; CSDH volumes in all patients, those treated surgically (surgical) and those treated 
conservatively (cons). Statistically significant differences denoted as p < 0.05 = *. 
 





















In clinical practice, midline shift is often measured on CT scans (as this is easy to do) and 
used as a correlate for how large the CSDH is and how urgently it should be operated on. 
However, when assessing midline shift and volume in all operative unilateral CSDHs (n = 
126), there was only a very weak, although significant, correlation with volume (Spearman r 
= 0.2145, p = 0.0159) (Figure 7.12A). This is likely to be because whilst midline shift is 
affected by CSDH volume, it is also highly dependent on the amount of cerebral atrophy, and 
thus redundant space, within the cranial vault. This is exemplified by grouping the patients by 
age into £65 years (n = 16) and >65 years (n = 110), where there was a much stronger 
significant correlation in the younger age group (Spearman r = 0.6618, p = 0.0065) and no 
correlation in the older group (Spearman r = 0.1213, p = 0.2070) (Figure 7.12B&C). This loss 
of correlation is likely to be due to the greater variation in atrophy in older patients. 
 
 
Figure 7.12; correlation between CSDH volume and midline shift: (A) all unilateral operative 
patients, n = 126, (B) all patients £65 years, n = 16, (C) all patients >65 years, n = 110. 
 
The 50 individual bilateral CSDHs were significantly smaller in volume than the 139 
unilateral CSDHs (Mann Whitney, p < 0.0001, Figure 7.13A). However, if the volume from 
both sides was combined in the bilateral cases, then they were significantly larger than 
unilateral cases (Mann Whitney, p< 0.0041, Figure 7.13B), showing a larger, combined, 
intra-cranial burden in patients suffering with bilateral CSDH.  
 






















































Figure 7.13; (A) unilateral and bilateral (each side separately) CSDHs, (B) unilateral and bilateral 
(both sides combined) CSDHs. Line (Median), bar (IQR), statistical significant differences denoted as 
p<0.0001 = ****, p<0.01 = **. 
 
7.3.2 Recurrence and outcome 
It has been previously suggested that larger diameter CSDHs are more likely to recur (Bartek 
et al., 2017). More specifically, CSDHs over 120-130mls in volume pre-operatively have 
been reported as a moderate predictor of recurrence (Stanisic & Pripp, 2017; Yan et al., 
2018). Greater pre-operative midline shift has also been shown as a predictor of recurrence 
(Kuhn et al., 2018). Therefore, it was hypothesised that larger pre-operative CSDHs 
(excluding conservatively managed CSDHs) would have a higher risk of recurrence, with 
recurrence measured as patients requiring further surgery for CSDH on the same side as 
previously operated within six months. The handling of bilateral CSDHs is important. As 
already displayed the volumes are significantly higher or lower than unilateral CSDHs 
depending on if each side is considered combined or seperately. Many studies exclude or do 
not mention bilateral CSDHs, but there are also several studies which report that bilateral 
CSDHs themselves have a higher risk of recurrence (Bartek et al., 2017; Han et al., 2017; 
Schwarz et al., 2015; Torihashi et al., 2008). In this study only 1/25 (4%) patients with 
bilateral CSDH experienced recurrence, compared to 13/126 (10%) unilateral operative 
CSDHs, suggesting the opposite is true. As the bilateral CSDHs were too few to analyse 
separately, three analyses were performed; unilateral CSDHs only (n = 113 non-recurrent, n 
= 13 recurrent), unilateral and bilateral with each side separately (n = 157 non-recurrent, n = 
15 recurrent), unilateral and bilateral with each side combined (n = 135 non-recurrent, n = 14 
recurrent). In all analyses, there were no obvious differences in volume between CSDHs that 
went on to recur and those that didn’t, making a definite case that volume is not a risk factor 












































Figure 7.14; volume in non-recurrent (NR) and recurrent (Recur) CSDH. Line (Median), bar (IQR), 
(bilat = bilateral, sep = separately). 
 
Further to this midline shift was also assessed in relation to recurrence but no significant 
differences were found (Figure 7.15).  
 
 
Figure 7.15; midline shift in non-recurrent (NR) and recurrent (Recur) unilateral CSDH. Line 
(Median), bar (IQR). 
 
Some studies agree with the finding that pre-operative CSDH volume, width or associated 
midline shift are not associated with recurrence (Huang et al., 2014; Kim et al., 2015; Ohba et 
al., 2013). It has also been suggested that it is not the pre-operative volume per se that is 
important, but the residual volume post-operatively, and the association only arises because 







































larger CSDHs can be more difficult to drain, leading to higher post-operative residuals (Jack 
et al., 2015). This theory is explored further in analysis of the post-operative imaging below 
(section 5.3.3).  
 
Haemtoma thickness above 3cm has been correlated with unfavourable outcome, as 
measured by an mRS of 2-6 (Kwon, Al-Awar, Richards, Izu, & Lengvenis, 2018). No studies 
have assessed outcome in relation to CSDH volume or midline shift. In this study, volume 
and MLS were compared between patients with an unfavourable (mRS 4-6) and a favourable 
(mRS 0-3) outcome. This dichotamisation is used throughout the Dex-CSDH study and is 
discussed further in chapter seven. Interestingly, despite the lack of significance in relation to 
recurrence, CSDH volume was significantly greater in patients with an unfavourable outcome 
compared to a favourable outcome at three months (Mann-Whitney p = 0.0006) and 6 months 
(Mann-Whitney p = 0.0106) (Figure 7.16A&B). When assessing the mRS on admission this 
also showed a strongly significant relationship between the volume of the CSDH and an 
unfavourable admission mRS score (Mann-Whitney, p < 0.0001, Figure 7.16C). This may 
explain to some degree the relationship between outcome and volume, as larger volume 
CSDHs can result in worsened neurological deficit, and thus a lower mRS on admission but 
also a poorer recovery in the long term. The significant correlation between admission and 3-
month mRS can be seen in Figure 7.17 (Pearson r = 0.3876, p < 0.0001, chi squared test p = 
0.0150). One previous study has already identified that the mRS score on admission is a 
significant predictor of death at six months (Santarius & Hutchinson, 2009)(Santarius). 
However, age was also significantly greater in the patients with an unfavourable outcome at 
three months (Mann-Whitney p < 0.0001). Therefore, although there was only a weak 
correlation between age and CSDH volume (see section 5.3.4), it may still be part of the 




Figure 7.16; dichotomised modified rankin scale (mRS) into favourable (Fav) or unfavourable in 
relation to: (A) CSDH volume and outcome at three months (fav n =153, unfav n = 29, 7 no data), (B) 
CSDH volume and outcome at six months (fav n = 158, unfav n = 28, 3 no data), (C) CSDH volume 
and admission mRS (fav n = 92, unfav n = 97), (D) age and outcome and three months (fav n = 153, 
unfav n =29) . Line (Median), bars (IQR), statistically significant differences denoted as P£0.0001 
(****), P£0.001 (***), P£0.05 (*). 
 
 



































































































7.3.3 Surgical techniques 
All CSDHs treated primarily with surgery (n = 172) were assessed for surgical technique; one 
burr hole (1BH), two burr holes (2BH) or a mini-craniotomy (MC), as well as placement of a 
subdural or subgaleal drain (SDD and SGD respectively). Due to a publication in 2009 
showing that SDD placement significantly reduces CSDH recurrence and in turn mortality, it 
has become common practice to place a SDD in the UK (Santarius & Hutchinson, 2009). The 
only circumstances where this is not done is if it is felt unsafe intra-operatively, usually due 
to brain re-expansion leaving insufficient subdural space to place a drain. A SDD was placed 
in 162/172 (94%) of surgical treated CSDHs, with one SGD placed and nine CSDHs with no 
drain placed.  
 
When comparing recurrence rates, there were 2/10 (20%) recurrences in CSDHs without a 
SDD, and 13/162 (8%) in those with a SDD. The tiny number of patients without a drain 
makes any meaningful statistical comparison difficult but the 8% recurrence rate in the drain 
group is comparable to the literature on patients treated with drains (Almenawer et al., 2014; 
Brennan et al., 2017; Santarius & Hutchinson, 2009). CSDH volume was significantly lower 
in cases where no SDD was placed (Mann-Whitney, p < 0.0001), which is perhaps 
unsurprising as the brain is more likely to re-expand rapidly, preventing SDD placement in 
smaller CSDHs (Figure 7.18). However, given the evidence for drain placement reducing 
recurrence and the 20% recurrence rate in the no SDD group, placement of a SGD, overlying 
the burr hole but not risking entry to the brain, may be the next best option to promote 
drainage of any residual fluid and preventing recurrence. This may be determined by a 
randomised trial currently running which is comparing subdural and sub-periosteal (same as 
SGD) drains (Soleman, Lutz, Schaedelin, Mariani, & Fandino, 2016).   
 
Figure 7.18; CSDH volume in relation to sub-dural drain (SDD) placement. Line (median), Bars 






















The most common surgical procedure was 2BHs, in 131/172 (76%) of operative CSDHs, 
followed by MC in 33/172 (19%) and 1BH in 8/172 (5%). In three cases the original 
operation was 2BH which was then converted into a MC, due to inability to evacuate acute 
blood or membranes through the BHs, but the remaining MCs were performed due to 
consultant preference. There was a trend to slightly lower CSDH volumes in the 1BH group 
compared to the other surgical groups, and may explain why 1BH was considered sufficient 
if the surface area of the CSDH was small (Figure 7.19). The highest volume outlier in the 
1BH group (volume 237cm3) was aged 98, therefore it may have been co-morbidities that led 
to a preference of a quicker operative procedure with 1BH in this patient. Otherwise the ages 
of patients were comparable between groups (data not shown). The two outliers in the MC 
group (292cm3 and 301cm3) were both patients with prior cerebral lesions, one with an 
arachnoid cyst and the other with an old stroke leading to significant cerebral atrophy. This 
provides anecdotal information on how pre-existing atrophy or enlarged subdural space can 
influence the volume of a CSDH. This was also assessed to some extent in chapter two, 
where a greater degree of cerebral atrophy (measured with bicaudate ratio) did correlate with 
larger CSDH volume. 
 
 
Figure 7.19; surgical techniques and CSDH volume. Line (median), bars (IQR), (BH = burr hole, MC 



























7.4 Primary CSDH density 
 
7.4.1 Density assessments in all patients 
The mean density within each CSDH was calculated for all 189 CSDHs (mean 40.81 HU, n = 
189), and was similar between those who had surgery as first-line treatment (40.67 HU, 
n=172) and those initially treated conservatively (42.20 HU, n = 17) (Figure 7.20). The 
spread of data on density followed a normal distribution, therefore parametric statistical tests 
were used for all analyses. 
 
 
Figure 7.20 mean density within each CSDH for all cases, surgical treated and conservatively (cons) 
treated. Line (mean) and bars (S.D.). 
 
Each CSDH was also categorised subjectively into one of the Nakaguchi classifications (as 
per Figure 7.8). The mean density calculations appeared to show the differences between the 
homogenous group classifications well, with a significant difference between hypodense, 
isodense and hyperdense CSDHs (One-way ANOVA, p < 0.0001, F = 70.96), although there 
was still considerable cross-over between groups (Figure 7.21). All the mixed density 
categories had similar mean densities, with an overall average sitting between isodense and 
hypodense.  
  
















Figure 7.21; automated mean density calculation compared to Nakaguchi classification. (Hypodense 
(hypo) n = 54, Isodense (Iso) n = 28, Hyperdense (Hyper) n = 16, Gradation (Gra) n = 19, Separated 
(Sep) n = 8, Trabecular (Trab) n = 58, Laminar (Lam) n = 6). Line (mean), bars (S.D), statistically 
significant differences denotes as p < 0.0001 = **** 
 
The automated split to calculate the percentage-hyperdense (see methods) was performed on 
141/189 CSDHs, as this could not be calculated on imaging where there was any movement, 
air or artefact. The percentage-hyperdense was compared between the Nakaguchi 
classifications (Figure 7.22) and showed a similar pattern to the mean densities, with a 
significant difference between the homogenous categories (One-way ANOVA, p < 0.0001, F 
= 64.12). It also highlights how similar all the separated CSDHs are, with just over 50% 
hyperdense in all five cases, whilst the other mixed density CSDHs (gradation, trabecular and 
laminar) tend to have a lower percentage of hyperdensity. The percentage of hyperdensity in 
the isodense CSDHs had the widest range from around 15% hyperdense to almost 100% 
hyperdense (which one might have been expected to be classified as hyperdense, as was 
highlighted in the intra-rater variability testing). 
 




















Figure 7.22; percentage hyperdense compared to Nakaguchi classification (Nakaguchi classification 
abbreviations and N as per Figure 7.21). Line (mean), bars (S.D.), statistically significant differences 
denoted as p < 0.0001 = **** 
 
No correlation was found between the mean density or the percentage-hyperdense and the 
CSDH volume or midline shift (examples in Figure 7.23). The fact that the amount of high 
density, which is suggested to come from recent bleeding or membranes, does not relate to 
the volume or midline shift, suggests this happens throughout the life cycle of the CSDH and 




Figure 7.23; correlation of: (A) CSDH volume and mean density, (B) percentage (%) hyperdense and 
midline shift. 
 






















































7.4.2 Density in relation to CSDH volume 
When the Nakaguchi classification was used, there was a significant difference in volume 
between the category with the lowest median volume (hypodense) and the highest median 
volume (separated) (Mann-Whitney, p = 0.0018) (Figure 7.24). Interestingly, this shows the 
opposite of what Nakaguchi hypothesised, which was that the later stages of CSDH 
evolution, when one would also expect the volume to be the highest, have a dormant, 
hypodense appearance (Nakaguchi et al., 2001). However, with very few patients in the 
separated group, it is hard to rely on this significant difference. 
 
 
Figure 7.24; CSDH volume by Nakaguchi classification. Line (median), bars (IQR), statistically 
significant differences denoted as P£0.005 (**), abbreviations as per Figure 7.21. 
 
There was no difference in the mean density between unilateral and bilateral CSDHs (Figure 
7.25).  
 
Figure 7.25; mean density in unilateral and bilateral CSDH. Line (mean), bars (S.D.).   


































7.4.3 Recurrence and outcome 
There was no difference in the mean density or percentage-hyperdense between primary 
CSDHs treated surgically that went on to recur (n=15) and those that did not (n = 157) 
(Figure 7.26A&B). However, when using the Nakaguchi categories, there were more 
heterogenous (mixed) density CSDHs in those that went on to recur (10/15, 66%) compared 
to those that didn’t recur (78/157, 50%), although the small numbers mean this does not reach 
statistical significance (Fishers’s exact test p = 0.2843) (Figure 7.26C). When this was broken 
down by individual categories, there was a clear increase in trabecular sub-types in CSDHs 
that recurred (9/15, 60%) compared to those that did not (44/157, 28%), and no hyperdense, 
laminar or separated CSDHs were found in the recurrence group (Figure 7.26D).  
 
 
Figure 7.26; comparison between recurrent and non-recurrent CSDHs in: (A) mean density, (B) 
percentage-hyperdense, (C) percentage classified as homogenous or mixed density, (D) percentage by 
each density classification (abbreviations as per Figure 7.21). Line (mean), bars (S.D.), (Recur = 
recurrence, NR = non-recurrence).   
 
The small number of CSDHs that went on to recur means that statistical analysis is limited. 
However, there appears to be a clear trend for trabecular CSDHs to be more likely to recur 
than any of the other density categories. This is the opposite finding to several previous 








































































in separated CSDHs (Huang et al., 2014; Nakaguchi et al., 2001; Ohba et al., 2013). 
However, there are previous reports of higher recurrence in mixed density CSDH (Jack et al., 
2015; Yan et al., 2018). Some of these differences in reporting may come from the variation 
in definition of trabecular or mixed density CSDHs. Clearly this is important, as the objective 
measurements show the actual breakdown of high and low density within the CSDH in not 
significant, but rather the pattern of density on imaging, which requires subjective 
interpretation. This may be because it is not hyperdensity from blood, but rather from 
membranes which is important, as these are a key difference seen in trabecular rather than 
other mixed density CDSHs. On the basis of these results, I would suggest that re-defining 
CSDHs into “membranous” and “non-membranous” may be a much more helpful 
classification in relation to predicting recurrence than the complex classification by 
Nakaguchi.  
 
Due to the complexities of applying seven different sub-groups to each analysis, further 
discussion in this chapter divides the density classification into mixed (heterogeneous) or 
homogenous only. With consideration that the majority of the mixed group comprises of 
trabecular (58/91), or in many cases “membranous” CSDHs.  
 
The breakdown between homogenous and mixed density CSDH was almost exactly equal in 
all surgical technique groups, with only a marginal increase of mixed density (60%) in the 
MC group (Figure 7.27). This may reflect the few patients where burr holes were converted 
to a mini-craniotomy to improve access to acute blood and membranes as 16/20 of the mixed 
CSDHs in the MC group were trabecular. 
 
 
Figure 7.27; percentage of homogenous (homo) and mixed density CSDHs by operative technique. 

















There were no differences in the mean density or percentage-hyperdense between CSDHs in 
patients with a favourable versus and unfavourable mRS at admission (data not shown), 3-
month follow-up (Figure 7.28A&B) or 6-month follow-up (data not shown). However, there 
were significantly more mixed density CSDHs compared to homogenous CSDHs in patients 
with an unfavourable admission mRS (Fishers Exact Test, p = 0.0008, Figure 7.28C). This 
significance was lost at three months but there was still a trend towards unfavourable 
outcome in the mixed density CSDHs (Fishers Exact Test, p = 0.0697, Figure 7.28D), whilst 
there was no trend at six months (Fishers Exact Test, p = 0.2180). This suggests that mixed 
density CSDHs are more likely to present with a lower mRS score on admission and thus be 
neurologically worse off. This may in turn contribute to poorer outcome at 3-months, but is 
lost at 6-months.  
 
 
Figure 7.28; (A) 3-month mRS and percentage (%)-hyperdense, (B) 3-month mRS and mean density, 
line (mean) and bars (S.D.), (C) admission (Ax) mRS in mixed and homogenous (homo) CSDHs, (D) 
3-month mRS in mixed and homogenous CSDHs. Statistically significant differences denoted as 
p<0.001(***). 
 
As previously shown, larger CSDHs are also more likely to have an unfavourable mRS on 

































































homogenous) CSDHs was assessed, and indeed found to be significantly higher in mixed 
density CSDHs (Mann-Whitney, p = 0.0061) (Figure 7.29A). As age was also a component 
in unfavourable outcome, this was also compared between density groups and was 
significantly higher in mixed density CSDHs (Mann-Whitney, p = 0.0012) (Figure 7.29B). In 
summary, mixed density CSDHs tend to be larger and found in older patients, therefore the 
combination of all these factors is likely to lead to an unfavourable mRS on admission and 
follow-up. 
 
   
Figure 7.29; (A) volume in mixed density and homogenous (homo) CSDHs, (B) age in mixed density 



































7.5 Post-operative imaging  
There are conflicting opinions on the value of routine post-operative imaging in the 
management of CSDH. Some surgeons consider it a necessity to get a baseline confirmation 
of adequate CSDH evacuation; although what is considered adequate is hard to evaluate. 
Others consider that post-operative imaging results in unnecessary radiation and leads to no 
change in management unless there were clinical indications for the scan in the first place. 
There is some evidence in the literature that post-operative scans have some value in 
predicting outcome in terms of recurrence (Dudoit, Labeyrie, Deryckere, Emery, & Gaberel, 
2016; Stanisic & Pripp, 2017; Yan et al., 2018; You & Zheng, 2018). Therefore, this section 
aims to explore what post-operative imaging can tell us about the evolution and resolution of 
CSDH in the post-operative period, with the hypothesis that excess post-operative air 
(pneumocephalus) may predispose to CSDH recurrence. 
 
Post-operative imaging was available for 100 CSDHs in 86 patients; 72 patients with 
unilateral CSDH and 14 patients with bilateral CSDH. All post-operative imaging was taken 
within one week of surgery, at a median of two days (see Table 7.2).  
 
Table 7.2: day post-operative imaging was performed 
Post-operative day Number of CSDHs 











7.5.1 Residual fluid and air on post-operative imaging 
Post-operative imaging usually contains a combination of fluid and air within the subdural 
cavity. The volume of both were measured using the watershed programme described in the 
methods and reported as; residual volume of fluid (RVF) and residual volume of air (RVA) 
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Figure 7.30; post-operative CSDH imaging showing: (A) pattern of residual air and fluid, (B) air 
(red) and fluid (green) highlighted by watershed programme to calculate volumes. 
 
The post-operative volumes were compared to the paired pre-operative CSDH, which was 
available for 97/100 CSDHs; three patients had pre-operative scans with movement/artefact 
not allowing accurate volume calculations. The patterns in pre- and post-operative volumes 
can be seen in Figure 7.31A, with a significant reduction from total pre-operative volume to 
TRV (paired T-test, p < 0.0001). There were also significantly higher volumes of fluid than 
air across all the post-operative scans (unpaired T-test, p < 0.0001). This can be seen in more 
detail when the TRV was divided into percentage of fluid and air, which shows a median of 
81.5% fluid to 18.5% air, but ranges from TRVs of 100% fluid to those that were 95% air 









Figure 7.31; (A) CSDH volumes from pre-operative (pre-op, n = 97), to post-operative total residual 
volume (TVR, n = 100), (B) percentage of TRV that is fluid compared to air, line (median), box 
(IQR), whiskers (range). Statistically significant differences denoted as P£0.0001 (****), (RVF = 
residual volume of fluid, RVA = residual volume of air). 
 
The day the post-operative imaging was performed (as per Table 7.2), showed no clear 
relationship to the RVF, suggesting any residual fluid remains relatively unchanged within 
the first week of surgery (Figure 7.32). 
  
 
Figure 7.32; correlation between day of post-operative (post-op) imaging and residual volume of 
fluid (RVF).  
 
When assessing each CSDH separately, bilateral CSDHs (n = 28) were smaller than the 
unilateral CSDHs (n = 72), as discussed previously. Therefore, it was unsurprising that the 
post-operative RVF was also significantly lower for bilateral CSDHs, with a similar decrease 
to that seen with the unilateral CSDHs from pre- to post-operation (Figure 7.33). Due to the 
significant differences in volume between bilateral and unilateral CSDHs, they are 
considered separately for some parts of the subsequent analysis, where appropriate. 
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Figure 7.33; comparison of pre-operative (pre) and post-operative (post) volumes of fluid in 
unilateral and bilateral CSDHs, line = median, box = IQR, whiskers = range, statistically significant 
differences denoted as P£0.0001 (****). 
 
During the operation, a drain is usually placed for up to 48 hrs post-operatively to help 
prevent recurrence of the CSDH. A drain was placed for 95/100 CSDHs imaged post-
operatively; three unilateral and one bilateral CSDH had no drains. Rapid brain re-expansion 
resulting in a lack of space for drain placement was reported in all cases with no drain. The 
numbers are too few for statistical analysis but the results shown in Figure 7.34 show that the 
five CSDHs with no drain placement tended to have small TRVs, suggesting there may not 
have been space for a drain. Whilst some of the CSDHs in the drain group have equally low 
volumes, this may be a result of the action of the drain.  
 
Figure 7.34; total residual volumes (TRV) in patients with no drain (n = 5) or a drain (n = 95) placed 
intra-operatively, line (median), bars (IQR).  
 





























Patients who were imaged before 48 hrs may have still had a drain in situ, to understand 
whether having the drain still in situ affected the RVF or RVA seen on the CT imaging at the 
time, all 95 CSDHs were divided into “drain in situ” or “no drain in situ”. 
 
There was a total of 29 images performed with a drain in situ (imaged at a median and mean 
of one day post-operatively) compared to 66 images performed with no drain in situ (imaged 
at a median and mean of three days post-operatively). The post-operative volumes were 
divided into unilateral and bilateral CSDHs, with 36% (25/69) of unilateral and 15% (4/26) of 
bilateral images performed with a drain in situ. There were no significant differences in the 
TRVs for unilateral or bilateral CSDHs, regardless of whether the drain was still in situ 
(Figure 7.35), and this was the case for both the RFV and RAV when considered separately 
(data not shown). This suggests that the process of removing the drain does not allow 
significant accumulation of air or fluid.    
 
 
Figure 7.35; total residual volume (TRV) in unilateral and bilateral CSDHs with and without a drain 
in situ: unilateral (no drain n = 44, drain n = 25), Bilateral (no drain n = 22, drain n = 4), line 
(median), bars (IQR). 
 
The patterns in the residual volumes of air (RVA) on post-operative imaging were reviewed. 
Unlike fluid, the volume of air appears to reduce dramatically the later imaging is performed 
after surgery, and Figure 7.36 suggests that most air is absorbed within seven days of surgery. 
This suggests that perhaps air does not have the persistent effect on limiting the ability of the 


















brain to re-expand, thus causing recurrence, as originally hypothesised. This is discussed 
further in section 7.3.3.2. 
 
 
Figure 7.36; residual volume of air (RVA) by day imaging performed post-operatively (post-op), n = 
100. 
 
To assess the extent of residual fluid as a function of the original CSDH volume, the 
“percentage evacuated” (%-evac) was calculated as;  
 
[Pre-operative CSDH volume - RVF]/ Pre-operative volume x 100.  
 
All patients with a pre- and post-operative scan (n = 98) were analysed for %-evac, with a 
mean of 56.7%. There was no correlation between the %-evac and the pre-operative CSDH 
volume (Pearsons r  = 0.028, p = 0.7824) (Figure 7.37A), suggesting that smaller CSDHs are 
no more likely to be well evacuated than larger ones. Although it is evident that some of the 
smaller CSDHs (<100cm3) increased in fluid volume (thus have a negative % evacuation), 
suggesting the operation led to expansion instead of reduction of the subdural space. Bilateral 
CSDHs (n=26) had a significantly higher %-evac than unilateral CSDHs (n = 72) (unpaired T 
test, p = 0.0263) (Figure 7.37B). The reasons for this are not clear but the physiology of brain 
re-expansion may be different in bilateral cases where there is no opportunity for the brain to 
shift to the contra-lateral side.  
 











Figure 7.37; (A) correlation between pre-operative (pre-op) CSDH volume and %-evacuated, (B) 
comparison of unilateral (n = 72) and bilateral (n = 26) CSDHs for %-evacuated (evac), line (mean), 
bars (S.D.), statistically significant differences denoted as P£0.05 (*). 
 
The true volume of original CSDH evacuated is likely to be higher than the mean of 56.7% 
suggests, as the RVF is not necessarily all residual CSDH, but instead an amalgamation of 
residual CSDH, saline wash used intra-operatively and any acute haemorrhage which 
occurred intra- or post-operatively. Observing the change in density of fluid from pre- to 
post-operative imaging can help understand this further. In some patients there is a decrease 
in mean density as iso-, hyper- or mixed-density CSDH blood is replaced with more 
hypodense saline (Figure 7.38A), whereas other cases will have an increase in density when a 
hypodense CSDH is replaced with some hyperdense fresh bleeding (Figure 7.38B).  
 
 
Figure 7.38; (A) pre-operative isodense CSDH (left) replaced post-operatively with hypodense saline 
(right), (B) pre-operative hypodense CSDH (left) replaced post-operatively with hyperdense acute 
haemorrhage (right).  
 
The mean densities from all pre-operative and post-operative scans were 40.15 HU and 36.79 
HU respectively, resulting in a significant decreased (paired T test, p = 0.0353) (Figure 
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7.39A). This suggests the majority of CSDHs are replaced with more hypodense fluid (i.e. 
saline) than with more hyperdense fluid (i.e. acute blood). There is also a weak negative 
correlation between pre- and post-operative density (Pearson r = -0.2465, p = 0.0144) such 
that the higher the density pre-operatively, the more likely it is to be lower post-operatively 
(due to washout and/or replacement with saline), whereas lower density CSDHs pre-
operatively are more likely to increase in density, as only a tiny volume of acute bleeding 
would be needed to shift the density positively. However, the correlation is very weak 
because many CSDHs show a random pattern on the change in density (Figure 7.39B). 
 
 
Figure 7.39; (A) change in mean densities from pre- to post-operative of CSDH, (B) correlation of 
pre- and post-operative densities, statistically significant differences denoted as P£0.05 (*). 
 
The TRV was significantly higher in patients who had 1BH (n = 5) in comparison to 2BH (n 
= 69) (Mann-Whitney, p = 0.0403), although the numbers are very small. There was no 
difference between 2BH and MC (Figure 7.40).  
 
 
Figure 7.40; comparison of operative techniques and total residual volume (TRV). 1 burr hole (BH) n 
= 5, 2BH n = 69, mini-craniotomy (MC) n = 26, line (median), box (range), statistically significant 
differences denoted as P£0.05 (*). 
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7.5.2 Post-operative imaging and recurrence risk 
Significantly higher TRV was seen in the patients who went on to develop recurrence 
compared to those that did not (Mann-Whitney, p = 0.0011) (Figure 7.41A). When this is 
investigated further by assessing the RVF and RVA, it is clear that it is an increase in residual 
fluid (Mann-Whitney, p < 0.0001) that is the driver of this, and not air, which is actually 
decreased in those that go on to recur (Figure 7.41B).  
 
 
Figure 7.41; (A) total residual volume (TRV) in non-recurrent (NR) and recurrent (recur) CSDH, (B) 
residual volume of fluid (RVF) and residual volume of air (RVA) between NR and recurrent CSDH, 
NR n = 90, recur n = 10, line (median), bars (IQR), statistically significant differences denoted as p < 
0.01 = **, p < 0.0001 = ****. 
 
Some of the current literature contradicts this finding, suggesting that pneumocephalus is the 
driver of recurrence rather than fluid (Dudoit et al., 2016; You & Zheng, 2018). However, 
both of these studies have irregular findings with one reporting an extremely high recurrence 
rate of 32.6% in patients with pneumocepalus and still 17.7% in those without (You & 
Zheng, 2018), and the other only reporting a 4.4% recurrence rate and comparing these 15 
recurrence patients with 30 selected matched controls (Dudoit et al., 2016). The latter paper 
also made a subjective assessment of air, only including “compressive pneumocephalus” if 
the cortex appeared flattened by the air. Some studies concur with my findings, that higher 
post-operative residual volumes of fluid are correlated to recurrence (Stanisic & Pripp, 2017; 
Yan et al., 2018).  
 
As it has already been identified that most air is rapidly absorbed (Figure 7.36), it is logical 
that residual fluid is more likely to drive recurrence. Although, rather than drive recurrence 




































that contributes to recurrence. This latter point is exemplified by the significantly lower %-
evac in recurrent CSDH (unpaired T-test, p <0.0001), suggesting it is not just the stand-alone 
residual volume that predisposes to recurrence but how this correlates to the pre-operative 
volume that is important (Figure 7.42).  
 
 
Figure 7.42; percentage (%)-evacuated of original CSDH in relation to subsequent non-recurrence 
(NR, n = 88) or recurrence (recur, n = 10), line (mean), bars (S.D.), statistically significant differences 
denoted as p < 0.0001 = ****. 
 
Finally, when assessing the mean density of the RVF, there was a trend towards higher mean 
density in cases that went on to recur compared to those that did not (unpaired T test, p = 
0.0968) (Figure 7.43). However, all the recurrence patients had mean densities over 34 HU, 
suggesting they were made up mostly of CSDH or ASDH, whilst the minimum density in the 
non-recurrent group was 15 HU, more in-keeping with low-density saline. This may indicate 
if there is a large RVF on a post-op scan but it appears very hypodense, consistent with 
saline, then recurrence is less likely than if there is persistent or new blood. 
 
 
Figure 7.43; mean density of post-operative residual volume of fluid in CSDHs that are non-recurrent 



























7.6 Clinical correlations to imaging  
 
7.6.1 Demographics and background 
The mean age of the 189 patients in the imaging sub-study was 76 years with a range from 
34-98 years. There was a very weak but significant correlation between age and volume of 
CSDH (Spearman r = 0.2674, p = 0.0002), (Figure 7.44). This suggests that older patients are 
slightly more inclined to have larger CSDHs, which would fit with increased atrophy in the 
elderly allowing more compensation for continued CSDH growth before presenting with 




Figure 7.44; correlation between patient age and CSDH volume, spearman r = 0.2674, p = 0.0002, 
linear regression line y = 69.47 + 0.0572x. N = 189. 
 
In 48/189 (25%) CSDHs the patient was female, reflecting the well-known predilection for 
CSDH in men. There was no significant difference in the CSDH volume or mean density 
between genders (data not shown). There was also no significant difference in the volume or 
mean density between patients who had been on anti-aggregants (AA), anti-coagulants (AC) 
or neither (data not shown). This is surprising as you might expect more bleeding and hence 
higher density in patients on AA/AC. The absence of a relationship suggests that although 
these medications may increase the risk of a patient getting a CSDH in the first instance, they 
do not appear to affect the final size or density of the CSDH on imaging.  
 
 













7.6.2 Relationship with traumatic injury 
A recent traumatic injury was reported in 134/189 (71%) of CSDHs with imaging available 
for analysis, of which 108 (81%) were unilateral and 26 (19%) bilateral. Of the 55 CSDHs 
with no reported history of trauma, 24 (44%) were bilateral. This high number of bilateral 
cases in the non-traumatic cases may be the reason why there is a small but significant 
decrease in volume compared to traumatic CSDHs (Mann-Whitney p = 0.0429) (Figure 
7.45A). As it has already been established that individual bilateral CSDHs are significantly 
smaller in volume than unilateral CSDHs (Figure 7.13A). This data also appears to validate 
the theory in chapter two, whereby CSDHs that transform from ASDHs (CSDH-AT), and 
hence are traumatic, are less likely to be bilateral than those that form de novo (and thus have 
no history of trauma). There was no difference in the mean density between traumatic and 
non-traumatic CSDHs, suggesting that trauma does not influence the degree of haemorrhage 
within the final CSDH (Figure 7.45B). 
 
 
Figure 7.45; (A) volume in CSDHs where the patient reported trauma or no-trauma, line (median), 
bars (IQR), (B) mean density in CSDHs where the patient reported trauma or no-trauma, line (mean), 
bars (S.D.). No trauma n = 55, trauma n = 134, statistically significant differences denoted as p<0.05 
= *. 
 
For patients where the time of trauma was known (n = 124), they were sub-grouped into <4 
weeks, 4-8 weeks and >8 weeks (as per chapter six). No significant differences were found in 
the volume or mean densities between time periods, although there did appear to be slightly 
lower mean densities in CSDHs presenting >8 weeks after trauma (Figure 7.46). 
 


































Figure 7.46; time from trauma in relation to mean density of CSDH, line (mean), bars (S.D.) 
 
 
7.6.3 Inflammatory profile 
Of the 189 imaged CSDHs, 65 had a neurochemistry sample collected which allowed 
comparison of the inflammatory profile within the CSDH to the imaging. 
 
No significant correlations were found between any of the inflammatory markers in the 
CSDH fluid and either the volume, percentage-hyperdense, mean density or Nakaguchi 
classification of the CSDH (see examples for IL-6 in Figure 7.47). There was also no 
difference in any of the inflammatory markers between homogenous and mixed density 
CSDHs. The fact that the final volume of the CSDH does not directly correlated to the 
underlying inflammatory profile is probably due to the multiple confounders and variation in 
both CSDH size and inflammatory response in each patient. For example; some patients may 
have small CSDHs, because of limited atrophy or young age, but still have a highly active 
inflammatory response, whilst another patient with a small CSDH may be in the earlier stages 
of CSDH development and have lower inflammatory markers. Density would be expected to 
be more related to the inflammatory profile, as membranes are the source for inflammatory 
markers and haemorrhage, therefore these may be likely to co-exist in similar concentrations.  
However, it was already shown in chapter 3 that blood breakdown (as measured with MetHb 
concentration) was not related to inflammation, therefore bleeding and inflammation to 
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Figure 7.47; correlation of IL-6 concentration with CSDH: (A) volume, (B) mean density, (C) 
percentage-hyperdense, (D) imaging sub-type (homogenous = homo), line (median), bars (IQR), n = 
64, 1 outlier with extremely high IL-6 excluded for easier graph representation. 
 
 
7.6.4 Dexamethasone and recurrence 
Of the 14 surgically treated patients who had a recurrent CSDH (one bilateral CSDH and one 
patient with two further surgeries), five received dexamethasone therapy (36%). However 
only 2/5 patients had been compliant with the medication with one patient withdrawn on day 
three for confusion, one on day seven for vomiting and one patient was given no 
dexamethasone on day two (missing 16mg in total). The remaining two patients did complete 
the full course of 154mg over 14 days. 
 
Of the 135 patients treated surgically who had no recurrence, 68 (50%) were on 
dexamethasone and the remainder on placebo. Therefore, there is a trend to higher recurrence 
in placebo patients; nine recurrences out of 76 placebo patients (12%) compared to five 
recurrences out of 73 dexamethasone patients (7%). Although not significant, this may 
provide some early evidence for the role of dexamethasone in preventing recurrence (Figure 




































































7.48). The volume between treatment groups was also comparable, so this did not influence 
the recurrence risk (data not shown).  
 
 
Figure 7.48; number of patients with CSDH recurrence (Recur) and no recurrence (NR) by treatment 
groups, line (median), bars (IQR), (dex = dexamethasone). 
 
A previous study has suggested that the earlier the dexamethasone is started pre-operatively, 
the greater the impact on recurrence risk (Sun, Boet, & Poon, 2005). Therefore, the start date 
of the dexamethasone course was assessed, as it was permitted to start pre- or post-
operatively in study patients (Table 7.3). Of the five dexamethasone-treated patients with 
recurrence, three patients started the course pre-operatively and the remaining two post-
operatively, whereas in the non-recurrent CSDH group, more patients stated the course post-
operatively (43/68). Therefore, there is no clear evidence from this data to suggest that 
starting the medication earlier is protective against recurrence.  
 
Table 7.3; number of days of dexamethasone treatment pre- or post-operatively in patients with 
recurrent or non-recurrent CSDH. 
Dexamethasone started Recurrent CSDH Non-recurrent CSDH 
Pre-operative; total n 
1 day  
2 days 
3 days 





































Of the 15 patients (two with bilateral CSDH) that were managed conservatively, three failed 
and required subsequent surgery. Two of which were on placebo and one bilateral CSDH 
patient was on dexamethasone. Interestingly the patient on dexamethasone who failed 
conservative treatment showed a large reduction in volume on both sides of the bilateral 
CSDH by 45% and 39% on the pre-operative follow-up imaging (Figure 7.49). Therefore, in 
hindsight it could be argued this patient was showing a therapeutic effect and could have 
continued with conservative management if clinically stable. The two patients on placebo 




Figure 7.49; volume of CSDH at original and follow-up imaging in CSDHs that failed conservative 
management, with percentage change in volume shown, (dex = dexamethasone treated patient, R = 
right, L = left).  
 
All three patients who failed conservative management had a pre-morbid mRS of 0; two out 
of three had a 3-month mRS of 0, whilst one placebo patient had a 3-month mRS of 3, this 
was the patient with the largest increase in CSDH size and may reflect that conservative 
management of CSDHs that are continuing to grow risks worsened neurological outcome. 
This advocates early follow-up imaging for any conservatively managed CSDHs, with 
careful assessment of the change in volume of the CSDH. 
 
Of the 12 patients with 13 CSDHs (one bilateral) who were successfully managed 
conservatively, 7/13 (54%) were on dexamethasone and the remaining 46% on placebo. 
Although conservative CSDHs have already been shown to be significantly smaller in 
volume than those treated surgically, there was no difference in volume between the 
treatment groups within the conservative cohort (Figure 7.50). The fact that almost the same 

















number of patients were successfully treated with placebo as dexamethasone suggests that 
perhaps these patients had CSDHs that were small enough to resolve without treatment 
anyway, hence why the surgeon opted for conservative management in the first place. The 
only clear exception is an outlier in the dexamethasone group with a CSDH of 250cm3, which 
one would not expect to resolve as part of the natural history of a large CSDH, suggesting in 
this patient the dexamethasone had an important therapeutic action leading to resolution of 
this large CSDH.   
 
 
Figure 7.50; CSDH volume in successfully managed conservative patients on dexamethasone (dex) 
or placebo compared to all surgically treated patients (all surgical), line (median), bars (IQR).  

















A mean volume of 103 cm3 was found across 189 CSDHs analysed in this study, with a 
significant but weak correlation between CSDH volume and age, suggested to some extent 
older patients have larger CSDHs. This is likely to relate to increased cerebral atrophy and 
hence more space for CSDH expansion, in older patients. This also helps explain why 
midline shift was found to be a good correlate for CSDH volume only in younger patients 
(<65), where presumably cerebral atrophy is less of a confounder.  
 
Unilateral CSDHs were significantly larger than the individual sides of bilateral CSDHs, 
which were present in 25/164 (15%) patients. CSDHs in patients who did not report a history 
of trauma were also smaller in volume, which may also relate to the fact that more of them 
were bilateral. CSDHs that were selected for conservative management were also 
significantly smaller in volume than surgical cases, with 4/17 (24%) failing conservative 
management and converting to surgical treatment. 
 
Subjective assessment of density, using the Nakaguchi classification, fitted well with mean 
densities and percentage-hyperdense calculated on objective computational analysis for the 
three homogenous sub-types. The mixed density sub-types could not be discriminated by 
mean density but the separated sub-type had the highest percentage-hyperdense. Volume and 
mean density of CSDH were not correlated and only hypodense CSDHs on the Nakaguchi 
classification were significantly smaller than the separated sub-type, with all other categories 
in between. 
 
Neither volume or density showed any correlation to the inflammatory marker profiles. 
Suggesting that imaging cannot be used as an assessment of the level of underlying 
inflammation occurring.  
 
Post-operative residual volumes were composed of significantly more fluid than air, with a 
median of 81.5% fluid, but with a wide range. Air also appears to be mostly absorbed within 
seven days of surgery, although few patients had post-operative imaging that late. 95% of 
patients had a drain placed intra-operatively, and it was only omitted if the space was 
considered too small for drain placement following brain re-expansion. The data here within 
and from previous studies supports the role of drains in preventing recurrence, therefore it 
should be placed wherever possible. 
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A mean of 56.7% of pre-operative CSDH volume was evacuated but the original size of the 
CSDH did not affect efficiency of evacuation, although bilateral CSDHs showed higher 
evacuation percentages than unilateral ones. Most CSDHs reduced in density from pre- to 
post-operative imaging, likely due to replacement of CSDH with hypodense saline. 
 
Recurrence and outcome 
Pre-operative CSDH volume and midline shift alone do not appear to be risk factors for 
CSDH recurrence, despite previous reports suggesting this in the literature. However, volume 
was significantly greater in patients with an unfavourable mRS on admission and at 3-month 
and 6month follow-up. Assuming that CSDHs grow over time, this leaves room to hypothesis 
that earlier diagnosis of CSDHs could potentially improve outcome by preventing 
neurological deterioration in relation to CSDH growth. However, age is likely to also have 
some influence here with older patients being more likely to have an unfavourable outcome 
and also more likely to have a larger CSDH.   
 
Although previous studies suggest recurrence is higher in bilateral CSDH, we found the 
opposite with 1/25 (4%) patients with bilateral operative CSDHs experiencing recurrence, 
compared to 13/126 (10%) unilateral operative CSDHs. 
 
Only mixed density (particularly trabecular) CSDHs had a trend towards increased 
recurrence. Significantly more mixed density CSDHs had an unfavorable mRS at admission, 
with the same trend at 3-months but none at 6-months, no difference was seen with mean 
density or percentage-hyperdense. As mixed density CSDH also had a significantly higher 
volume and older age, these three factors are likely to all contribute to some degree to the 
cause of poorer outcome. The complexity of the Nakaguchi classification with conflicting 
results in the literature and the finding that mean density calculations are not predictive of 
recurrence suggests that a new classification is needed. This could involve grouping CSDH 
appearance simply into “membranous” or “non-membranous” and is an important area for 
future research. 
 
Significantly higher total residual volumes were found on post-operative imaging in patients 
that experienced subsequent recurrence compared to CSDHs that did not recur. Contrary to 
the original hypothesis, this was primarily due to residual fluid, not air, and may be the driver 
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for recurrence, particularly if the fluid is hyperdense, suggesting perhaps either acute 
bleeding or residual membranes are the driving force.  
 
Higher recurrence in placebo compared to dexamethasone patients (12% versus 7%), with an 
overall rate of 9.4%, was found, although this difference was not significant. This data is 
comparable to recent UK literature showing a 9% recurrence rate amongst 1205 CSDH 
patients (Brennan et al., 2017). Whether the dexamethasone was started pre-operatively or 
immediately post-operatively appeared to make no difference. For patients treated 
conservatively, close assessment of CSDH volume on imaging may help determine whether a 
therapeutic effect is being seen. The growing use of dexamethasone may prove essential in 
both conservative CSDH treatment and prevention of recurrence in surgical patients, but the 
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Randomised controlled trials (RCTs) are considered the most rigorous way of determining 
the efficacy of an intervention (Dechartres et al., 2017), and represent the gold standard 
within clinical evidence based medicine. However, method design, particularly 
randomisation and blinding must be robust and clearly reported to avoid bias (Dechartres et 
al., 2017).  
 
Neurosurgeons have reported a clear preference for data collected from an RCT (Barker, 
2016), indicating that such data may be more likely to alter their clinical practice. However, 
there are several factors which can cause concern to clinicians when conducting an RCT, 
such as randomising to treatments perceived as inferior, or indeed any alternative treatment to 
a well-established standard, and the high time and cost investments required (Sibbald & 
Roland, 1998).  
 
Several studies have published evidence that steroids, with their potent anti-inflammatory 
effect, can be used as a primary or adjunctive treatment for CSDH (Bender, 1974; Berghauser 
Pont, Dammers, Schouten, Lingsma, & Dirven, 2012; Berghauser Pont, Dirven, Dippel, 
Verweij, & Dammers, 2012; Delgado-Lopez et al., 2009; Qian, Yang, Sun, & Sun, 2017; 
Sun, Boet, & Poon, 2005; Thotakura & Marabathina, 2015). However, none are RCTs and 
equipoise in this area has led to inconsistent prescribing of steroids for CSDH patients 
(Santarius, Lawton, Kirkpatrick, & Hutchinson, 2008).  Thus, it was determined that an RCT 
would be an appropriate method of providing definitive evidence on whether steroids are an 
efficacious treatment for CSDH. The Dex-CSDH (Dexamethasone for CSDH) trial was 
designed by a consortium of clinicians as a randomised, double-blind, placebo-controlled trial 
of dexamethasone for adult patients with symptomatic CSDH.  
 
The original intention of the trial was that all patients admitted to a neurosurgical unit (NSU) 
with a CSDH would be treated with the trial drug (investigational medicinal product; IMP) as 
first-line management. If successful, this could negate the risks associated with any surgical 
intervention. However, although dexamethasone has a rapid onset of action, its effect on 
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reducing the size of a CSDH would take time, as the blood and fluid would still need to be 
broken down and reabsorbed. Thus, patients who are admitted in extremis with significant 
mass effect from a CSDH would still need urgent surgery. It was therefore determined that 
trial patients would have the IMP in addition to their standard care as determined by the 
treating neurosurgeon. This meant that patients requiring urgent surgery could start the IMP 
before or after surgical intervention, with the aim of the IMP being to prevent recurrence and 
thus the need for further surgery. For more stable patients the IMP could be started as first-
line treatment and the patient potentially avoid surgery altogether if they improved. However, 
as is discussed in the data section, the majority of patients had combination treatment with 
surgery and IMP, with very few patients managed conservatively with the IMP alone. 
 
The Consolidation Standards of Reporting Trials (CONSORT) group have written a 
statement on the minimum requirements for reporting of trials, most recently updated in 2010 
(Kenneth F Schulz, Altman, & Moher, 2010). This defines what needs to be included in a 
trial report to facilitate transparency on how the trial was run. The Dex-CSDH trial protocol 
was designed in accordance with these recommendations; I was not involved in the original 
study design but helped finalise the protocol details and publication (Kolias et al., 2018). 
  
This trial was funded by the National Institute for Health Research Health Technology 
Assessment (NIHR-HTA) scheme. As the Dex-CSDH is a Clinical Trial of an Investigational 
Medicinal Product (CTIMP), it is subject to The Medicines for Human Use (Clinical Trials) 
Regulations 2004 (UK Parliament, 2004).  This legislation outlines essential processes in 
clinical trial conduct including Research and Ethics Committee (REC) approval, Clinical 
Trials Authorisation (CTA), Good Clinical Practice (GCP), pharmacovigilance and 
manufacture of the IMP. In the UK, the Medicines and Healthcare products Regulatory 
Agency (MHRA) are responsible for CTA and provided authorisation for the Dex-CSDH 
trial. This is considered a phase IV trial, as the IMP is already licensed, but being investigated 
for a new use (Medicine and Healthcase products Regulatory Agency, 2014). All trials should 
be registered before commencement, and the Dex-CSDH trial was registered on the European 




A Trial Steering Committee (TSC) was set up to enable supervision of the trial on behalf of 
the sponsors (University of Cambridge and Cambridge University NHS Healthcare Trust) 
and meets biannually to review trial progress. They are supplied with reports from the 
Independent Data Monitoring and Ethics Committee (IDMEC), who are an independent 
group of clinicians who have access to unblinded trial data. The IDMEC review safety 
reports 3-monthly and full trial data reports 6-monthly, in order to determine whether it is 
safe and ethical to continue the trial. Further to this, a trial management group (TMG), 
including myself, the trial principal investigator (PI), a statistician and the data manager, 
meet weekly to discuss general administration, recruitment and any working issues. 
 
The Dex-CSDH trial has completed recruitment at the time of submitting this thesis but 
follow-up is on-going, therefore final unblinded results are not available. This chapter will 
explore specific aspects of the trial design, the recruitment planning and blinded results from 
the internal pilot and interim data analysis. The trial is anticipated to complete in by June 




















8.2 Trial design  
Historically, neurosurgery has published fewer RCTs than almost any other medical or 
surgical specialty (Barker, 2016). RCTs in neurotrauma (which CSDH is considered to fall 
under) are particularly rare, comprising only two out of 61 RCTs published between 2000-
2014 (Mansouri, Cooper, Shin, & Kondziolka, 2016). This may be due in part to the 
constraints an emergency situation places on time and consent opportunities for clinical trials. 
This was recognised as an issue by the UK clinical trials directive in 2006, leading to an 
amendment to the Medicines for Human Use (Clinical Trials) Regulations such that patients 
could be enrolled into emergency trials even if they are lacking capacity and there is no next-
of-kin (NOK) to provide assent (UK Parliament, 2006). Relevant REC approval would be 
required, but this would significantly broaden the opportunities to recruit patients into trials 
on emergency interventions, particularly relevant to neurosurgery.  
 
A public opinion survey in 2013 reported that 91% of respondents would be happy for an 
independent doctor to assent for patient inclusion in a severe traumatic brain injury trial (Clark 
et al., 2013). This has helped support the implementation of Independent Healthcare 
Professional (IHP) consent, where a trained trial team member and an independent doctor 
caring for the patient, can co-sign to enrol the patient into an approved clinical trial. As patients 
with CSDH commonly have cognitive impairment and treatment is urgent, during which time 
a NOK may not be able to attend, IHP consent was included in the study protocol to maximise 
the opportunities for enrolment. 
 
With a mean age range of 68-77 years in CSDH patients, the Dex-CSDH trial needed to recruit 
almost exclusively from the elderly population (Baechli, Nordmann, Bucher, & Gratzl, 2004; 
Gelabert-Gonzalez, Iglesias-Pais, Garcia-Allut, & Martinez-Rumbo, 2005; Goto et al., 2015; 
Santarius & Hutchinson, 2009; Wada et al., 2014). Older patients are often under-represented 
in medical research, even for pathologies or medicines most relevant to their age group (Aapro, 
Kohne, Cohen, & Extermann, 2005; Konrat et al., 2012; McMurdo, Witham, & Gillespie, 
2005).  Indeed, it is recognised that elderly patients can be perceived by clinicians as being 
vulnerable and needing “protection from researchers”, despite their desire to engage in trials 
(McMurdo et al., 2005). Members from a local public involvement research group (INsPIRE) 
were involved in the trial design to help ensure it would be acceptable for our elderly patient 
group. 
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Evidence that elderly patients are more likely to participate if follow-up if it is done from home 
led to the design of remote trial follow-up for the Dex-CSDH trial (Watts, 2012). Easy to follow 
questionnaires were designed to be completed by post or over the phone. This would negate 
any issues with poor mobility, lack of transport or other confining medical conditions. In the 
case of cognitive, visual or hearing problems, the questionnaires could be completed over the 
phone or with the NOK where appropriate. 
 
 
8.2.1 Drug regimen 
Simple drug regimens also aid compliance with elderly patients (Aapro et al., 2005). Steroids 
require weaning before stopping, therefore reducing doses would be required. To try and 
simplify this, a medication diary with pictures of the tables to be taken each day was designed 
by the trial team (Figure 8.1). 
 
 
Figure 8.1; medication diary 
 
Balancing the efficacy of the drug regimen against side effects and tolerability was also 
essential. Particularly as concerns on the use of steroids in head injury were raised following 
an increased 2-week and 6-month mortality reported in the “Corticosteroid Randomisation 
After Significant Head injury” (CRASH) trial (Edwards et al., 2005; Roberts et al., 2004). 
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Elderly patients also frequently have pre-existing co-morbidities such as diabetes, which can 
increase complications from high dose steroids (Caughey, Preiss, Vitry, Gilbert, & 
Roughead, 2013). Use of steroids in general have been linked with higher rates of sepsis, 
venous thromboembolism and fractures (Waljee et al., 2017). However, steroids are 
commonly prescribed for many conditions in the elderly including polymyalgia rheumatica, 
temporal arteritis and COPD exacerbations (Buttgereit, Dejaco, Matteson, & Dasgupta, 2016; 
Vondracek & Hemstreet, 2006; Walters, Tan, White, & Wood-Baker, 2018). They are also 
widely used in neurosurgery for cerebral oedema in brain tumour patients, where their 
efficacy was first proven in the 1960’s (Maxwell RE, 1972). The peak age group for 
development of glioblastoma multiforme (GBM), the most common type of primary brain 
tumour, is 65-75 years, thus is a similar population to those affected by CSDH (Brodbelt et 
al., 2015). The side effects of steroids are dose and duration dependent, which must also be 
considered (Vecht, Hovestadt, Verbiest, van Vliet, & van Putten, 1994; Vondracek & 
Hemstreet, 2006).  
 
The trial drug regimen was determined by the trial team, including a pharmacology specialist, 
and pragmatic clinical experience of prescribing steroids to neurosurgical patients. A review 
of the current literature on steroid dosing in CSDH can be seen in Table 8.1. The regimen in 
the Dex-CSDH trial starts with a high dose (16mg/day) and tapers down quickly to stop over 
14 days, providing an average weekly dose of 62mg dexamethasone. This is comparable to the 
average steroid doses reported in previous CSDH studies, and is at the lower end of course 













Table 8.1; review of dexamethasone dosing schedules, adverse events and outcomes in the CSDH 






Dex dosing schedule  
(average weekly dose and 
no. of weeks given) 







8mg BD for 3D, 6mg BD 
for 3D, 4mg BD for 3D, 
2mg BD for 3D, 2mg OD 
for 2D (62mg for 2 weeks) 
See Tables 8.9 & 
8.10 
Primary outcome will be 






60-120mg prednisolone for 
average of 21 days  
(Equivalent 70-140mg for 
3 weeks) 
None reported.  Reduced bed rest & 
hospitalisation. 71% 
patients avoided surgery. 
Sun 
(2005)  
26 dex  
69 dex & 
surgery 
13 surgery 
Dex alone: 16mg daily for 
approx. 21 days.  
(112mg for 2 weeks) 
 
2/4 DM patients 
needed additional 
insulin, resolved on 
stopping treatment. 
84% favourable outcome 
in dex alone. Recurrence 








12mg daily, tapering by 
1mg every 3 days 
(46.8mg for 5 weeks) 
Hyperglycaemia 
(14.8%) and 
infections (9%), 1 
gastric ulcer (<1%).  
78.2% dex patients 
avoided surgery. 







dex 16mg daily starting 






only whilst on dex. 
Longer pre-operative dex 
dose associated with 
lower recurrence and no 
increased morbidity. 
Berghauser 
Pont (2012)  
Metanalysis 
of 5 studies 
with total 520 
patients 
Study 1-3 as per Bender, 
Delgado-Lopez, Sun.  
Study 4: 16mg/day tapering 
over 8wks.  
Study 5: 0.5mg/kg pred = 
6mg dex/day for 4 wks. 
Infections 9% 




with long-term use) 
Good outcome in 83-
100% with steroids and   
64-92% surgery alone 
Recurrence: 4-27.8% 
with steroids and 15-






6 day course of dex from 
16mg/day to, 4mg/day. 
(68mg for 1 week) 
Trial on-going since 
2014: no safety 
issues reported  
Primary outcome will be 








16mg for 4D, 6mg for 3D, 
2mg for 3D  
(61.6mg for 1.5 weeks). 
No increase in 
adverse events with 
dex  
6.6% recurrence dex & 
surgery, 13.5% surgery 
only. 83-85% favourable 






12mg/day for 3D, then 
tapered over 4 weeks 
(27.5mg for 4 weeks) 
1 hyperglycaemia 
1 gastritis. 






12mg/day for 21D,tapered 
over 7D (70.25mg for 4 
weeks) 
4 hyperglycaemia,  
5 other SAEs 




75 dex  
167 no dex 
4.5mg TDS for 4D, weaned 
every 4D (155.13mg for 3.5 
weeks)  
5/13 DM patients 
with 
hyperglycaemia. 
Recurrence 8% with dex, 
19.8% without dex. 
(BD = twice a day, D = day, dex = dexamethasone, DM = Diabetes Mellitus, GI = Gastrointestinal, OD = Once a 
Day, SAE = Serious Adverse Event, TDS = Three times a Day) 
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8.2.2 Trial outcomes 
The modified Rankin Scale (mRS) is a core instrument for measuring the degree of disability 
or dependence in daily activities of living (Figure 8.2). It is one of the two most common 
global functional outcome measures used in CSDH studies, with the other being Glasgow 
outcome scale (GOS) (Chari et al., 2016). However, the mRS was originally designed for, 
and continues to be used in stroke studies, particularly RCTs, whereas the GOS was designed 
for evaluating outcome after severe traumatic brain injury (TBI) (Banks & Marotta, 2007; 
Jennett & Bond, 1975; Sulter, Steen, & De Keyser, 1999; van Swieten, Koudstaal, Visser, 
Schouten, & van Gijn, 1988). The severe TBI population is usually young and patients suffer 
profound cognitive impairment in the long term (Shukla, Devi, & Agrawal, 2011). CSDH 
was considered more akin to the stroke population, with similar mean ages and clinical 
manifestations such as limb weakness, speech and cognitive disturbance (Santarius & 
Hutchinson, 2009; stroke association). Thus, the mRS was selected as the primary outcome 
measure in this trial. 
 
 
 Figure 8.2; modified Rankin Scale, category 6 added (van Swieten et al., 1988) 
 
Although the mRS is an ordinal scale, dichotomised values have been used in previous 
studies to optimise the statistical power to demonstrate change (Manickam, Marshman, & 
Johnston, 2016; Santarius & Hutchinson, 2009). Therefore, outcome would be recorded as 
either favourable (mRS of 0-3) or unfavourable (mRS of 4-6).  A recent UK multi-centre 
audit on 798 CSDH patients showed that unfavourable pre-operative mRS, lack of a drain 
placement at operation, higher age and post-operative bed rest were all associated with a 
poorer outcome (mRS 4-6) on discharge (Brennan et al., 2017). Unfavourable admission and 
No symptoms at all
No significant disability despite symptoms; able to carry out all usual duties and activities
Slight disability; unable to carry out all previous activities, but able to look after own affairs 
without assistance
Moderate disability; requiring some help (e.g. with shopping/managing affairs) but able to 
walk without assistance
Moderately severe disability; unable to walk without assistance and unable to attend to own 
bodily needs without assistance










discharge mRS scores have also been correlated with higher mortality at 6-months and one 
year (Manickam et al., 2016; Santarius & Hutchinson, 2009).  
 
As it is hypothesised that dexamethasone leads to reduced CSDH recurrence and the need for 
surgical intervention, it was important to allow time for the effect of any surgical event on 
outcome. Although recurrence can occur up to one year later, the majority occur in the first 
four weeks, and nearly all by four months (Schmidt, Gortz, Wohlfahrt, Melbye, & Munch, 
2015). Therefore, assessing outcome at six months was considered appropriate to capture the 
effect of surgical recurrence and subsequent recovery. The primary outcome measure in the 
Dex-CSDH trial was therefore determined as the modified Rankin Scale (mRS) at 6 months’ 
post-randomisation, dichotomised into favourable (mRS 0-3) and unfavourable (mRS 4-6) 
outcome. A validated version of the mRS which can be used in postal questionnaires was 
adopted (Bruno et al., 2011). Secondary outcome measures are listed in Table 8.2 and include 
assessment of treatments given in addition to the IMP, additional function outcomes such as 
Barthel Index and EQ-5D as well as cost-effectiveness of the IMP. 
 
Table 8.2; secondary outcome measures. 
Purpose of outcome  Outcome measure  
(time point) 
Assess CSDH treatment in 
addition to IMP 
Number of CSDH surgical interventions in first admission and 
subsequent admissions during follow-up 
Assess functional outcome mRS  
(discharge from NSU and 3 months) 
 Barthel Index  
(discharge from NSU, 3 months and 6 months) 
 EQ-5D  
(discharge from NSU, 3 months and 6 months) 
 Glasgow Coma Scale 
(discharge from NSU and at 6 months) 
Other assessments of 
outcome 
Mortality 
(30 days and 6 months) 
 Adverse events 
(first 30 days) 
Assess cost effectiveness of 
IMP 
Length of stay in NSU and secondary care 
(all admissions) 
 Discharge destination from NSU 
(all admissions) 
 Health economic analysis 
(all admissions and home care/support) 
Assess action of IMP Exploratory outcome measures 
(all admissions to NSU) 
(IMP = investigational medicinal product, mRS = modified Rankin Scale, NSU = neurosurgical unit) 
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The Barthel Index (BI) is a disability scale, commonly used alongside the mRS as a validated 
tool for assessing functional recovery from stroke, including both self-care (feeding, 
grooming, bathing, dressing and continence) and mobility (ambulation, transfers and 
climbing stairs) assessments (Sulter et al., 1999). The EQ-5D was designed to provide a 
standard instrument for describing and evaluating quality of life, and has been widely used in 
a range of studies and disease states (Brooks, 2015). All the functional outcome measures 
were assessed in one consolidated trial questionnaire, which could be completed by the 
patient, NOK or blinded research assessor. 
 
Cost-effectiveness is a critical factor when considering new treatment interventions for the 
National Health Service (NHS), and is determined by assessing the impact of the intervention 
on how long a patient will live multiplied by their quality of life in those years, the so-called 
quality-adjusted-life-years (QALY) (Ogden, 2017). During the Dex-CSDH trial, costs to the 
NHS and personal social services will be estimated by looking at length of stay in 
neurosurgical, intensive care and rehabilitation units. Additionally, informal care given by 
family, friends and carers will also be assessed in the final follow-up questionnaire at 6 
months. This will allow a final comparison between treatment groups and an incremental 
cost-effectiveness ratio associated with dexamethasone to be estimated in relation to cost-
effectiveness thresholds. For example, £20,000 - £30,000 per QALY is recommended by the 
National Institute for Health and Care Excellence (NICE, 2013).  
 
Exploratory outcome measures were also assessed during the trial and refer to the scientific 
data discussed throughout this thesis, such as the biological markers and imaging findings in 
CSDH. This data was all collected and analysed separately, without involvement of the main 
study team. 
 
8.2.3 Randomisation, blinding and safety 
Patients were randomly assigned by an interactive web-based system to the intervention 
group (dexamethasone) or control group (placebo). There was a 1:1 allocation as per a 
computer-generated randomisation schedule stratified by site using permuted blocks of 
random sizes.  
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To maintain blinding, dexamethasone was over-encapsulated so that it was visibly 
indistinguishable from placebo.  The IMP was then supplied in identical, individually 
numbered patient bottles. There were some potential scenarios where unblinding could occur, 
such as; 
 
i) Nasogastric administration 
In some situations, CSDH patients were unable to take oral medication, due to cerebral 
compression resulting in drowsiness or swallowing dysfunction. To avoid exclusion of such 
patients it was determined that the IMP could also be given via the nasogastric (NG) route. 
This entailed opening capsules to dissolve the contents and deliver via an NG tube. Whilst 
opening the capsule was potentially unblinding, it was determined as acceptable as long as it 
was performed by a ward nurse (who were not trial study members) and the contents not 
disclosed to the patient and/or in any written record. This maintained the double blinding of 
patient/NOK and the research team/outcome assessors.  
 
ii) Hypergylcaemia 
Hypergylcaemia is the most common and well recognised side-effect of steroids, occurring in 
up to 48% of non-diabetic patients on high-dose steroids (Fong & Cheung, 2013). However, 
it is important to recognise that hyperglycaemia can occur in any acutely unwell patient 
admitted to hospital, reported in around 35% (Levetan, Passaro, Jablonski, Kass, & Ratner, 
1998). To maintain safety, blood glucose was monitored during in-patient stay, and therefore 
higher measurements could have indicated but not proven that the patient was in the active 
treatment arm.  
 
iii) Emergency unblinding 
Finally, as with all studies, patients could undergo emergency un-blinding in any case where 
the clinical team felt that knowledge of the treatment was necessary in order to improve 
management of the patient. In such cases the patient was withdrawn from the study following 
unblinding. 
 
Close monitoring for adverse events occurred for all patients during the first 30 days of the 
trial, which is in-keeping with reporting periods for other CSDH studies (Sun et al., 2005). 
Both serious adverse events (SAEs) and adverse events of special interest (AESIs) were 
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reported. The latter were adverse events the trial team pre-specified as expected in relation to 
steroid use, from clinical experience in neurosurgery and included; hyperglycaemia, new-onset 
diabetes, psychosis and gastric symptoms (e.g. dyspepsia, gastric ulcer). Some SAEs were 
classified as “expected” as they commonly occur in patients operated on for CSDH, and 
therefore were exempt from expedited reporting, but recorded on an SAE log instead (Table 
8.3).  
 
Table 8.3; adverse events of special interest and expected serious adverse events  
Adverse Events of Special Interest  
 
Expected Serious Adverse Events 
(non-reportable) 
METABOLIC 
- Hyperglycaemia necessitating treatment 
or stopping of IMP 
- New onset diabetes necessitating on-
going medical treatment at day 30 
follow-up 
- Hyperosmolar hyperglycaemic state 
PERI-OPERATIVE 
- Re-bleeding into cavity forming ASDH 
- Tension Pneumocephalus 
- Intracerebral Haemorrhage 
- Residual CSDH exerting mass effect 
- Seizures 
- Neurological worsening 
- Anaesthetic complications 
PSYCHIATRIC 
- New onset psychosis 
EARLY 
- Residual CSDH 
- Expansion of contralateral CSDH 
- Seizures 
GASTRIC 
- Upper gastrointestinal side (e.g. 
heartburn, vomiting) 
- Peptic ulceration and gastro-intestinal 
bleeding  
INTERMEDIATE and LATE 
- Recollection of CSDH 
- Wound complications 





8.2.4 Patient eligibility 
CSDH is such a heterogeneous condition, ranging from very small collections which exert no 
mass effect on the underlying brain and resolve spontaneously, to large haematomas resulting 
in significant neurology and even coma. To try and target an appropriate population, only 
patients with a CSDH severe enough to warrant admission to an NSU were eligible for the 
trial. This excluded patients being managed in the community with very small CSDHs which 
were unlikely to ever require any treatment.  
 
The eligibility criteria were planned in a way that would maximise participation and thus 
support eventual translation of findings to as broad a CSDH population as possible (Table 
8.4). 
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Adult patients (aged 18 and older) 
 
Patients with conditions where steroids are 
clearly contra-indicated 
Symptomatic CSDH confirmed on cranial 
imaging (e.g. CT/MRI). 
Patients who are on (or within 1 month) of 
regular PO or IV glucocorticoid steroids  
Informed consent or IHP authorisation Time interval from time to admission to NSU to 
first dose of trial medication exceeds 72 hours 
 Previous enrolment in this trial for a prior 
episode or concurrent enrolment in any other 
trial of an IMP 
 Patients with CSF shunt or history of psychotic 
disorders 
 Severe lactose intolerance or known 
hypersensitivity to dexamethasone or other IMP 
excipients, or desire to avoid gelatin 
(CSF = Cerebrospinal Fluid, CT = Computerised Tomography, IMP = Investigational Medicinal 



















8.3 Sample size and recruitment  
 
8.3.1 Sample size calculation 
The Dex-CSDH trial aimed to detect an 8% increase in the rate of favourable outcome (mRS 
0-3) with dexamethasone versus placebo at 6 months, which was considered to represent a 
clinically relevant treatment effect. A favourable outcome was estimated to occur in 80-85% 
of the control group based on studies investigating treatment effects in the CSDH population 
(Santarius & Hutchinson, 2009; Sun et al., 2005). Using a 2-sided test at the 5% significance 
level, a sample of 750 patients (allowing 15% loss to follow-up) would detect an absolute 
difference of 8% with a power of 81-92%. The study would be analysed on an intention-to-
treat basis.  
 
Given the large sample size, an internal pilot was performed to ensure feasibility before 
committing resource to the substantive trial. Pilot trials normally conduct the RCT on a smaller 
scale to try and answer whether the trial can be done, should be done and if so, how (Eldridge 
et al., 2016). Thus, we designed the Dex-CSDH pilot trial to act as an internal pilot due to the 
well-recognised benefit of data collected in the pilot contributing to the final trial analyses 
(Avery et al., 2017). Reviewing the results of pilot trials is helpful to inform the design of future 
pilot trials and their progression to substantive trials and therefore the recruitment and blinded 
outcome data is discussed later in this chapter (Avery et al., 2017).  
 
The Dex-CSDH pilot recruited patients from 5-10 NSUs ranging in catchment population, 
research experience and resources, to reflect a realistic picture of multi-centre recruitment 
(Avery et al., 2017). Hospital episode statistics indicated that a medium sized NSU admits 60-
80 CSDH patients per year. Setting a conservative estimate, a recruitment rate of two patients 
per month for each NSU was assumed, with an overall target of 100 patients to be recruited 
within 12 months for the pilot study. Pre-determined criteria had to be met to progress to the 






Figure 8.3; progression criteria for Dex-CSDH pilot trial. 
 
 
8.3.2 Recruitment strategies 
Recruiting to target is a challenge for every clinical trial and multi-centre trials often require 
an extension to meet their original target (Treweek et al., 2013). Of 64 neurosurgical RCTs 
registered between 2000-2012, 26.6% were discontinued early, mainly because of insufficient 
patient recruitment (Jamjoom, Gane, & Demetriades, 2017).  Poor recruitment also 
contributes to the median time of 7.6 years taken from trial start to publication for 
neurosurgical trials (Jamjoom et al., 2017). These issues with recruitment to neurosurgical 
trials are likely to be due to a combination of limited research experience and infrastructure 
within NSUs, challenging patient populations often lacking capacity and the time-poor 
clinical neurosurgeon. To try and overcome some of these issues, the Dex-CSDH trial was 
performed in collaboration with the British Neurosurgical Trainee Collaborative (BNTRC) 
(Chari et al., 2018). The BNTRC identified an interested local neurosurgical trainee in each 
unit to act as a “Co-PI” (co-principal investigator) and aid trial set-up and recruitment.  
 
A recent review on strategies to improve recruitment to RCTs suggested that only open-label 
studies and telephone reminders have been shown to increase recruitment 31. As neither of 
these strategies were appropriate for this blinded trial in an acute neurosurgical population, 
we considered that efforts would be best directed towards promoting site engagement and 
incentivising investigators at each site to screen and enrol patients. Specific strategies to do 














Table 8.5; recruitment strategies for site engagement 
Strategies to promote initial site engagement Strategies to promote continued recruitment 
at sites 
Trainee co-PI at all sites; to support PI with site 
set-up administration and encourage local 
recruitment 
Monthly screening logs; to monitor screening 
and allow early identification of any 
institutional reasons for screen failures 
Face-to-face initiation; to engage maximum 
number of people in clinical team and answer 
questions/concerns before starting the trial 
Trial website and regular newsletters with 
local and national recruitment figures and trial 
updates 
Promotion of trial at regular neurosurgical 
meetings 
Annual investigators day - all local PIs, co-PIs 
and research nurses invited. 
 Top recruiting site every six months invited to 
attend academic neurosurgical meeting  
(PI = principal investigator) 
 
I was responsible for organising and running the annual investigators day and involvement of 
real trial patient in a simulated consent session gave research team members the opportunity 
to understand the patient perspective and experience. Patient involvement in study set-up and 
running has become recognised as the gold standard in modern trial design and management 
(Gray-Burrows et al., 2018). Often funding cannot be gained without appropriate public and 
patient involvement (PPI) from the early stages. Early patient-researcher interactions also 
allow recruiters to gain insight into the barriers and drivers for patients to be involved in trials 
and feedback from trial members was that patient training promotes confidence in recruiting.  
 
 
8.3.3 Recruitment results 
The trial opened to recruitment on August 12th 2015, six months later than anticipated due to 
delays in approvals. The internal pilot was completed by seven NSUs by May 2016, in nine 
months instead of 12, but still behind the original target recruitment line due to the delayed 
start. The trial continued into the substantive stage and completed recruitment nine months 





Figure 8.4; final recruitment graph with original target in blue and actual recruitment line in green. 
 
The opening times and average recruitment rates per site during the pilot and substantive trial 



















































































































































































Table 8.6; site opening timetable and recruitment in order of site openings.  
Site R+D to site 
opening 
(months) 
Date of site 
opening 
Pilot:  











19 Aug 2015 75 8 172 5.7* 
Plymouth 7 Oct 2015 5 0.7 28 0.9 
Imperial 5  Jan 2016 2 0.5 3 0.1 
Southampton 4 Jan 2016 13 3.3 71 2.4* 
Middlesbrough 5 Mar 2016 2 1 21 0.7 
Sheffield 5 Mar 2016 2 1 55 1.8 
Birmingham 8 April 2016 1 1 28 0.9 
Brighton 6 May 2016 N/A N/A 26 0.9 
Leeds 7 May 2016 N/A N/A 59 2.0* 
Glasgow 7 May 2016 N/A N/A 61 2.0* 
Stoke 9 June 2016 N/A N/A 20 0.7 
Preston 11 Aug 2016 N/A N/A 8 0.3 
Aberdeen 9 Sep 2016 N/A N/A 10 0.4 
Edinburgh 11 Oct 2016 N/A N/A 15 0.6 
Newcastle 12 Nov 2016 N/A N/A 9 0.4 
Dundee 8 Nov 2016 N/A N/A 6 0.3 
Hull 15 Mar 2017 N/A N/A 15 0.7 
Romford 9 May 2017 N/A N/A 7 0.4 
Cardiff 11 July 2017 N/A N/A 1 0.06 
RLH 6 Sept 2017 N/A N/A 12 0.8 
SGH 26 April 2018 N/A N/A 15 1.9* 
Oxford 8 June 2018 N/A N/A 7 1.2 
Manchester 38 Nov 2018 N/A N/A 1 1 
Total  
(per site)  
227 exc. lead 
(10 months 
per site)  






*top 5 recruiting sites from substantive trial (ST). 
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The time from research and development (R+D) first contact to site opening was an average 
of 5.7 months in the pilot trial (excluding the sponsor site which required a more rigorous 
opening procedure), and increased to 10 months for the whole trial. Extensive administrative 
R+D approval processes can be a significant source of delayed recruitment for multi-site 
trials, such as is seen here and therefore early contact with all sites is necessary. 
 
The average recruitment rate of 2.2 patients/month per site during the pilot trial exceeded the 
target of two patients/month per site. Therefore, the target recruitment plan was considered 
realistic and projected recruitment remained unchanged into the substantive trial. However, in 
hindsight, it would have been important to assess recruitment patterns in addition to the 
absolute numbers in order to understand recruitment feasibility and guide the recruitment 
projection for the substantive trial.  
 
During the Dex-CSDH pilot trial the recruitment target was far exceeded in two of the sites 
(8/month in Cambridge and 3.3/month in Southampton), and was below the target in the 
remaining five sites. Of these five sites, two were small centres (Plymouth and Imperial) with 
limited populations to recruit from and the remaining three had only been open two months. 
However, there were clues that perhaps not all sites would attain the two patients/month target. 
Further to this, recruitment curves are traditionally exponential in design, but this often does 
not reflect the realities of trial recruitment, which after an initial take-off can remain constant. 
Recruitment fatigue can also mean that previously well-recruiting centres may decline over the 
course of the years it takes to complete a large trial. Many of the sites opened after the pilot 
phase recruited less well than those opened during the pilot phase, with three of the seven pilot 
sites being in the top five recruiting sites for the substantive trial. This may mean that strong 
sites were opened during the pilot period, or that the longer sites are open the better they are at 
recruiting. However, recruitment rates at these top centres have also remained stable or 
declined. Overall this led to a decline in recruitment from an average of 2.2 patients per site 
per month to 1.1, resulting in recruitment falling behind target in the substantive trial despite 
exceeding the pilot targets (Figure 8.4).  
 
The earliest part of the recruitment process involved screening patients, and the rate of 
screening directly related to the subsequent recruitment rate. This was exemplified by the top 
two recruiting sites from the pilot, who also screened the highest number of patients (11-14 
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per site per month), whilst other sites only screened 2-4 patients per month (Table 8.7). 
Higher screening rates may have been related to the staffing at these sites, as both had a 
research fellow and nurse dedicated to trials. This enabled them to invest more time and 
effort into identifying, approaching and discussing the trial with potential patients. Most other 
centres were reliant on the clinical staff to screen and enrol patients, adding to their daily 
workload and therefore requiring significantly more motivation. There was also variable 
availability and support from local research nurses (RN), who often do not have a 
neuroscience background.  It is self-evident that limited infrastructure and research staffing 
has an impact on the delivery of RCTs, as was seen with this trial. 
 
Table 8.7; screening and recruitment rates at pilot sites, in order of sites opened. 









Cambridge 126 14 75 60% 
Plymouth 25 4 5 20% 
Imperial 9 2 2 22% 
Southampton 43 11 13 30% 
Middlesbrough 5 2.5 2 40% 
Sheffield 2 2 2 100% 
Birmingham 4 4 1 25% 





8.4 Blinded interim trial data  
 
The following data is based upon a review of interim trial data analysed on the 19th October 
2017. Data was available on 461 patients at this time point. Not all data points were available 
for all patients, but each section had no more than 10% missing data points. Percentages have 
been used throughout to avoid confusion about variations in the exact number of patients for 
each section of data. 
 
8.4.1 Baseline data 
It is well established that CSDH affects the elderly, therefore although the range of patients 
recruited to was from 21-95 years, the mean age was 74.1 and median 75, showing the 
majority are clustered in the expected age group. This age distribution is likely to affect the 
incidence of CSDH, which will undoubtedly increase as the elderly population expands. A 
recent report from the Office of National statistics showed an increase in the percentage of 
the population aged over 65 years from 14.2% in 1976 to 18% in 2016 and projected a rise to 
24.7% by 2046 (Office for National Statistics, 2017).   
  
In total, 73.3% of the patients recruited were male, which is similar to other large CSDH 
studies, reporting 64% - 82% male patients (Aspegren, Astrand, Lundgren, & Romner, 2013; 
Baechli et al., 2004; Brennan et al., 2017; Kanat, Kayaci, Yazar, Kazdal, & Terzi, 2010; Ro 
et al., 2016; Santarius & Hutchinson, 2009). It has been postulated that this gender bias 
relates to earlier and more significant brain atrophy occurring in men (Kanat et al., 2010). 
Although other studies have shown that atrophy, alongside other potential risk factors such as 
anti-coagulant and anti-aggregant use, trauma and alcohol abuse affect both genders equally 
(Aspegren et al., 2013; Marshman, Manickam, & Carter, 2015). Thus, the male 
preponderance remains a clinical conundrum. 
 
Of the 461 patients analysed, 97.6% were Caucasian. Although the 2011 census revealed that 
85.4% of UK residents were Caucasian, this increased to 95.3% when looking at those aged 
over 65 (Office for National Statistics, 2016). Therefore, although we wanted to include an 
ethnically diverse population, this is relatively representative of the elderly people living in 
the UK.  
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The use of anti-coagulants (AC) and anti-aggregants (AA) are often considered a risk factor 
for the development of CSDH, and their increasing use for conditions such as atrial 
fibrillation over recent years may also contribute to a growth in the number of CSDHs 
(Gonugunta & Buxton, 2001; Hansen et al., 2018). Interestingly, they may be most relevant 
to CSDH pathophysiology in patients who do not report a history of trauma (Aspegren et al., 
2013). The rates of AC and AA use in the Dex-CSDH interim data can be seen in Table 8.8. 
Compared with previous literature on CSDH, there were higher rates of AC use (25% versus 
14-16%) and similar rates of AA use (27.4% aspirin and clopidogrel versus 25-26%) 
(Aspegren et al., 2013; Marshman et al., 2015). 
 
Table 8.8; anti-coagulant and anti-aggregant medication and reversal in Dex-CSDH patients  
Anti-Coagulants (AC) Percentage of patients  
Warfarin 19.6% 
Novel Oral AC:  
(Apixiban, Dabigatran, Rivoroxaban, Edoxaban) 
4.2% 
Low Molecular Weight Heparin  
(Dalteparin, Enoxaparin, Tinzaparin) 
0.7% 
Anti-Aggregants (AA)  
Aspirin 21% 
Clopidogrel 6.4% 
Other (Dipyridamole, Ticagrelor) 1.4% 
All reversal treatments (can include more than one) 26.3% 
Vitamin K 12.1% 
Pro-thrombin Complex Concentrate 10% 
Platelets 11.3% 
Other (e.g fresh frozen plasma) 4.1% 
 
Whether AC and AA increase the risk of CSDH recurrence is widely debated, with evidence 
on both sides (Aspegren et al., 2013; Fornebo et al., 2017; Gonugunta & Buxton, 2001; Wang 
et al., 2017). In the case where higher recurrence rates are reported in association with AAs, 
this can be negated by delaying surgery for at least 3 days to allow recovery of platelets 
(Wada et al., 2014). Often treatments are given to aid the reversal process, with Vitamin K 
and Pro-thrombin Complex Concentrate (PCC) used for warfarin reversal and platelets given 
to patients on AAs. Although approximately half the Dex-CSDH patients were on either AC 
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or AA, only 26.3% of patients were given any reversal, with the remainder simply given time 
for the medication effects to wear off. Vitamin K was the most common reversal treatment 
given, and was nearly always in combination with PCC, as the latter is recognised to lead to 
more rapid reversal (Cartmill, Dolan, Byrne, & Byrne, 2000; Woo et al., 2014). A 
comparison between recurrence rates and outcome for patients on AA/AC versus no 
treatment will be performed on trial completion to provide further definitive evidence 
regarding this. 
 
Recent head trauma was reported in 69.4% of patients, which is similar to the literature rates 
of between 61-80% (Baechli et al., 2004; Gelabert-Gonzalez et al., 2005; Sambasivan, 1997; 
Santarius & Hutchinson, 2009; Stroobandt, Fransen, Thauvoy, & Menard, 1995). The timing 
of the trauma was known in 97% of these patients and most commonly occurred one to three 
months prior to CSDH diagnosis (Figure 8.5).  
 
 
Figure 8.5; time from head trauma to CSDH diagnosis 
 
The majority of patients (36%) had symptoms for less than a week prior to diagnosis of 
CSDH. A further 29% had symptoms for 1-2 weeks, 22% for 2-4 weeks, 7% 4-6 weeks and 
6% for >6 weeks. 
 
Throughout the trial approximately 10% of patients were managed conservatively with the 
trial IMP only, whilst the remaining 90% received surgery in addition to the trial IMP. Of 
those who received surgery, 84% had burr holes and 16% a mini-craniotomy. 84% of patients 
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also had a subdural drain inserted, which has become common practice following a recent 




8.4.2 Adverse events 
Adverse event data was available on 655 patients recruited up to July 2018. In this time 
period, 95 Serious Adverse Events (SAEs) occurred in 81 patients (12%). Of these, 10 
patients in the pilot period and 71 in the substantive study experienced an SAE (Table 8.9). 
This resulted in similar SAE rates in the pilot (10%) and substantive trial (13%), suggesting 
pilot studies can be useful in providing preliminary data of the safety of an intervention. 
 
The most common SAE classifications during the pilot also remained frequent in the 
substantive trial, and included; infections (most commonly pneumonia and not including 
wound infections as per Table 8.3), nervous system (most commonly stroke) and injuries 
(such as falls). Infections are common in hospitalised elderly patients, with reported rates 
ranging from 18.5 - 38.5%, increasing with intravenous and urinary catheterization (Hussain 
et al., 1996; Laurent et al., 2012). A meta-analysis in the stroke population, which affects a 
similar patient group to CSDH, also showed an overall infection risk of 30% (Westendorp, 
Nederkoorn, Vermeij, Dijkgraaf, & van de Beek, 2011). In this trial only 3% (20/655) of 
patients had an infection reported as an SAE, suggesting that CSDH patients are lower risk 
than most other elderly in patients. However, it may also be that most infections did not meet 
the benchmark to be reported as “serious”, thus under-estimating the true infection rate. 
However, these findings still allay some of the concerns about steroid prescribing in the 
elderly predisposing patients to a much higher risk of serious infections.  Vascular events 
such as deep vein thrombosis (DVT) and pulmonary embolism (PE), were the next most 
common SAEs occurring in 1.98% (13/655) of patients. This is within the reported range of 
1.4 -4.1% DVTs and PEs in neurosurgical patients, and therefore doesn’t suggest that 
dexamethasone increases the thrombosis risk (Chibbaro et al., 2018).  
 
The SAEs that were considered “possibly”, “probably” or “definitely” related to 
dexamethasone were termed serious adverse reactions (SAR). This accounted for only 8% of 
all SAEs and included five infective conditions (pneumonia, UTI, abscess and shingles), two 
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endocrine (hyperglycaemia and adrenal insufficiency) and one case of acute psychosis. As 
the determination of whether an SAE is “related” to the IMP is subjective, each recruiting 
doctor may classify this differently. For example, most episodes of pneumonia, a common 
surgical complication in elderly post-operative patients, were not classified as SARs, but two 
were. It can be argued that the classification of SAR has little value until the end of the trial 
when the treatment allocation is known. 
 
Data was also collected on adverse events of special interest (AESIs) in the same 655 
patients. These are adverse events anticipated to occur in this population of patients in 
relation to steroid use (see Table 8.3). An AESI was reported in 12 pilot patients and 36 
substantive trial patients, making an overall rate of 7% (Table 8.10).  
 
As previously discussed, hyperglycaemia is a common side-effect of dexamethasone, and 
was reported in six patients during the pilot (one patient had two episodes). An additional 10 
patients experienced hyperglycaemia in the substantive trial, making an overall rate of 2.4% 
(16/655). This is significantly lower than the rates of up to 15% reported in the literature 
(Berghauser Pont, Dirven, et al., 2012; Fong & Cheung, 2013). This low rate may be for 
several reasons; firstly although diabetes is not an exclusion, due to the perceived high risk of 
hyperglycaemia with steroids, patients with diabetes or pre-existing hyperglycaemia of any 
cause may have been screened out from trial inclusion. Secondly the most unwell patients 
with multiple co-morbidities (who are probably also those at higher risk of hyperglycaemia) 
may also be screened out prior to recruitment if they are not seen as fit enough to take part in 
the trial or lack the ability to consent. Although IHP consent is available, we found very low 
uptake of this method of consent, suggesting that if the patient or NOK were not available to 
consent then the patient tended not to be recruited. Finally, the broad terminology used in the 
exclusion criteria of any patient in whom “steroids are clearly contraindicated” is open to 
interpretation and may be used as a reason for excluding diabetic or unwell patients. The only 
way to determine whether this rate of hyperglycaemia is higher than it would normally be in 
the CSDH population would be to take random blood sugar readings from all CSDH patients 
admitted and compare this with the trial cohort. 
 
 262 
Table 8.9 - SAEs in pilot and substantive study grouped by systems. 
System classification 
 
N of events 
(total) 
SAES during pilot SAEs during substantive trial 
 (* = SAR) 
Cardiac 
 
5 0 4 cardiac failure 
1 acute myocardial infarction 
Endocrine 
 
3 0 1 hyperglycaemia* 




6 1 large bowel perforation 1 vomiting 
1 dysphagia 
1 incarcerated hernia 




6 1 general health decline 2 deaths of unknown cause 
1 general health decline  
1 non-cardiac chest pain 
1 pyrexia of unknown origin 
Immune system 
 
1 0 1 Anaphylactic reaction 
Infections 
 
23 1 pneumonia 
1 urinary tract infection 
11 pneumonia (2*) 
3 c.difficile colitis/sepsis 




1 axillary abscess* 
1 shingles* 
Injury 10 2 lacerations 
1 fractured hip 
5 falls 
1 laceration 
1 head injury 
Metabolism and 
Nutrition 
3  2 hyponatraemia 
1 reduced oral intake  
Musculoskeletal 1 0 1 intermittent back pain 
Neoplasm 1  1 cholangiocarcinoma 
Nervous system 14 2 acute subdural haematoma 
1 stroke 
4 stroke 
2 acute subdural haematoma 
1 intracerebral haemorrhage 
1 transient ischaemic attack 
1 brain oedema 
1 dysphasia 
1 headache and vomiting 
Psychiatric 5  2 confusional state 
1 acute psychosis* 
1 senile dementia 
1 alcohol withdrawal 
Renal and urinary                   1  1 acute kidney injury 
Respiratory                             1  1 pneumothorax 
Skin and tissue                       1  1 facial swelling 
Vascular                                14 1 deep vein thrombosis 5 pulmonary embolisms 
3 deep vein thromboses 
2 syncope 
2 dizziness 
1 intestinal infarction 
Total no. of events 95 11  84 
Total no. of patients 81/655 (12%) 10/100 (10%) 71/555 (13%) 
SAR (% of events) 8/95 (8%) 0/11 (0%) 8/84 (10%) 
(SAR = serious adverse event) 
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During the pilot period 11% (12/100) of patients experienced an AESI, with hyperglycaemia 
most common (Table 8.10). Two episodes of hyperglycaemia resolved without treatment, 
two resolved after stopping study medication and three required short-term treatment with 
either an increase in normal diabetes medication or addition of insulin. As the patients remain 
blinded to everyone apart from the IDMEC, we do not know whether the AESIs occurred in 
patients on dexamethasone or placebo. However, the current AESI rate in the substantive 
study is significantly lower at 7% (46/655) which is reassuring. All unblinded safety data was 
also regularly scrutinised by the IDMEC and there was no suggestion that the trial needed to 
be halted on safety grounds at any time point. 
 






AESIs during internal 
pilot 
AESIs during substantive 




5 3 2 
Hyperglycaemia 
requiring treatment 
12 4 8 
New onset Diabetes 
 
2 1 1 
Upper GI symptoms 
 
14 3 gastric reflux 4 gastric reflux 
4 nausea and vomiting 
1 abdominal pain 
1 instestinal obstruction 
1 haematemesis (normal OGD) 
Psychosis 
 







2  1 diarrhoea 
1 constipation 
Total no. of events 48 12 36 
Total no. of 
patients (%) 
46/655 (7%) 11/100 (11%) 35/555 (6%) 




8.4.3 Outcome data 
Data on the primary outcome measure, mRS, was reviewed once all 100 pilot patients had 
completed their 6-month follow- up (at which point 242 patients had been recruited). A 
further interim analysis was performed when approximately 300 patients had completed 6-
month follow-up (Table 8.11). Trial retention was excellent during the pilot with only 2/110 
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(1.8%) patients withdrawn and 2/110 (1.8%) lost to follow-up (LTFU) at six months, 
resulting in a 96.4% follow-up rate for the primary outcome. This translated into the main 
trial (for the first 293 patients) with a slightly higher patient withdrawal rate (4.8%), and 
similar rate LTFU at six months (1.7%), resulting in an overall follow-up rate of 93.5% in the 
interim review. This small difference of just under 3% in the final follow-up rate suggests 




Data was considered transiently missing (TM) if it could not be collected at three months, and 
was often due to difficult tracking patients who may still be in a care or rehabilitation facility. 
By six months nearly all patients had returned home or to a permanent new location known to 
the General Practitioner (GP), enabling improved follow-up at this final time point. Patients 
were only considered lost to follow-up (LTFU) if data could not be collected at six months.  
 









Data received  
n (%) 
PILOT 242 recruited    
Pre-morbid mRS    175 
Admission mRS    170 
Discharge data  11  157 
3-month follow-up 160 6 (3.75%) 22 (13.75%) 132 (82.5%)  
6-month follow-up 110 2 (1.8%) 2 (1.8%) 106 (96.4%) 
MAIN TRIAL 461 recruited    
Pre-morbid mRS    385 
Admission mRS    378 
Discharge data  16  389 
3-month follow-up 373 16 (4.3%) 27 (7.2%) 330 (88.5%) 
6-month follow-up 293 14 (4.8%) 5 (1.7%) 274 (93.5%) 
(LFTU = lost to follow-up, TM = transiently missing) 
 
After completion of the pilot generous follow-up windows of -4/+8 weeks were added for the 
follow-up time points. This was because it was clear that there is little change in mRS scores 
between three and six months (Figure 8.7) and we wanted to maximise inclusion of all data 
received which would often trickle in between three and six months and later.  
  
The three and six-month follow-up rates during the pilot were representative of that 
experienced in the main trial. This is impressive considering the number of trial sites 
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increased from seven to 21 in the main trial and extended from England into Scotland and 
Wales, which could make tracking patients more challenging. The follow-up rate at three 
months improved due to a decline in TM data (from 13.75% to 7.2%), this was achieved 
through changes to the questionnaire assessment of mRS. Originally the mRS was assessed 
with a validated questionnaire (often completed by the patient or carer), which involved 
instructions tracking which questions to go complete, although if not followed correctly then 
the final mRS could not be calculated (Bruno et al., 2011), see Figure 8.6A. This was 
simplified and the instructions removed so that all questions were answered, leading to a 
large reduction in missing data (Figure 8.6B). An adjudication process was also introduced so 
that all questionnaires where checked by a clinician before sending to the data entry team, 
allowing repeat patient contact within the time window if needed. These processes reduced 
the errors in collection of mRS data and highlight the importance of testing questionnaires in 
the target research population prior to use, even when previously validated. Follow-up rates 
were also improved by implementing a dedicated research nurse to track and do all follow-
ups, instead of the administrative team who do not have clinical experience. 
 
 




The very low rate of LTFU is likely to reflect the trial design aspects intended to maximise 
engagement from the target elderly population. Such that follow-up was remote and could be 
done by NOK/carer or a blinded assessor over the phone. A review of strategies to improve 
retention in randomised trials reported that money incentives improve return of postal and 
electronic questionnaires, however this was not considered appropriate in an NHS setting 
(Brueton et al., 2014). Brueton et al. also suggested that reminders have no significant effect 
on follow-up, however we found follow-up telephone reminders very helpful. This may be 
specific to our patient cohort who may suffer from cognitive and physical impairments that 
make filling in and returning a written questionnaire challenging. Some patients reported 
preferring to answer the questionnaires over the phone, therefore this is an important 
alternative.  
 
Withdrawal rates have been suggested to minimise bias to trial results if maintained under 5% 
(K. F. Schulz & Grimes, 2002). Therefore, the current rate of 4.8% withdrawal at six months 
is just about acceptable and has been closely scrutinised to understand how we can minimise 
it. Most withdrawals relate to patients who experience an adverse event soon after starting the 
IMP, represented by a mean withdrawal time of 3.7 days from starting IMP (range 0-19 days). 
Even if the adverse event is considered unrelated to the trial IMP, experiencing such an event 
can change the patient’s perspective and desire to participate in a trial. Wherever possible, 
patients who withdraw from the IMP are still encouraged to remain in the trial for follow-up to 
minimise the bias of missing data (Ye et al., 2011). The final study results will be analysed on 
an intention-to-treat basis but data on IMP non-compliance is collected so that a further analysis 
can be done in relation to different levels of medication compliance. 
 
Other causes of withdrawal include patients or NOK who changed their mind or in rare cases 
where a clinician determined the need for withdrawal or unblinding. Unblinded data was 
reviewed by the IDMEC every three months throughout the trial and no ethical or safety issues 
were raised.   
 
The pooled (dexamethasone and placebo patients) mRS scores from the pilot and interim 
substantive trial data are displayed in Figure 8.7. This includes the time points; pre-morbid 
(prior to onset of CSDH symptoms), admission to NSU (also termed enrolment), discharge 
from NSU, three month and six month follow-up.  
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Figure 8.7; (A) pooled mRS scores from all pilot study patients (n = 106 at 6 months), (B) pooled mRS 
scores from interim data review (n = 273 at 6 months). X-axis; chronological outcome assessments 
(enrolment refers to admission to NSU), Y-axis; percentage of patients.  
 
The pooled change in mRS scores from pre-morbid to six months are remarkably similar in 
the pilot and interim substantive trial results, suggesting the pilot was helpful in determining 
expected outcomes. Pilot data is often used to confirm the sample size of a larger trial for this 
reason. However, there has been a small shift in the pooled favourable outcome (mRS 0-3) 




could be a sufficient difference to alter the sample size needed, and hence a secondary sample 
size calculation was performed after 500 patients reached six months to ensure a sufficient 
recruitment target. This secondary analysis suggested that 750 patients would be sufficient. 
 
Interestingly there is little change in the rate of favourable outcome from three to six months, 
only that those with a poor mRS (4 or 5) at three months are more likely to be dead (mRS 6) 
at six months. The biggest change in mRS score from unfavourable to favourable occurs from 
admission to discharge, exemplifying the immediate and successful results from in-patient 
CSDH treatment (surgery in most cases). However, there is also a substantial increase in the 
number of favourable mRS scores from discharge to three months, which appears to be a 
more important time of recovery than from three to six months. To understand the patterns of 
change in mRS more fully, an ordinal analysis will be performed in addition to the primary 
dichotamised analysis.   
 
The results from other functional secondary outcome measures can be seen in Table 8.12. 
The EQ-5D has been broken down into two parts; the visual analogue scale (VAS) and the 
Utility Index (UI). The VAS comprises of a vertical scale from 0 to 100 and asks the patient 
to grade their health from “worst possible” (0) to “best possible” (100). This method of data 
collection is well understood by the majority of patients leading to high rates of completion 
and is a good overall measure of the patients own perception of their health (Feng, Parkin, & 
Devlin, 2014). The UI incorporates scores from all the answers on the EQ-5D (excluding the 
VAS) into one overall score representing the “health state”, where one is equivalent to full 
health, zero is death, and a negative score is when living is considered worse than death 
(Devlin, Shah, Feng, Mulhern, & van Hout, 2018).  The BI is represented as the total score 
(maximum 100) of function in all the different activities of daily living and mobility.  
 
Table 8.12; secondary outcomes measure results. 
 Discharge 3 month 6 month 








EQ-5D UI (SD) 0.788 (0.23) 0.844 (0.219) 0.87 (0.214) 








(BI = Barthel Index, SD = standard deviation, UI = utility index, VAS = visual analogue scale) 
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The high rates of favourable outcome as assessed with the mRS is corroborated by the high 
mean BI and EQ-5D scores (Table 8.12), which also showed the most improvement from 
discharge to three months and little change thereafter. The high mean BI scores show that 
many patients have good independent function across a spectrum of daily activities, although 
the lowest score of 0 does mean that some patients are dependent for all care even at six 
months. Equally, the EQ-5D scores suggest high overall patient satisfaction with their quality 
of life, but again the very lowest limit in the VAS score (3/100 at three months) shows some 
patients perceive their health as close to the “worst possible”. There is also a relatively wide 
standard deviation for both the secondary outcome scales showing variability in functionality 
and quality of life. The difficulty with analysing these outcomes is that there is no “pre-
morbid” scoring to compare to, therefore those patients with the worst perceived health and 
functionality may have been like this prior to their CSDH. A small number of patients did 
have an mRS of four (moderately severe disability) pre-morbidly, and therefore were unable 
to mobilise independently and would have been dependent for care. Further to this some 
patients sustained further injuries, falls and medical illnesses during their follow-up time 
which were not necessarily directly related to the CSDH but severely affected their quality of 
life. This is to be expected in a cohort of elderly individuals with multiple co-morbidities, 
therefore the mean outcome scores (which are high) are more valuable than any extreme 
outliers.  
 
The only facet of outcome which was not sufficiently assessed during follow-up was 
cognitive function. Originally the Montreal cognitive assessment (MOCA) tool was going to 
be used to assess cognition in all patients on discharge from the NSU and at follow-up but it 
requires face-to-face assessment and most patients did not have clinic follow-up. Therefore. 
this tool was excluded due to extremely high missing data. This does make it difficult to 
make any inferences on the impact CSDH has on long-term cognitive function and dementia 
risk, as discussed in chapter two. This is an area for future research.  
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8.5 Conclusions  
The Dex-CSDH trial is the first randomised control trial to assess the role of dexamethasone 
in treating patients with CSDH. Whilst recruitment is on-going, scrutiny of the design and 
methodology of the trial is important as the final results are likely to significantly impact the 
clinical practice of CSDH treatment worldwide. 
 
Recruitment feasibility was assessed as adequate during the internal pilot period, but closer 
review of the recruiting patterns may have signified that this was skewed by data from the 
lead site, and the recruitment target was unlikely to be met at all centres. Strategies were 
implemented to attempt to maximise recruitment but the clinical trials community should 
review the common practice of exponential recruitment projections, which are often 
unattainable. 
 
With regards to trial design, the intention was to meet the needs of the elderly population as 
much as possible and to maximise participation and engagement with follow-up. This appears 
to have been successful, reflected in the excellent follow-up rates with an extremely low rate 
of LTFU (1.7%) and an acceptable withdrawal rate (4.8%). The drug regimen also appears to 
have been well tolerated with an SAE rate of only 12% overall and most events as expected 
with this population. The AESI rate was also only 7% and therefore is lower than one might 
expect when treating elderly patients with a course of steroids. True causal relationships 
between these adverse events and dexamethasone can only be determined once the data in 
unblinded, but the IDMEC have raised no safety or ethical concerns to date.  
 
Finally, the outcome measures appear to have been successfully collected via postal and 
telephone questionnaire and patients have engaged well with this. The results from secondary 
outcomes such as BI and EQ-5D also corroborate the findings from the mRS scores of a high 
rate of favourable outcome at three months and little change up to six months.  The pooled 
rate of favourable outcome measured with the mRS is within the range anticipated in the 
original sample size calculation, and no changes to the sample size have been required. This 
suggests that patients recruited to the Dex-CSDH trial have similar outcomes to the CSDH 
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Chapter 9: Conclusions and future work 
 
 
9.1  Pathological origins of CSDH 
The review of 41 patients who had baseline imaging prior to their CSDH diagnosis, 
demonstrated two different pathological origins of CSDH; De-Novo formation from a normal 
scan (CSDH-DN), and acute subdural haematoma that transforms (CSDH-AT). Perhaps 
surprisingly, CSDH-DN was more common in 26/41 (63%) of CSDH patients. This 
challenges the general perception that CSDH always progresses from acute haemorrhage and 
wider understanding of this in the medical community is necessary so that elderly patients 
with a “normal” scan immediately following trauma are not assumed to have experience no 
injury. This also highlights the importance of on-going clinical assessment in elderly patients 
following trauma, with a low threshold for re-imaging in the case of new or progressive 
symptoms. Even if symptoms progress long after the trauma this may indicate related 
pathology, as the mean time of diagnosis of CSDH-DN was 56 days (eight weeks) from 
original trauma imaging, and occurred as late as 145 days (approximately five months). 
Ideally, one would be able to predict the patients who will develop a CSDH following 
trauma, enabling earlier diagnosis and treatment. One possible route of doing this is better 
identification of patients with subdural hygroma, as this is likely to be involved in the 
pathophysiological chain of events forming a CSDH-DN, and was present in 14/25 (56%) 
baseline trauma images. It is more commonly apparent at scans delayed from trauma, so it is 
particularly important to assess for this in any imaging performed later. However, as the 
incidence of subdural hygromas that resolve is unknown, this may still have limited 
predictive value for CSDH.  Overall, greater awareness of this pathophysiological mechanism 
should lead to closer follow-up and research on this patient group to improve early diagnosis 
and allow possible preventative treatment options. This is particularly relevant in the era of 
the new application of pharmacological therapies, which, if proven to work, could 
conceivably be applied early to prevent the progression from subdural hygroma to CSDH 
entirely.  
 
The mean time from ASDH to CSDH-AT diagnosis was 16 days, suggesting 10-14 days 
would be a good time delay for re-imaging conservatively managed ASDHs to diagnose 
those developing CSDHs needing treatment.  
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Importantly the pathological origin of CSDH did not influence the outcome as measured with 
GCS at discharge or mRS at three and six months. However longer and more detailed follow-
up studies with greater patient numbers would be valuable in confirming that this. There is a 
growing body of research interested in the long-term impact of head injury and cerebral 
atrophy, as this may also have an impact on dementia risk. This is highly relevant to the 
CSDH population, who are already largely elderly and often have established, and in some 
cases significant, cerebral atrophy. Therefore, studies with follow-up times exceeding the 
normal 6-12 months should be planned in the future, with a focus on long-term imaging 
changes as well as detailed cognitive as well as functional assessment.  
 
 
9.2  CSDH composition, inflammation and the impact of dexamethasone 
This work has demonstrated that CSDHs contain significant amounts of haemorrhage, with 
an average red cell density approximately 1/3 of that measured in paired venous blood. This 
haemorrhage is of differing ages, which can be measured to some extent by evaluating the 
methaemoblobin content by UV-Vis spectroscopy. CSDHs that are low density on imaging 
are likely to contain more methaemoglobin and be larger in volume compared to those which 
are more hyperdense, containing more acute haemorrhage. Importantly, this latter group have 
a higher recurrence risk, therefore perhaps clinicians should try and either avoid operating on 
CSDHs whilst they contain higher concentrations of acute haemorrhage/hyperdensity if the 
patient is well and/or engage alternative treatments such as dexamethasone, if shown to be 
beneficial in the final Dex-CSDH trial results, to avoid recurrence.  
 
All CSDHs were found to contain an abundance of inflammatory markers, including the 
novel markers IL-1a, MIP-1a and MIP-1b which contribute to the pro-inflammatory 
environment in CSDH. VEGF was the marker with highest concentrations in comparison to 
peripheral plasma and therefore likely to be critical in CSDH development, with a role in 
both inflammation and angiogenesis. The next highest concentrations were seen with MCP-1, 
IL-6, IL-8 and IP-10, all pro-inflammatory markers, several of which were correlated with 
VEGF or one another, supporting the theory of an interactive inflammatory cascade. Despite 
the belief that CSDHs are all independently contained collections, patients with bilateral 
CSDHs showed congruity between the inflammatory profiles on each side in most cases, 
suggesting either communication or co-ordination of the response in each patient.  
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Many of the inflammatory markers were higher in the recurrent samples compared to primary 
samples, suggesting on-going escalating inflammation as a cause of recurrence. The markers 
in primary CSDH were not predictive of recurrence risk, apart from IL-10 which was 
significantly lower in primary CSDHs that went on to recur. This may suggest that a lack of 
an appropriate anti-inflammatory response contributes to recurrence. MMP-9 may also be 
important for driving recurrence as it was more commonly lower in CSDH than plasma in 
most primary CSDHs, whereas the opposite pattern was observed for most recurrent CSDHs. 
This may implicate MMP-9 in the early development of CSDH membranes, which is then re-
activated by surgery, particularly as very high concentrations were seen in post-operative 
drain samples (mean 1557% increase at 41-65 hrs). Interestingly, most of the markers 
escalated in the post-operative drain samples, suggesting there is a reactive increase in the 
first few days rather than an obliteration of inflammation from “washing out” during surgery; 
MIP-1, MMP-9 and IL-1b escalated to the highest levels post-operatively. However, those 
patients treated with dexamethasone did appear to show reduced peaks in inflammatory 
markers post-operatively, although this only reached statistical significance for VEGF at 25-
40hrs. Conversely, the intra-operative samples had higher concentrations of inflammatory 
markers, including VEGF, in the dexamethasone treated group. This either suggests that 
dexamethasone only works post-operatively, or that VEFG (and some other markers) are 
stimulated in the initial stages of “repair” and resolution of CSDH.  
 
Dexamethasone is rapidly metabolised within the peripheral circulation and it is unclear 
whether it can pass freely into the subdural space, but it does not accumulate there. Its 
relationship with the inflammatory markers is clearly complex, and many more samples in 
dexamethasone treated patients are needed to understand this fully. Unfortunately, post-
operative concentrations of inflammatory markers cannot be measured for longer than 48 hrs 
in most cases as the drains are removed, therefore it is impossible to know what on-going 
pattern of inflammation occurs between primary and recurrent CSDH. It was hoped that the 
inflammatory markers may correlate to patterns on imaging, so that this could be used as an 
alternative measure of inflammation, but no such correlations were found. This may be due to 
the fact that the inflammatory marker profiles were also unrelated to the degree of acute 
haemorrhage found within each CSDH sample, suggesting that although they must interact, 
rates of haemorrhage and inflammation are relatively independent processes during CSDH 
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growth. Imaging is much better aligned to measure the haemorrhage, rather than 
inflammation, thus the only way to measure the outcome of any effective anti-inflammatory 
treatment is by the final end-point; CSDH resolution.  
 
 
9.3  Clinical outcome and the role of imaging in CSDH 
Overall, clinical outcome in good for most patients who suffer with CSDH, with 87% of 
patients showing a favourable mRS score at six months. There is also complimentary data 
showing high mean scores with functional and quality of life assessments (BI and EQ-5D) at 
three and six months. However, it is evident that some patients still have a poor outcome, and 
significant morbidity or even mortality in relation to CSDH, and therefore an opportunity to 
improve this.  
 
The imaging results from this study have shown that larger and mixed density CSDHs have 
the highest potential for a poor outcome, but not necessarily recurrence. This appears to relate 
to two issues; the correlation with older age and more significant neurological deficit on 
admission. It is logical that patients whose initial neurology is worse have a lower potential 
for recovery and this supports the need for earlier diagnosis and treatment of CSDH, before 
severe neurological deterioration occurs. There is a lot of interest in classifying the density of 
CSDH, but the results in the literature are conflicting on how and whether this can predict 
recurrence. The very poor inter-rater reliability shown with the most common density 
classification used (Nakaguchi, Tanishima, & Yoshimasu, 2001) may explain why data is 
conflicting and this advocates a simpler and more user-friendly approach. Quantative 
evaluation of density in this thesis has not shown to be predictive either, and I suggest that a 
new approach to assessing just the “membranous” pattern of the CSDH may yield more 
useful information in the future. 
 
The widespread implementation of subdural drain placement during CSDH surgery has 
reduced recurrence rates in the last decade, and is advocated in the literature. Despite this 
there is an on-going recurrence rate of around 9% and potential to improve this. Post-
operative imaging to assess residual volumes of fluid, particularly when hyperdense, may 
help predict those patients at the highest risk of recurrence, indicating closer follow-up. Such 
patients may also be eligible for targeted adjuvant treatments such as post-operative 
 283 
dexamethasone. The Dex-CSDH trial is aimed at answering whether dexamethasone 
significantly improves the functional outcome (as measured with mRS) in all CSDH patients. 
If shown to be efficacious then it is likely to be widely adopted into clinical practice, however 
if the trial does not show significance then it may be that dexamethasone needs to be more 
selective applied rather than completely disregarded (i.e. given only to those patients at 
greatest risk of recurrence). The cost-effectiveness of the treatment will also be assessed in 
the trial, with the anticipation that preventing operative intervention or re-intervention will 
allow a significant cost saving in terms of the surgery, in-patient stay and associated 
morbidly. However, for patients in whom urgent surgery is indicated anyway, the addition of 
dexamethasone for all cases may be an unnecessary cost and risk, when it could be targeted at 
only those patients suspected to be at high risk of recurrence and/or poor outcome. 
 
 
9.4  Future CSDH research 
Widespread identification of CSDH as DN or AT will help determine whether this 
pathophysiological division is useful clinically. Prospective radiological and clinical review 
of elderly patients with “normal” post-trauma CT imaging may help identify markers (i.e. 
subdural hygroma) than can lead to earlier diagnosis of CSDH-DN before clinical 
deterioration and surgery is required. 
 
Longer-term follow-up studies on CSDH patients will aid our understanding of whether this 
condition increases the risk of cerebral atrophy and/or accelerated cognitive decline and 
dementia. An area of critical importance in the ever-aging population, particularly if adjuvant 
therapies such as dexamethasone, not only reduce recurrence but improve cognitive recovery 
in general. This, as always, must be finely balanced against the risks and side-effects of such 
therapies, although these have shown to be acceptable in the pilot data presented here. 
 
The small number of patients who started their dexamethasone therapy prior to surgery has 
limited the data available for analysis on the mechanism of action of dexamethasone. 
Therefore, further work is needed, ideally with large numbers of samples from 
dexamethasone-treated patients. The availability and value of such data will depend almost 
entirely on the success or failure of the Dex-CSDH trial. If dexamethasone is adopted into 
clinical practice following trial results then this will provide the opportunity to collect and 
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interrogate samples further. Information gained here on the varying patterns of inflammatory 
profiles with different areas of CSDH should promote multiple-sampling were possible. If the 
Dex-CSDH trial is neutral or negative then further study on its mechanism will be more 
challenging. However, assessment of the inflammatory profiles seen in CSDH fluid and how 
they change over time and in response to medical therapies is clearly an area for on-going 
research. It may be that a more appropriate treatment solution for CSDH is targeted anti-
VEGF treatment, which is already being applied to angiogenic diseases such as macular 
degeneration (Pieramici & Rabena, 2008).   
 
There is individual case-based data within this thesis to suggest that dexamethasone does 
reduce recurrence post-operatively, but also that it can aid conservative management of 
CSDH. As the Dex-CSDH trial has mainly recruited surgically-treated CSDH patients, a 
further study focused on early, conservative treatment of CSDH with dexamethasone is likely 
to be indicated. Such a study could also provide more information about the natural course of 
CSDH, as surprisingly some CSDHs just over 100cm3 in volume resolved despite receiving 
only placebo treatment. There is a fine balance to be met between early CSDH treatment to 
prevent deterioration and over-treating CSDHs which would otherwise have resolved.  
 
Finally, relatively little has been explored on the role of anti-platelet and anti-coagulant drugs 
in the pathophysiology of CSDH development and recurrence. This was due to the limited 
and heterogenous data available, with varying time points from stopping and reversing these 
medications. However, as hyperdensity, and increased recent haemorrhage is clearly 
implicated in CSDH growth and recurrence, these drugs are likely to be important. Therefore, 
prospective clinical data needs to be collected and amalgamated with imaging and surgical 
findings to understand this further.  
 
Clearly there is still much to learn about the pathophysiology and treatment algorithms for 
this interesting and complex condition. Hopefully the findings of this thesis have improved 
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